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1.1 Heterogeneity of patients in clinical trials
Randomized clinical trials (RCTs) are essential to evaluate the usefulness of 
treatments and interventions 1. Trials inform and influence clinical practice 2. 
Clinicians rely increasingly on RCTs to distinguish between worthwhile, useless 
and harmful interventions. 
RCTs are often performed in patients who are heterogeneous with respect to 
prognosis. Heterogeneity occurs in many clinical fields, such as traumatic brain 
injury (TBI), acute coronary syndromes (ACS), stroke, and cancer. Even with 
strict inclusion criteria, patient prognosis can vary according to baseline charac-
teristics (e.g. age, gender, disease severity). For instance, the 6-month mortality 
for TBI patients older than 65 years is around 72%, in contrast to 21% for patients 
younger than 35 years 3. Likewise, patients with unstable angina/non-ST-seg-
ment elevation acute coronary syndromes and 7 strong prognostic variables have 
a nuch higher risk to develop an adverse outcome than those without prognostic 
variables (41% vs. 5%) 4. 
1.2 Problems related to heterogeneity of patients
Heterogeneity may lead to imbalance of randomized groups with respect to prog-
nosis. This imbalance is due to pure chance when a proper randomization proce-
dure was followed 5. Stratified randomization reduces the chances of imbalance 
between treatment groups for known factors 6. This is a two-stage procedure in 
which patients who enter a clinical trial are first grouped into strata according to 
predictors. Within each stratum, patients are then assigned to a treatment accord-
ing to separate randomization schedules. For example, patients over 65 years may 
be randomized separately from patients under 65. 
Heterogeneity may dilute the beneficial effect of treatments in some sub-
groups of patients satisfying the inclusion criteria. For instance, TBI patients 
with good prognosis (<20% of 6-month unfavorable outcome) or bad prog-
nosis (>80% of 6-month unfavorable outcome) may not receive benefit from 
a treatment, because they are too healthy or too sick. It can be hypothesized 
that patients with an intermediate prognosis (e.g. between 20% and 80%) may 
benefit most from a treatment 7. Such a prognostic category can be defined 
by a combination of baseline characteristics. Clinical staging in cancer is 
a way to combine patients characteristics, and it is frequently used in oncol-
ogy clinical trials. Moreover, a treatment may be more effective in subgroups 
of patients with some characteristics, especially those related to a mechanism
of action of the treatment. For example, it could be that TBI patients with mass
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lesions may benefit more from certain treatments than others 7. 
1.3 Possibilities of analysis in trials with heterogeneous patients
The heterogeneity of patients offers some possibilities to deal with the cited 
problems. Two methods are often used in the analysis phase of a trial: covari-
ate adjustment and subgroup analysis. Covariate adjustment leads to adjusted 
estimates of the treatment effects, in contrast to unadjusted estimates. An un-
adjusted estimate of the treatment effect may be interpreted as relating to an 
“average” patient with a certain disease. Adjusting for one predictor (e.g. age) 
results in an estimate for “a patient with a certain age”. Adjusting for all known 
predictive baseline characteristics results in a treatment effect in patients with 
“a certain risk profile” 8. Covariate adjustment also corrects for imbalance, and 
increases the statistical power to detect a significant treatment effect 8, 9. Thus, 
it potentially reduces the sample size requirements. For instance, adjustment of 
the treatment effect for 17 predictors of 30-day mortality of patients with acute 
myocardial infarction (MI) enrolled in the GUSTO-I trial reduced the required 
sample size by 15% 8. In a simulation study using a TBI registry, adjustment 
for age and Glasgow Coma Scale (GCS) motor score reduced the sample size 
requirements by 30% 10. However, the quantification of the increase in power and 
the potential reductions in sample size requirements in empirical RCTs has been 
insufficiently studied.
Subgroup analysis assesses differences in treatment effect between diffe-
rent subpopulations of patients 11-13. A subgroup is a group of patients with a 
common set of  baseline characteristics. Journals have devoted a large number of 
pages describing treatment effects in particular groups of patients 11. However, 
subgroup analyses have been generally misused and overinterpreted in the last 
two decades 12, and it is not known if their use has improved in recent years. 
Trials of a size adequate to detect an overall effect cannot be expected to provide 
reliable effect estimates within smaller groups 11. This problem can be tackled 
by a meta-analysis of RCTs, which may substantially increase the power to detect 
differential treatment effects across subgroups of patients 13. 
1.4 Heterogeneity in traumatic brain injury and acute coronary syndrome 
trials
Heterogeneity is a major problem in the field of TBI, where the risks of a poor 
6-month outcome vary widely between patients (e.g. risks varying from <10% 
to >90%). All recent RCTs in TBI have shown negative results, i.e. that the 
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new treatment was not significantly better than placebo 14. Heterogeneity was 
insufficiently considered in the design and analysis of the treatment effect in 
these studies. Adjustment for important predictors of the outcome may decrease 
the sample size requirements in TBI trials. The reduction is sample size will be 
larger where the inclusion criteria are less strict, and hence the population is 
more heterogeneous. 
 Patients with non-ST-segment elevation acute coronary syndromes essen-
tially differ in their short and long term outcome, and prognostic categories are 
commonly used to allocate a less or more aggressive treatment 15. Platelet glyco-
protein IIb/IIIa (GP IIb/IIIa) receptor blockers decrease the risk of death or MI at 
30 days in patients with non-ST-segment elevation acute coronary syndromes not 
routinely scheduled for early revascularization 16. Elderly patients (>80 years) 
may be undertreated with these drugs because they were underrepresented in 
previous RCTs, and because the drugs can produce more harmful effects than in 
younger patients. There has been no demonstration that these drugs are equally 
efficacious in old and young patients 17. A meta-analysis of large international 
RCTs may help to define the benefits and risks of GP IIb/IIIa receptor blockers in 
elderly patients. 
 Stroke is an uncommon and serious event in patients with non-ST-segment 
elevation acute coronary syndromes 18. However, few papers have been performed 
to establish which patients are at higher risk to develop this serious complication. 
This group of patients can potentially benefit from preventive interventions after 
the ACS, such as statins 19. An evaluation of predictors in a population with a 
larger number of stroke events is required to define predictors accurately. 
 
1.5 Scope of the Thesis
This thesis describes both methodological aspects and clinical applications of 
covariate adjustment and subgroup analysis in RCTs. The following research 
questions are addressed in this thesis:
1. Which are the pros and the cons of adjustment of the treatment effect in 
RCTs for baseline covariates?
2. How well are covariate adjustment and subgroup analysis used, reported and 
interpreted in current internal medicine, oncology, cardiology, and neurosurgery 
trials?
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3. How much reduction in sample size can be obtained from adjustment for 
important predictors of unfavorable outcome in TBI trials?
4. Are the effects of GP IIb/IIIa receptor blockers similar in the young and the 
elderly in a meta-analysis of non-ST-segment elevation acute coronary syndrome 
trials?
5. Which subgroups of patients are at higher risk to develop a stroke after a 
non-ST-segment elevation acute coronary syndrome? 
These issues have been insufficiently studied and quantified in theoretical and 
empirical data. The first part of this thesis considers simulation studies to quan-
tify the gain in power and the reduction in sample size requirements in trials with 
dichotomous outcomes, with the use of the logistic regression model (Chapter 2) 
and the Cox proportional hazards models (Chapter 3). The reduction in sample 
size indicates that adjusted analyses might give the same power as an unadjusted 
analysis but with smaller sample size. 
The second part describes the current practices of reporting and interpreta-
tion of covariate adjustment and subgroup analysis in 84 trials from high Impact 
Factor journals in General Internal Medicine, Cardiology and Oncology (Chapter 
4), in 63 therapeutic cardiovascular clinical trials (Chapter 5), and in 18 trials of 
moderate and severe traumatic brain injury with more than 100 patients (Chapter 
6).  
The third part describes clinical applications of relevant methods in heteroge-
neous trial populations: an analysis of the reduction in sample size requirements 
with covariate adjustment for strong predictors in 8 trials of moderate-severe 
traumatic brain injury (n=6298) (Chapter 7), a subgroup analysis of the effects 
of the platelet glycoprotein IIb/IIIa receptors blockers by age in a meta-analysis 
of  6 trials of patients with non-ST-segment elevation acute coronary syndromes 
(n=31402) (Chapter 8), and an analysis to find predictors of all-cause stroke in 
heterogeneous patients with non-ST-segment elevation acute coronary syndromes 
(Chapter 9). 
This thesis ends with a discussion of the theorethical and practical results, 
and gives recommendations for appropriate analysis of RCTs with heterogeneous 
populations.
General Introduction
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ABSTRACT
Background and Objective: Randomized controlled trials (RCTs) with dichoto-
mous outcomes may be analyzed with or without adjustment for baseline cha-
racteristics (covariates). We studied type I error, power and potential reduction in 
sample size with several covariate adjustment strategies. 
Methods: Logistic regression analysis was applied to simulated data sets (n=360) 
with different treatment effects, covariate effects, outcome incidences and co-
variate prevalences. Treatment effects were estimated with or without adjustment 
for a single dichotomous covariate. Strategies included always adjusting for the 
covariate (‘pre-specified’), or only when the covariate was predictive or imbal-
anced. 
Results: We found that the type I error was generally at the nominal level. The 
power was highest with pre-specified adjustment. The potential reduction in 
sample size was higher with stronger covariate effects (from 3% to 46%, at 50% 
outcome incidence and covariate prevalence) and independent of the treatment 
effect. At lower outcome incidences and/or covariate prevalences, the reduction 
was lower. 
Conclusion: We conclude that adjustment for a predictive baseline characteristic 
may lead to a potentially important increase in power of analyses of treatment 
effect. Adjusted analysis should hence be considered more often for RCTs with 
dichotomous outcomes.
Covariate adjustment in trials with dichotomous outcomes using logistic regression 
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Introduction
Randomized controlled trials (RCTs) have emerged as the principal research 
tool to inform and influence clinical practice 1, 2 . Clinicians rely increasingly 
on efficient, well designed RCTs to distinguish between worthwhile, useless or 
harmful interventions 2. Efforts have been made to improve quality in reporting 
RCTs 3, but the way to analyze RCTs properly  is still under discussion 4-7.
In particular, the treatment effect in a RCT can be analyzed and shown either 
as an average effect, as an adjusted effect, or both 8. Adjusted effect estimates 
attempt to take the heterogeneity of patients in RCTs into account. The hetero-
geneity of patients is related to their prognostic baseline characteristics 4, which 
may be used to obtain adjusted treatment effects. Common methods of adjust-
ment are baseline imbalance adjustment 5, 9, subgroup analysis 5, 10-12, stratified 
randomization plus adjustment 13, and covariate adjustment (post-stratification) 
14-18.  
Covariate adjustment provides more individualized effect estimates, espe-
cially in non-linear models such as logistic regression and Cox proportional 
hazards regression 8, 13-20. Further, adjusted effect estimates take into account 
chance differences in baseline characteristics between treatment arms 14, 15 and 
improve the power, i.e. the ability to identify treatment effects when they really 
exist 15-22. 
The use of covariate adjustment in the current literature is not consistent 5, 11, 
probably because the strategies have not been fully developed and tested 23, 24. A 
key aspect of the adjustment strategies is the way of selection of the covariate to 
be adjusted for 25. Moreover, the effects on power and type I error after adjust-
ment have not been studied thoroughly. 
We used various strategies for covariate adjustment in simulated logistic 
regression models with one dichotomous covariate. Our aim was to identify the 
pros and the cons of each covariate adjustment strategy, with a focus on changes 
in statistical power. We expressed any increase in statistical power as the decrease 
in sample size that gives the same power as an unadjusted analysis.
Methods
Treatment effects and adjustment strategies
Logistic regression models were used to analyze the effects of treatment on a 
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dichotomous outcome (e.g. 30-day mortality). A dichotomous baseline charac-
teristic was entered as covariate to achieve adjustment of the treatment effect. 
The formula is: log odds (outcome) = β0 + β1*Treatment + β2*Covariate. The 
logistic regression coefficients and their standard errors (SE) were estimated with 
standard maximum likelihood procedures. Statistical significance was based on 
the Wald statistic (coefficient/SE), with two-sided p-values < 5% considered 
significant. 
We used three approaches for covariate adjustment. In practice, they should be 
clearly described in the protocol. ‘Adjustment’ refers to a pre-specified adjusted 
analysis. Pre-specified analysis uses a known predictive covariate, e.g. derived 
from previous research. This leads to a stratified estimate of the treatment ef-
fect, which is also corrected for imbalance 14. Further, the predictive effect of 
a baseline characteristic can be used for adjustment if statistically significant 
using chi-square test (p< 5%) and this is referred to as ‘Predictor p<5%’. This chi 
square is not adjusted for treatment. The imbalance according to a baseline cha-
racteristic may also be used for adjustment if statistically significant according to 
a chi-square test (p<5%) and it is referred to as ‘Imbalance p<5%’. Moreover, ‘No 
adjustment’ refers to an unadjusted analysis of the treatment effect. We report 
the results with the default significance level of 5%. We also explored the effects 
of applying a more liberal criterion for covariate selection (p<20%). 
Data sets and simulations 
The various approaches to estimation of the treatment effect were applied in 
different data sets. First, we simulated RCTs of 360 patients, 180 randomized to 
treatment A and 180 to treatment B, based on a previously discussed hypotheti-
cal example (Table 1), using mortality as outcome (number of events equal to 
180 on average) 14. The distributions of gender and outcome were generated by 
sampling with replacement from the data set underlying the same table. Here, 
the prognostic effect of gender was very strong, with a 16% mortality rate in 
men compared to 84% in women (Odds Ratio [OR] = 30). The treatment effect 
for treatment B showed a mortality OR of 1.43 in comparison with treatment A 
in the unadjusted analysis, which used the total table and ignored heterogeneity 
(p=0.09). In contrast, the mortality OR was 2.0 in the strata formed by gender, 
meaning that treatment A reduced the odds of death in men and women by half 
(p=0.02). This example illustrates that the unadjusted OR may substantially di- 
ffer from the adjusted OR. 
     
We analyzed more hypothetical data sets using combinations of different 
unadjusted covariate effects (No covariate effect [OR=1], moderate covariate 
Covariate adjustment in trials with dichotomous outcomes using logistic regression 
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effect [OR = 2], strong covariate effect [OR = 5] and very strong covariate effect 
[OR = 30]). Unadjusted treatment effects were varied from no treatment effect 
[OR=1], weak treatment effect [OR = 1.4] to mild treatment effect [OR = 1.7]. 
These effects are within the range of 1.1 to 1.9 that we observed in a survey of 13 
large cardiovascular RCTs reported in The Lancet, The New England Journal of 
Medicine and JAMA during 2001 and 2002. 
We simulated RCTs of 360 patients (180 to treatment A and 180 to treatment 
B, on average) and their distributions were generated by sampling with replace-
ment from each hypothetical data set. The number of outcomes considered in the 
main analysis was 180 on average (50% of total number of patients). Because 
the outcome incidence and the covariate prevalence may be lower in RCTs, we 
also considered situations with a lower outcome incidence and a lower covariate 
prevalence (25%, 12.5% and 6.25% of the total number of patients in both cases). 
Simulations were performed with 20,000 repetitions when a treatment effect was 
truly present and 100,000 when no treatment effect was present (i.e. under the 
null hypothesis). 
Table 2 shows the 12 logistic regression models considered. For example, the 
model with weak treatment effect and very strong covariate effect was made 
from a data set such as shown in Table 1. Unadjusted covariate and treatment 
ORs are the univariate ORs (either covariate or treatment introduced in the 
logistic model). Adjusted covariate and treatment ORs are the multivariate ORs 
(both covariate and treatment introduced in the logistic model). The covariate 
and treatment ORs are higher in adjusted analyses, specially when the covariate 
effects are stronger. We repeated the analyses using double sample size (i.e. 720 
patients, with 360 in each treatment arm). When the outcome incidences and 
Table 1. Hypothetical example of stratification in a randomized clinical trial, 
where treatment A is compared to treatment B, while gender is balanced.
Total: OR=1.43 Males: OR=2.0 Females: OR=2.0 
Treatment Dead Survive Total Dead Survive Dead Survive
A
B
% of death 
82
98
(50%)
98
82
180
180
10
18
(16%)
80
72
72
80
(84%)
18
10
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Model
Unadjusted Adjusted Unadjusted Adjusted
No covariate effect:
Strong TE:     - 0.268+ 0*Covariate+ 0.54*Tx 1.0 1.0 1.7 1.7
Moderate TE: - 0.178+ 0*Covariate+ 0.36*Tx 1.0 1.0 1.4 1.4
No TE:                   0+ 0*Covariate+     0*Tx 1.0 1.0 1.0 1.0
Moderate covariate effect:
Strong TE:     - 0.64+ 0.73*Covariate+ 0.55*Tx 2.0 2.1 1.7 1.7
Moderate TE: - 0.55+ 0.72*Covariate+ 0.36*Tx 2.0 2.1 1.4 1.4
No TE:           - 0.36+ 0.71*Covariate+     0*Tx 2.0 2.0 1.0 1.0
Strong covariate effect:
Strong TE:     - 1.12+ 1.63*Covariate+ 0.63*Tx 4.9 5.1 1.7 1.9
Moderate TE: - 1.01+ 1.61*Covariate+ 0.42*Tx 4.9 5.0 1.4 1.5
No TE:           - 0.79+ 1.59*Covariate+     0*Tx 4.9 4.9 1.0 1.0
Very strong covariate effect:
Strong TE:     - 2.32+ 3.58*Covariate+ 1.08*Tx 29.4 35.9 1.7 2.9
Moderate TE: - 2.08+ 3.47*Covariate+ 0.69*Tx 29.4 32.1 1.4 2.0
No TE:           - 1.69+ 3.38*Covariate+     0*Tx 29.4 29.4 1.0 1.0
OR: Odds ratio; TE: Treatment effect; Tx: treatment
OR
Covariate Treatment
Table 2. Characteristics of the models used for adjusted and unadjusted 
analyses of the treatment effect.
covariate prevalences were small (12.5% and 6.25%), we used bigger sample 
sizes (n=1200) to facilitate the construction of adequate data sets.
Evaluation
We studied the actual type I error (α) when there was no treatment effect (OR=1), 
Covariate adjustment in trials with dichotomous outcomes using logistic regression 
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and power (1-β, where β indicates type II error) when there truly was a treatment 
effect (OR>1), in each of the strategies of covariate adjustment. The 95% CI for 
the type I error of 5% ranged from 4.87% and 5.14% with 100 000 simulations. 
The formula used to calculate the type I error and the power for each strategy 
was: 100* (number of simulations with statistically significant treatment effect 
/ total number of simulations), where the statistical significance was established 
according to the Wald statistic. We calculated the reduction of sample size to 
express the gain in power with each of the adjustment strategies. The formula 
used was: 100 - 100*[(mean of  Z score of unadjusted strategy)/(mean of Z score 
of the adjusted strategy)]² (see appendix), where Z score is equal to the Wald 
statistic of the treatment effect coefficient 6. We used S-plus software (version 
2000, Insightful Inc, Seattle, WA) for all calculations.
Results
Table 3 shows the main results of our simulations. When there was no treatment 
effect (OR=1), SEs from adjusted analysis were larger in direct relation to the 
strength of the covariate effect. The type I error was rather similar for most 
adustment strategies and for all covariate effects. The results were mainly slightly 
below 5%, especially when the covariate effect was strong and the significant 
imbalance strategy was used (type I error 3.8%). When there were no covariate 
effects, covariate adjustment strategies did not markedly change the treatment 
effect coefficients and SEs. The power was slightly reduced and the required 
sample size was slightly increased (<0.1%). This indicates that very limited dam-
age was done when a noise covariate was included in the adjusted analysis. 
     
When there were treatment effects and covariate effects (OR>1), the pre-speci-
fied covariate adjustment strategy yielded on average a more extreme treatment 
effect coefficient compared to no adjustment. Consequently, power increased, as 
expected. Adjustment for one statistically significant predictor generated similar 
results to pre-specified adjustment, since the latter was nearly always statistically 
significant. Statistically significant imbalance adjustment generated on average 
only a slightly higher coefficient than the unadjusted coefficients, leading to a 
small increase in power.
A potential reduction in sample size was evident when covariate adjustment 
was pre-specified or based on the predictive significance of the covariate. The 
reduction in sample size was largest when the covariate effect was strongest. The 
range of reductions in sample size was from 3% to 46%, corresponding to unad-
justed covariate OR from 2 to 30. When the significant imbalance strategy was 
used, the reduction in sample size was less than 3%. Remarkably, we observed 
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the same reduction in sample size when different treatment effects were used, 
given a certain covariate effect. For example, when pre-specified adjustment was 
used, the reduction in sample size was 13.8% if the treatment effect was weak 
(OR=1.4) and 13.6% if it was mild (OR=1.7). 
When either the outcome incidence or the covariate prevalence or both were 
lower, the reduction in sample size was also lower (Table 4). For example, with 
a covariate OR of 5, an outcome incidence of 25% and a covariate prevalence 
of 50%, the average reduction in sample size was 10.4% instead of 13.7%. The 
reduction in sample size was the same when the outcome incidence was 50% 
with a covariate prevalence of 25% and when the outcome incidence was 25% 
with covariate prevalence of 25%. Smaller outcome incidences and/or covariate 
prevalences yielded even lower reductions in sample (e.g. 3.0% when outcome 
incidence 6.25% and covariate prevalence 6.25%). The reductions in sample 
size were similar when the sample size was increased, and when we considered 
p<20% instead of  p<5% as covariate selection limit.
     
Discussion
Covariate adjustment increased the power of statistical analyses of a treatment 
effect in the context of a randomized trial, without inflation of type I error. The 
increase in power was translated into moderate potential reductions in sample 
size, indicating that adjusted analyses might give the same power as an unadjusted 
analysis but with a smaller sample size. We found that pre-specified covariate and 
significant predictor covariate adjustment strategies were the most statistically 
efficient, with reductions in sample size between 3% and 46%, depending on the 
covariate strength. The potential reduction in sample size was independent of the 
magnitude of the treatment effect or sample size, which makes it an attractive 
summary measure to express the benefit of adjustment strategies. There was very 
limited damage when adjustment was performed if there was no true covariate 
effect. 
Adjusted and unadjusted estimates in RCTs with homogeneous groups show 
on average similar results, as confirmed by our simulations with no covariate 
effects. However, several problems arise when dealing with heterogeneous popu-
lations. For example, adequate randomization sometimes produces unbalanced 
groups (statistically or non-statistically different at the 5% level) with respect to 
the baseline characteristics 4. Moreover, the effect of non-statistically significant 
imbalance between groups is not negligible, especially if the prognostic effect is 
strong 4, 9, 14, 17. Further, the overall clinical trial result is not directly applicable 
to individuals 7, 8.
Chapter 2.1
20
Covariate adjustment may overcome some of the problems of heterogeneous 
populations 4, 5, 8, 13-17, 24. The reported potential benefits of adjustment for 
covariates include the removal of confounding due to imbalance 4, 8, 14, 19, the 
acquisition of a more subject-specific estimate instead of a population-averaged 
estimate 8, 14, and the gain in statistical power 8, 14, 15, 17, 19, 24. The gain in sta-
tistical power in logistic regression is explained by a larger increase in expected 
size of the adjusted treatment effect than the increase in the SE 16, 19, 24. 
We found that adjustment for a strong covariate (either pre-specified or tested) 
led to a more extreme estimate of the treatment effect, as expected 5. The relative 
difference between unadjusted and adjusted estimates on the logistic scale was 
approximately constant for a given covariate effect and independent of the treat-
ment effect. We also confirmed that the variability (SE) of the adjusted estimates 
was larger in direct relation to the strength of the covariate 14-18; the opposite 
of what happens in linear regression 19, 25. We obtained a conservative type I 
error when the covariate effect was strong and the imbalance strategy was used. 
This conservatism is explained by the fact that imbalance constrains the outcome 
variability between treatment groups 17. 
The power to detect a true treatment effect increased with the pre-specified 
and the statistically significant predictor strategies, which was translated into 
reductions in sample size up to 46%. In practical situations, the covariate effect 
may be either moderate or strong (OR from 2 to 5, corresponding to Spearman’s 
correlations (ρ) between 0.17 and 0.38 9, 17]), and the treatment effect may be 
weak (OR of 1.4). Therefore, the potential reductions in sample size would be 
moderate, maximally between 3% and 14% with a 50% outcome incidence and 
50% covariate prevalence. 
Our results agree with Pocock et al. 17 who found a reduction in sample size 
of 10% with adjustment for a covariate with ρ= 0.3, in the context of RCTs with 
continuous outcomes. When the covariate was very strong (OR: 30; ρ= 0.69) 
the reduction of sample size was highest (46%), in agreement with a previously 
found 50% reduction at ρ= 0.7. These similarities in the reduction in sample 
size are attributed to the similarity of effects of the covariates in the linear and 
logistic regression models with 50% outcome incidence. 
When we chose a covariate with the significant imbalance strategy the gain in 
power was not observed. Therefore, this procedure is not advised, in concordance 
with others 4, 5, 8. The results of the combination of strategies (‘predictor and im-
balance’ and ‘predictor or imbalance’) were similar to the significant imbalance 
Covariate adjustment in trials with dichotomous outcomes using logistic regression 
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and significant predictor strategies, respectively (results not shown). 
In contrast to the scenario with 50% outcome incidence and 50% covariate 
prevalence, we found that the potential reduction in sample size was lower when 
the event incidence or the covariate prevalence were lower than 50%. For ex-
ample, this situation is commonly seen in published cardiovascular RCTs, where 
the outcome incidences range typically from 5% to 25% 26-28. Remarkably, the 
reduction in sample size was similar given a value of either the event incidence or 
the covariate prevalence or both. Moreover, when the event incidence was lower 
and the covariate prevalence was higher than 50%, the reduction in sample size 
was the lowest (1.6 % in the example given in table 4). 
The unadjusted strategy yields an average treatment effect, without any con-
sideration of heterogeneity in prognosis among patients. Covariate adjustment 
and subgroup analyses both consider heterogeneity and attempt to provide more 
individualized estimates of the treatment effect. They are however substantially 
Outcome Covariate Reduction in
Situations incidence(%) prevalence(%) sample size(%)
Decreasing event incidence
50 50 13.7
25 50 10.4
12.5 50 5.5
6.25 50 2.9
Decreasing covariate prevalence
50 25 10.4
50 12.5 5.5
Decreasing event incidence and covariate prevalence
25 25 10.5
12.5 12.5 5.7
6.25 6.25 3.0
Decreasing event incidence and increasing covariate prevalence
12.5 75 2.8
12.5 87.5 1.6
Table 4. Reduction in sample size with pre-specified covariate adjustment, 
considering different outcome incidences and covariate prevalences 
(Unadjusted covariate OR = 5).
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different. Covariate adjustment obtains a single more individualized treatment 
effect estimate, which is assumed to be applicable to all patients 15, 17. Subgroup 
analyses provide multiple treatment effect estimates, assuming that treatment 
effects differ between particular groups of patients 12. Covariate adjustment 
commonly is achieved with regression models 14-18 while adequately performed 
subgroup analyses apply tests of interaction 10, 12, 17. Covariate adjustment is 
sometimes used in the primary analysis of RCTs. Remarkably, unadjusted 
analyses receive generally more emphasis. This may be caused by a suspicion 
of data-driven adjustment, or because adjustment is more difficult for readers 
to understand 5. Subgroup analyses are often performed 17, but they rarely have 
enough power to detect differential treatment effects. Tests of interaction are 
underused and subgroup analyses results are commonly over-interpreted 12.
We advise to perform adjusted analyses because of several advantages, includ-
ing a more individual-oriented treatment effect corrected for imbalance, a gain in 
power and, as a consequence, a potential reduction in sample size. Even when the 
event incidence and covariate prevalence are low, there is a potential reduction 
in sample size. If a strong predictive covariate is known before the analysis of 
the RCT, for example, after a literature review 4, 8, 9, 14, 24, the best strategy of 
covariate adjustment is to pre-specify adjustment. If a number of covariates are 
potentially predictive, a second best option is to use the ‘significant predictor’ 
strategy. Here, bias may be introduced by the selection procedure, particularly 
in the context of small sample sizes 29. This theoretical objection was not found 
important in our simulations. Moreover, Edwards 30 pointed out that if the model 
is chosen with blinding of the treatment indicator variable, the type I error may 
be controlled.
We did not present calculations for covariate adjusted sample size in RCT de-
sign. To quantify any anticipated sample size gains with covariate adjustment, we 
would need to specify covariate effects and covariate distributions 31. In practice, 
the study would then have to meet these assumptions to achieve the calculated 
power. Therefore, we advise to perform an unadjusted sample size calculation, 
which needs less assumptions.
Our work has several limitations. We presented results from analyses of simu-
lated models, using hypothetical treatment effects and covariate effects, without 
real patient data. We did not study the effect of covariate adjustment using con-
tinuous covariates. We used the Wald test for statistical significance, although 
the Likelihood Ratio test may yield better results. We chose only one covariate 
to simplify the simulation process and to clarify the presentation. When more 
prognostic covariates are pre-specified for adjusted analysis, the same conclu-
sions are expected on treatment effect estimation, power and potential reduction 
Covariate adjustment in trials with dichotomous outcomes using logistic regression 
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in sample size 8, 17, 18. However, when many potential predictors are available, 
a complication may be which variables to choose. A selection procedure, e.g. 
stepwise backward elimination, might be considered to choose a limited number 
of covariates, but the effects of such a procedure on effect estimation and power 
require further study.
In conclusion, adjustment for a predictive baseline characteristic increased 
the power of statistical analyses of a treatment effect, without inflation of Type 
I error and with potentially important reductions in sample size. The covariate 
ideally has to be pre-specified in the RCT protocol. Alternatively, testing for a 
statistically significant predictive effect is suggested. Adjustment for important 
predictors should be considered more often in the analysis of RCTs with dichoto-
mous outcomes.
Appendix
Deduction of the Reduction of Sample Size formula
In the context of a RCT, we defined nu and na as the unadjusted and adjusted 
sample sizes respectively, Zα is Z value at α =0.05, Zβu is the Z value of the 
unadjusted power 1-βu, Zβa is the Z value of the adjusted power 1-βa, Zu is the 
mean standardized Z score of the estimated unadjusted coefficient defined as 
coefficient /SE for each simulation, and, Za is the mean standardized Z score of 
the estimated adjusted coefficient defined as coefficient /SE for each simulation.
We expressed any increase in statistical power of the adjusted analysis as the 
decrease in the sample size that gives the same power of an unadjusted analysis 
(i.e. Zβu = Zβa ). This assumption gives approximately:
 na / nu = ( Zu / Za )2      (1)
The potential reduction in sample size (RSS) between unadjusted and adjusted 
strategies is expressed in percentage as:
 [(nu – na )/ nu ]*100  ,  or  
 100 – [100*(na /nu )]       (2)
Replacing (1) in (2):
            RSS = 100 – 100* ( Zu / Za )2                 (3)
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ABSTRACT
Purpose: We evaluated the effects of various strategies of covariate adjustment 
on type I error, power and potential reduction in sample size, in randomized 
controlled trials (RCTs) with time-to-event outcomes. 
Methods: We used Cox models in simulated datasets with different treatment 
effects (Hazard Ratio [HR]= 1, 1.4, 1.7), covariate effects (HR=1, 2, 5), covariate 
prevalences (10%, 50%) and censoring levels (No, low, high). The treatment and 
a single covariate were dichotomous. We examined the sample size that gives 
the same power as an unadjusted analysis, for three strategies: pre-specified, 
significant predictive and significant imbalance. 
Results: Type I error was generally at the nominal level. The power to detect a 
true treatment effect was higher with adjusted than with unadjusted analyses, es-
pecially with pre-specified and significant predictive strategies. Potential reduc-
tions in sample size with covariate HR between 2 and 5 were between 15% and 
44% (covariate prevalence 50%) and between 4% and 12% (covariate prevalence 
10%). The significant imbalance strategy yielded small reductions. The reduction 
was higher with stronger covariate effects, but was independent of the treatment 
effect, sample size and censoring level. 
Conclusions: Adjustment for one predictive baseline characteristic yields higher 
power to detect a true treatment effect than unadjusted analysis, without infla-
tion of type I error and with potentially moderate reductions in sample size. 
The analysis of RCTs with time-to-event outcomes should adjust for predictive 
covariates.
How much does covariate adjustment increase power in trials with time-to-event outcomes?
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Introduction
Randomized controlled trials (RCTs) are important research tools to evaluate the 
usefulness of treatments and interventions 1. Heterogeneity is common among 
patients participating in RCTs with time-to-event outcomes 2. Prognosis com-
monly varies according to patient baseline characteristics, which are routinely 
recorded in RCTs. After proper randomization, imbalance in patient characteris-
tics may arise by chance 3. 
Covariate adjustment for prognostic baseline characteristics is usually 
performed with Cox proportional hazards model in RCTs with time-to-event 
outcomes 3-10. The inclusion of a strongly predictive covariate in addition to the 
treatment variable in a Cox model provides three important benefits: correction 
for imbalance 3, 4, 6, 9, acquisition of more individualized treatment effects 3, 7, 
9 and increase in statistical power, i.e., the ability to detect a treatment effect 
when it really exists 2, 5-9. Moreover, omission or misspecification of prognostic 
covariates in the analysis produces deviations from the proportional hazards as-
sumptions 5, 10-15.
The power of covariate adjustment strategies in RCTs with time-to-event out-
comes depends on various characteristics: strength of treatment effect, strength 
of covariate effect, covariate prevalence and censoring level 2, 5-7, 9, 11-13, 22. The 
effects of the covariate adjustment strategies on statistical power and type I error, 
using plausible clinical scenarios, have been insufficiently studied 16, 17. Some 
examples of covariate adjustment in RCTs with survival outcomes are available 
in the medical literature, specially in oncology and cardiology 18-21.
We used various strategies for choice of covariates (pre-specified, predictive 
and imbalance strategies) in simulated Cox proportional hazards models with 
one dichotomous covariate, using different treatment effects, covariate effects, 
covariate prevalences and censoring levels. We aimed to identify the pros and 
the cons of each covariate adjustment strategy, with a focus on the quantification 
of changes in statistical power. We expressed the gain in statistical power in the 
decrease in the sample size that gives the same power as an unadjusted analysis.
Methods
Models and adjustment strategies
Cox proportional hazards models were used to analyze the effects of treatment on 
a time-to-event outcome (e.g. time to death). For simplicity, a single dichotomous 
baseline characteristic was considered as covariate to adjust the treatment effect. 
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We expected that our results were generalizable to more complex cases (i.e. more 
covariates included), as demonstrated by others 2, 5-7, 9, 11, 13, 22. The Cox model 
coefficients and standard errors (SE) were estimated with standard maximum 
likelihood procedures. 
We used three strategies for choice of covariates. The ‘adjustment’ strategy 
refers to a pre-specified adjusted analysis, which uses a known predictive covari-
ate. This strategy should be written in advance in the protocol. This leads to a 
stratified estimate of the treatment effect, which is also corrected for imbalance. 
‘Predictor p<5 percent’ refers to a strategy in which the predictive effect of a 
baseline characteristic can be used for adjustment if statistically significant using 
Pearson’s chi-square test (p<5 percent). The treatment effect was not included in 
this predictive model. The imbalance according to a baseline characteristic may 
also be used for adjustment if statistically significant (‘Imbalance p<5 percent’) 
16, 22. Statistically significant imbalance was based on Pearson’s chi-square test 
with 1 degree of freedom. 
Data and simulations
The various approaches to estimate the treatment effect were applied in different 
hypothetical data sets. We simulated RCTs of 200 patients, 100 randomized to 
treatment A and 100 to treatment B on average. Simulations were performed with 
20,000 repetitions when a treatment effect was truly present and 100,000 when 
no treatment effect was present (i.e. under the null hypothesis). 
In each simulation, survival times were generated from an exponential distri-
bution with hazard rate exp(γU + βV), where γ was the coefficient of the treat-
ment effect, β the coefficient of the covariate effect, U the random dichotomous 
value of treatment with 50 percent prevalence for treatment A on average and 
V the random dichotomous value of covariate at a given prevalence 7, 8. The 
coefficients (γ and β) are equal to the natural logarithm of the Hazard Ratio (HR) 
of the treatment effect and covariate effect, respectively. Censoring times were 
independently generated from an exponential distribution given a pre-defined 
censoring hazard rate and a randomly selected censoring prevalence (i.e. censor-
ing time = -log [1-(censoring prevalence)] /censoring hazard rate) during each 
simulation. The survival and censoring prevalences followed a uniform distribu-
tion.
Multivariable models were constructed using different covariate effects: No 
covariate effect (HR = 1), moderate covariate effect (HR = 2) and strong covari-
ate effect (HR = 5). Treatment effects varied from no treatment effect (HR = 
1), weak treatment effect (HR = 1.4) to mild treatment effect (HR = 1.7).  The 
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covariate prevalence (proportion of patients with a positive covariate value) was 
set at 50 percent and 10 percent. Three censoring levels were defined according 
to censoring hazard rates: No censoring (hazard rate 0), low level censoring (cen-
soring between 8 percent and 18 percent, corresponding to a censoring hazard 
rate of 0.22) 7 and high level censoring (censoring between 25 percent and 50 
percent, corresponding to a censoring hazard rate of 1). We repeated the analyses 
using sample sizes of 500 and 1000 patients. 
An example of one of the simulations with treatment HR of 1.7, 50 percent 
covariate prevalence, and no censoring is displayed in Figures 1a and 1b. We 
observe that the average treatment and placebo survival curves (Figure 1a)  are in 
between the survival curves fitted with the covariate with strong effect (HR=5), 
(Figure 1b).
Figure 1a: Average survival curves for the treatment (Tx) and placebo (Pl) 
arms in a hypothetical RCT (Treatment HR= 1.7, covariate HR=5, covariate 
prevalence 50% , No censoring, n=1000).
Evaluation
We studied the actual type I error (α) when there was no treatment effect, and 
power (1-β, where β indicates type II error) when there was a true treatment 
effect, in each of the strategies of covariate adjustment. Statistical significance 
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Results
Covariate prevalence 50 percent and no censoring
When there was no treatment effect, the type I error was rather similar in all ad-
justment strategies and with all covariate effects (Table 1). The type I error was 
mainly slightly below 5 percent, especially when the covariate effect was very 
was based on the Wald statistic (coefficient/SE) (16), with p-values < 5 percent 
considered significant. We expressed the gain in statistical power with adjusted 
strategies as the potential decrease in the required sample size that gives the 
same power of an unadjusted analysis. The formula of the potential reduction 
in sample size is shown in the Annex I 23. We report the results with the default 
significance level of 5 percent. We also explored the effects of applying a more 
liberal criterion for selection (p<20 percent). We used S-PLUS software (version 
2000, Insightful Inc, Seattle, WA, USA) for all calculations.
FIGURE 1b: Survival curves for the treatment and placebo arms in the same 
hypothetical RCT as Fig. 1a. The covariate (Cov) was included in the Cox model. 
The upper 2 curves correspond to each arm in the absence of the covariate. 
The lower 2 curves correspond to each arm in the presence of the covariate. 
The difference between the upper and lower curves corresponds to a HR=5.
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strong (3.8 percent for imbalance adjusted strategy at covariate HR=10). This 
conservative estimate implies that fewer false-positive effects were identified. 
When there was no covariate effect, covariate adjustment strategies on average 
did not change the treatment effect coefficients and slightly reduced the power 
and increased the required sample size (around 0.1 percent).
When there were treatment and covariate effects (Table 1), the pre-speci-
fied covariate adjustment (‘adjustment’) strategy yielded on average a more 
extreme treatment effect compared to no adjustment, as theoretically expected. 
Adjustment for one statistically significant predictor (‘predictor p<5 percent’) 
generated similar results to pre-specified adjustment since nearly always the pre-
specified covariate was a statistically significant predictor. Significant imbalance 
adjustment (‘imbalance p<5 percent’) on average generated coefficients smaller 
than both pre-specified and significant predictive coefficients and nearly similar 
to the unadjusted coefficients.
With both the pre-specified and the significant predictor strategies, power was 
higher than with unadjusted analyses. In contrast, power with the significant im-
balance strategy was only slightly increased. The increase in power was directly 
related to the strength of the covariate effect. A potential reduction in sample 
size was evident when pre-specified and significant predictor strategies were 
performed (between 15 percent and 44 percent, corresponding to covariate HR 
between 2 and 5) as shown in Table 1. The imbalance adjustment yielded smaller 
reductions (between 1 percent and 3 percent, covariate HR 2 to 5). 
Remarkably, we observed a similar reduction in sample size when different 
treatment effects were used given a certain covariate effect (e.g. 44 percent if 
treatment effect was weak and 43 percent if treatment effect was mild, with co-
variate HR=5). The potential reduction in sample size was similar in simulations 
with larger sample sizes (n=500, n=1000) and  when we considered p<20 percent 
instead of  p<5 percent as covariate selection limit. The same similarities were 
also found in all the following scenarios.
Covariate prevalence 50 percent and censoring 
Compared to covariate prevalence 50 percent and no censoring, the treatment 
effect coefficients and type I error were similar. In the same comparison, power 
was slightly reduced with all unadjusted and adjusted strategies with low level 
censoring, but moderately reduced with high level censoring (e.g. from 96 percent 
to 84 percent, with covariate HR=2, treatment HR=1.7, n=200). The potential 
reduction in sample size was similar with the pre-specified and significant pre-
dictor strategies (between 12 percent and 44 percent, covariate HR 2 to 5). There 
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Table 3. Summary of the percentage of reduction in sample size according to 
censoring, covariate prevalence and covariate effect.
was only a small reduction in sample size with the imbalance strategy (between 
1 percent and 3 percent, covariate HR 2 to 5). 
Covariate prevalence 10 percent and no censoring
Adjusted treatment effect coefficients had slightly higher values than the unad-
justed ones, in contrast to the situation with covariate distribution 50 percent and 
no censoring, where the difference was larger. Type I error was close to the nomi-
nal level, without important conservative estimates (Table 2). Power estimates 
of adjusted strategies were closer to the unadjusted power estimate, because of 
the similarity of unadjusted and adjusted treatment effects. Consequently, the 
potential reduction in sample size was lower with adjustment for pre-specified 
or significant predictor covariates (between 4 percent and 12 percent, covariate 
HR between 2 and 5) as shown in Table 2. The imbalance strategy reduced the 
sample size only slightly (between 0.4 percent and 0.6 percent). 
Covariate prevalence 10 percent and censoring
Compared to covariate distribution 10 percent and no censoring, the treatment 
effect coefficients were similar. Type I error was mainly slightly below 5 percent, 
without a clear relation among adjustment strategies. The power was slightly 
lower for all unadjusted and adjusted strategies with low level censoring, but 
mildly reduced with high level censoring. The potential reduction in sample size 
with pre-specified and significant predictive strategies was between 4 percent and 
           No Censoring           High level censoring 
 50% CP†     10% CP       50% CP       10% CP
 Moderate covariate
 effect  (HR =2)‡: 
   Adjustment/ Predictor p<5% 
   Imbalance p<5%
        15 
          1
        4 
        0.4
          12 
            1
           4 
           0.1
Strong covariate
 effect (HR =5): 
Adjustment/ Predictor p<5% 
   Imbalance p<5% 
44
          3 
      12 
        0.6 
 44 
           3 
         14 
           0.8 
† CP= covariate prevalence; ‡ HR= Hazard ratio. 
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14 percent (covariate HR 2 to 5). The imbalance strategy only slightly reduced 
the sample size (0.1 percent to 0.8 percent). Table 3 shows a summary of the 
potential reductions in sample size within plausible scenarios.
Discussion
Covariate adjustment yields a higher statistical power than an unadjusted analysis 
of a randomized controlled trial with time-to-event outcomes. In our study, the 
gain in power was translated into potential reductions in sample size, without 
inflation of the type I error. We used several approaches of covariate adjustment 
in simple simulated Cox models with different treatment effects, covariate ef-
fects, covariate prevalences and censoring levels. We found that pre-specified 
and significant predictor adjustment strategies, with covariate HR between 2 and 
5, yielded a potential reduction of sample size between 15 percent and 44 percent 
(covariate prevalence 50 percent) and between 4 percent and 12 percent (covari-
ate prevalence 10 percent). This reduction was greater if the covariate effect was 
higher. The reduction in sample size was independent of the treatment effect, 
sample size and censoring level. The significant imbalance adjustment strategy 
showed smaller potential reductions in sample size. There was very limited dam-
age when adjustment was used in the absence of a true covariate effect.
The use of covariate adjustment strategies has been previously studied in 
RCT with different outcomes: continuous 22, dichotomous 23, 24, and time-to-
event 7-9, 16. However, it is not known what truly constitutes the best strategy for 
covariate-adjusted analyses 22. The significant predictor, significant imbalance 
and predictor plus imbalance adjustment strategies were previously described 
by Beach and Meier in RCTs with time-to-event outcomes analyzed with Cox 
proportional hazards models 16. The imbalance strategy for one covariate yielded 
similar values of treatment effect than the predictive strategy, probably related to 
the low number of events or low predictive significance of the variable included 
in their example.  However, they did not give a clear recommendation about the 
most efficient strategy to perform covariate adjustment. Pocock et al. 22 described 
the pre-specified, significant predictor and significant imbalance adjustment 
strategies in RCTs analyzed with linear and non-linear regression models, and 
they advised to use pre-specified predictors in the analysis. Our results agree 
with this recommendation. We did not report the results of the combination of 
strategies (‘predictor and imbalance’ and ‘predictor or imbalance’) because they 
were similar to the significant imbalance and significant predictor strategies, 
respectively.
A potential problem of covariate adjustment when analyzing RCTs with Cox 
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models is that we may misspecify a prognostic variable (e.g. by categorizing 
a continuous variable or by linear modeling of a non-linear relationship). This 
situation produces deviations of the proportional hazards assumption and under-
stimation of the treatment effect 5, 10-15. This leads to a loss of power of the test 
of no treatment effect. In contrast, the misspecification of predictive covariates 
in linear models does not produce biased estimates of the treatment effect. It 
however leads to a loss of precision of the estimate 3, 5. Consequently, the recom-
mendation to adjust for a predictive covariate in Cox models is based on really 
different arguments than in the classical linear models 6, 10.
We found that type I error was maintained closely below to the nominal level 
with the pre-specified and predictive adjustment strategies, using the Wald test. 
Li 7 found type I error values very close to the nominal level of 5 percent in 
the context of the covariate-adjusted Cox score test. The imbalance adjustment 
strategy was conservative, since this strategy constrains the outcome variability 
between treatment groups 22.  We also confirmed that there was only a small 
loss in power when adjustment was used in the absence of covariate effect, as 
suggested by others 7, 9, 22, 25. Further, we quantified a substantial gain in power 
when a strong predictive covariate was included in the Cox model, especially 
with 50 percent covariate prevalence and independently of censoring. 
We expressed the gain in statistical power as a potential reduction in the 
required sample size. The potential reductions in sample size with pre-specified 
and significant predictor strategies were moderate (between 12 and 44 percent) in 
plausible scenarios (treatment HRs between 1.4 and 1.7, covariate HRs between 
2 and 5 [Spearman’s correlation between 0.29 and 0.57], covariate prevalence of 
50 percent). The imbalance strategy yielded lower reductions (below 3 percent). 
With 10 percent covariate prevalence, the reductions in sample size were below 
13 percent in the pre-specified/predictor strategies, and below 1 percent in the 
significant imbalance strategy. Furthermore, censoring levels in RCT popula-
tions in some medical fields are high (e.g. Oncology). Remarkably, the proposed 
potential reduction in sample size in the high level censoring situation was similar 
to the no or low censoring scenarios. Hence, censoring was not relevant to the 
choice of adjustment strategy. 
Moreover, the potential reduction in the sample size was independent of the 
treatment effect. We used treatment effects (HRs 1.4 and 1.7) in the range sug-
gested in simulations by others (range of treatment effects HRs from 1 to 2.7) 
2, 5-7, 16 and similar to the treatment HR of some recently published RCTs in 
Oncology and Cardiology, which range from 1.1 to 1.5 18-21. Different sample 
sizes of the simulated RCTs did not change the benefit in the potential reduction 
in sample size, as suggested previously 22. Nevertheless, low covariate prevalence 
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(10 percent) yielded lower reductions in sample size. The stability of the potential 
reduction of sample size calculations in common clinical scenarios makes it an 
attractive summary measure to express the benefit of adjustment strategies, as 
was suggested in RCTs analyzed with logistic models 23.
Reductions in sample size given a covariate effect are not directly comparable 
between a RCT with dichotomous outcomes 23 and a RCT with survival outcomes, 
using covariate prevalence of 50 percent and no censoring. Values of Odds Ratios 
(OR) and HR are related to each other through the formula: OR= HR*(p2/p1), 
where p2 is the survival in the covariate group with the best prognosis and p1 is 
the survival in the covariate group with the worst prognosis (see Annex II). So, 
a given value of HR corresponds to a higher OR. For example, a reduction of 
sample size of 16 percent can be achieved after adjustment for a covariate effect 
with HR = 2. A comparable reduction of sample size (14 percent) can be obtained 
after adjustment for a covariate effect with OR = 5 ref. 23. Conversely, for the 
same numerical values of OR and HR (e.g. 2), we obtained reductions in sample 
size after adjustment of 3 percent and 16 percent, respectively. 
We did not present calculations for covariate adjusted sample size in RCT de-
sign. To quantify any anticipated sample size gains with covariate adjustment, we 
would need to specify covariate effects and covariate distributions. In practice, 
the study would then have to meet these assumptions to achieve the calculated 
power. Therefore, we advise to perform an unadjusted sample size calculation, 
which needs fewer assumptions. The actual analysis will have more power if the 
pre-specified or significant predictor strategy is followed.
The role of covariate adjustment in nonlinear analyses of randomized con-
trolled trial is a matter of debate 3, 13, 22, 24. Hauck et al. recommended that 
the primary analysis should be adjusted for important prognostic covariates in 
order to come as close as possible to the clinically most relevant subject-specific 
measure of treatment effect 3. However, this practice is not common 22. Further, 
Chastang et al. also noted that if important differences are found between un-
adjusted and adjusted analyses, it is probably preferable to base inference on 
the latter 13. However, a recent survey indicated that the number of trials with 
a difference between adjusted and unadjusted analyses sufficient to affect the 
conclusions is very low 22. The importance to pre-specify the covariates to adjust 
for has been also highlighted 3, 13, 22, 26.  Nevertheless, this recommendation 
may be unrealistic because prognostic covariates might not be available in the 
study design stage. Despite of the criticisms about their data-driven nature and 
potential for manipulation, variable selection procedures may have a useful role 
on formulating covariate adjustment, especially in large trials 22, 26. Further, the 
variable selection procedures may be applied to select covariates in a way that 
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does not affect the type I error for the test for no treatment effect 26.  
Finally, if a covariate is not predictive of an outcome, a statistically significant 
imbalance of this covariate is irrelevant 22. What it is useful is to adjust for predic-
tive covariates,  independently of their imbalance status. Thus, some researchers 
have suggested the use of a limited number of pre-specified, prognostic covari-
ates, and the avoidance of the assessment of  and the adjustment for imbalance 
22-25. 
Our work has several limitations. We only included results of simulations with 
plausible covariate and treatment effects and not real data. We only considered 
covariate prevalences of 10 percent and 50 percent. Nevertheless, results with 
covariate distribution of 90 percent are rather similar to results of covariate dis-
tribution of 10 percent 5, 12. We did not study the effect of covariate adjustment 
using a continuous covariate. We used the Wald test for statistical significance, 
although the Likelihood Ratio test may yield statistically more appropriate re-
sults. Also, we did not address the consequences of covariate adjustment when 
more than one covariate is available. If we had ten covariates, five of them were 
predictive and five were not but allowed the choice to vary randomly from simu-
lation to simulation, then a strategy of pre-specification would work less well. A 
selection procedure, e.g. stepwise backward elimination, might be considered to 
choose a limited number of the covariates, but the effects of this procedure would 
require further study. Edwards 26 has suggested a method of blinded selection of 
covariates, in which a family of possible models and a model selection criterion 
are pre-specified.
We recommend use of the adjusted analysis in time-to-event RCTs because 
we obtained more appropriate treatment effects (corrected for imbalance, indi-
vidually oriented), a higher power than the unadjusted effects and consequently 
a reduction in sample size. The best strategy of covariate adjustment should be 
pre-specified adjustment if a strong predictive covariate is known before the RCT 
analysis 7, 9, 22. An alternative is to use the significant predictor strategy, when 
a strong predictive covariate is not known. The analysis of RCTs with time-to-
event outcomes should adjust for predictive covariates.
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Annexes
I. Deduction of the Reduction in Sample Size (RSS) formula
In the context of a RCT, we defined nu and na as the unadjusted and adjusted 
sample sizes respectively, Zα is Z value at α =0.05, Zβu is the Z value of the 
unadjusted power 1-βu, Zβa is the Z value of the adjusted power 1-βa, Zu is the 
mean standardized Z score of the estimated unadjusted coefficient defined as 
coefficient /SE for each simulation, and, Za is the mean standardized Z score of 
the estimated adjusted coefficient defined as coefficient /SE for each simulation.
We expressed any increase in statistical power of the adjusted analysis as the 
decrease in the sample size that gives the same power of an unadjusted analysis 
(i.e. Zβu = Zβa ). This assumption gives approximately:
 na / nu = ( Zu / Za )2      (1)
The potential reduction in sample size (RSS) between unadjusted and adjusted 
strategies is expressed in percentage as:
 [(nu – na )/ nu ]*100  ,  or  
 100 – [100*(na /nu )]      (2)
Replacing (1) in (2):
              RSS = 100 – 100* ( Zu / Za )2                             (3)
II. Relation between Hazard Ratio (HR) and Odds Ratio (OR)
Let us consider a randomized controlled trial with survival outcomes, one di-
chotomous covariate, covariate prevalence of 50 percent and no censoring. Each 
covariate group has different prognosis, according to its baseline characteristics. 
Survival curves of each covariate group (group 1 and group 2) go from time t0 
until time t1 (t1>t0). The survival proportions at t1 are p1 (group 1) and p2 (group 
2). The number of patients is the same for each covariate group (n=n1=n2).
Let us assume that group 1 has worse prognosis and that the hazard rates (h) 
are constant from t0 until t1. So, the h for each covariate group (g1 and g2) are 
defined as:
           
h1= (number events g1)/(total follow-up1) = [(1-p1)*n1]/ t1*n1 = (1-p1)/t1 
     
h2= (number events g2)/(total follow-up2) = [(1-p2)*n2]/ t1*n2 = (1-p2)/t1 
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The hazard ratio (HR) of the covariate (g1 vs. g2) is defined as:
           HR = h1/h2 = [(1-p1)/t1]/[ (1-p2)/t1] = (1-p1)/(1-p2)              (4)
At time t1, the Odds Ratio (OR) of  death of g1 vs. g2 is defined as:
           OR = [(death g1)*(alive g2)]/ [(death g2)*(alive g1)] = 
[(1-p1)*p2]/[(1-p2)*p1]                 (5)
Then, replacing (4) in (5), we have:
           OR = HR* (p2/p1)                  (6)
which implies that OR is always larger than HR in this particular situation. 
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ABSTRACT
We aimed to describe current reporting of uses of patient baseline character-
istics (baseline comparability, covariate adjustment, and subgroup analysis) in 
randomized controlled trials (RCTs), and to determine whether reporting viola-
tions decreased since the introduction of the revised CONSORT (Consolidated 
Standards of Reporting Trials) statement. Main reports of phase III RCTs with 
more than 100 patients, published in high impact factor clinical journals between 
September 1 and November 30, 2002 were used. Our main outcome measure was 
the appropriateness of reporting of baseline comparability, covariate adjustment 
and subgroup analysis. We identified 84 RCTs (general medicine=46, cardiol-
ogy=21 and oncology=17). Remarkably, 34 RCTs (40%) tested baseline imbal-
ances, which is methodologically unjustified. Forty-four RCTs (52%) performed 
covariate adjustment as the primary analysis, and they used mainly predictive 
covariates. Of these, 30 RCTs gave more emphasis to the adjusted analysis. 
Forty-seven RCTs (56%) reported subgroup analyses. Appropriate statistical 
interaction tests were used in only 20 of these trials, while subgroup differences 
were emphasized in 22. Adherence to methodological standards was not better in 
CONSORT adopting journals. Inappropriate analyses of baseline characteristics, 
especially subgroup analyses, are still frequent. Recommendations on appropriate 
reporting need to be further implemented in current practice, since conclusions 
of RCTs may be misleading otherwise.
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Introduction
In the current era of evidence-based medicine, randomized controlled trials 
(RCTs) are the key to guide clinical decision making 1. Adequate reporting of 
RCTs provide clinicians with valuable information that helps them to accept or 
reject treatments or interventions, and, therefore, to improve their practice 2. 
Several patient characteristics are usually recorded at inclusion. These baseline 
characteristics may serve several purposes, including demonstration of balance 
between treatment groups (baseline comparability) 3, and implementation of 
more elaborate analyses (such as covariate adjustment and subgroup analyses) 
4.
The revised recommendations of the Consolidated Standards of Reporting 
Trials (CONSORT) statement has condensed some appropriate and inappropriate 
uses of baseline characteristics in RCTs (Table 1) 5, 6. Baseline characteristics 
among trial arms should be displayed without testing for imbalances, since these 
are the product of chance if a proper randomization method was followed 5. 
Important covariates might be used for covariate adjustment. Such adjustment 
should be pre-specified, and be focused on a limited number of covariates. The 
reasons for choosing covariates should be clearly described 7. Likewise, sub-
group analyses should be pre-specified and be restricted to a small number of 
subgroups. Interaction tests should be applied when differences in treatment ef-
fect are claimed. Subgroup analyses should generally be considered as secondary 
analyses 4, 7.
The reporting of the use of baseline characteristics in RCTs has been found 
inappropriate: overuse of baseline comparisons, misuse of significance tests 
for baseline comparisons, inconsistencies in the use of covariate adjustment, 
underuse of tests of interactions, and overinterpretation of subgroup analyses 
7. These problems were demonstrated in RCTs from general medical journals 
during the past two decades 4, 8, 9. The use of the revised CONSORT statement 
led to improvements in the quality of reporting 10, 11, but whether the reporting of 
the use of baseline characteristics has also improved has not yet been evaluated. 
Moreover, the quality of reporting on RCTs may be better in general medical 
journals than in specialist journals 12. 
We studied adherence of the reporting of baseline data in RCTs to method-
ological standards. Secondarily, we studied differences between CONSORT-
adopting and non-adopting journals, and explored differences according to type 
of journal and overall result. 
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Methods
Selection of clinical trial reports
We handsearched RCTs from 16 journals with the highest Impact Factor in their 
categories (general medicine, cardiology, and oncology), published between 
September 1 and November 30, 2002. This period was arbitrarily chosen, and 
the 3-month period resembled the one used in a previous study 4. The journals 
were at the top of the list in their respective subject category (ISI Journal Citation 
Reports 2002) and published RCTs regularly. 
General medicine journals were N Engl J Med, JAMA, Lancet, Ann Intern 
Med, BMJ, and Arch Intern Med. Cardiology journals included Circulation, J 
Am Coll Cardiol,  Eur Heart J, Am Heart J, and Am J Cardiol. Oncology  jour-
Topic
Revised
CONSORT 
Item
Appropriate Inappropriate
Baseline
comparability 
15 Describe comparison of
  baseline characteristics
  between arms. 
Do not show p values in
  table 1.
Test for imbalance of baseline  
  characteristics between arms. 
Show p values in table 1.
Covariate
adjustment 
       12, 18 Adjust for a limited number    
  of covariates. 
State clearly the reasons to    
  choose covariates. 
Examine many models and  
  discuss only the model with  
  the largest treatment effect. 
Do not state the reasons to
  choose covariates. 
Subgroup
analysis 
12, 18 Perform a limited number of  
  pre-specified subgroup
  analyses. 
Use interaction tests. 
Consider as secondary
  analyses.
Perform a large number, post  
  hoc subgroup analyses. 
Use separate group p values. 
Consider as important as or  
  more important than primary  
  analysis
RCTs denotes randomized controlled trials; CONSORT denotes Consolidated Standards of 
Reporting Trials. 
Table 1. Appropriate and inappropriate use of baseline characteristics in RCTs, 
according to the revised CONSORT statement.
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nals included J Nat Cancer Inst, J Clin Oncol, Cancer, Brit J Cancer, and Eur J 
Cancer. We included main reports of phase III parallel RCTs, with individual 
randomization 13, and excluded cross-over trials, cluster-randomized trials, 
equivalence/non-inferiority trials, trials with less than 50 patients per arm, and 
factorial trials 7, 14. We excluded secondary trial reports designed to address 
additional hypotheses and subgroup comparisons specifically.
Assessment of trial reports and definitions
We examined RCTs and collected information in standard formats. Information 
about reporting of background information, baseline comparability, covariate 
adjustment and subgroup analyses was similar to a previous study 4 (Table 2). We 
measured the correspondence between the reporting of uses of baseline charac-
teristics and methodological standards (Table 1). Our main outcome measure was 
the appropriateness of reporting of baseline comparability, covariate adjustment 
and subgroup analysis.
For consistency of evaluation across RCT reports, one of us (A.V.H.) selected 
the RCTs, checked inclusion and exclusion criteria and collected the information. 
To examine the reproducibility of the information, another reviewer (E.W.S.) 
also assessed the RCTs while blinded to the initial assessments. We found small 
differences in the extracted data, which were resolved by consensus.
An interaction test directly assesses differences in treatment effect between 
complementary subgroups and involves one statistical test irrespective of the 
number of subgroups. A significant interaction test means that the treatment ef-
fect in one subgroup is different from the treatment effect in the other subgroup. 
In contrast, the separate subgroup p value method assesses treatment effects in 
each group independently, which is inappropriate from a methodological point 
of view 5. 
Secondary analyses
We compared baseline use between RCTs from journals which adopted the 
CONSORT statement (JAMA, Lancet, Ann Intern Med, BMJ, Arch Intern Med, 
J Nat Cancer Inst, Eur J Cancer) and journals which did not (N Engl J Med, 
Circulation, J Am Coll Cardiol, Am Heart J, Am J Cardiol, J Clin Oncol, Brit J 
Cancer) 15. Our focus was on baseline data (revised CONSORT item 15), covari-
ate adjustment and subgroup analyses (revised CONSORT items 12 and 18). We 
hypothesized that CONSORT-adopting journals would report these issues better 
than non-adopting journals 10, 11. 
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Background information 
     Number of patients 
     Number of treatment arms 
     Length of follow-up 
     Number of centers 
     Primary outcome 
Baseline comparability 
     Number of baseline characteristics 
     Use of significance tests 
     Number of imbalances reported  
     Reporting of p values in table of baseline characteristics (“Table1”) 
Covariate adjustment 
     Pre-specification
     Number of covariates 
     Selection strategy (e.g. prognostic, center, imbalanced, etc) 
     Statistical method 
     Primary use of covariate adjustment 
     Emphasis of adjusted analysis with respect to unadjusted analysis 
     General judgement  
Subgroup analyses 
     Pre-specification 
     Number of subgroup factors 
     Number of subgroup outcomes 
     Number of subgroup analyses (product of factor by outcomes) 
     Statistical method (interaction test/separate subgroup p value) 
     Claiming of subgroup effects  
     Emphasis of subgroups effects with respect to overall effect 
     General judgment 
       RCT denotes randomized controlled trial. 
Table 2. Data collected from RCT reports
The baseline use between RCTs published in general medicine journals and 
those in specialty journals (cardiology and oncology) was also compared. The 
reporting of baseline characteristics would be better in general medicine jour-
nals than specialty journals, based on a recent paper comparing the quality of 
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reporting (12). Finally, we searched whether covariate adjustment and subgroup 
analyses were related to the overall trial results (positive or negative). A posi-
tive trial reports a statistically significant treatment effect. Negative RCTs might 
report covariate adjustment and/or subgroup analyses more frequently 7. 
Statistical analyses
Differences between continuous variables were compared with t-tests or Mann-
Whitney U tests. Categorical variables were tested with Chi-square tests 16. We 
used tests for trend (one degree of freedom) for testing differences in time and 
differences in ordered variables. Statistical significance was defined as p<0.05. 
The software used was EXCEL and SPSS 10.0 (SPSS Inc., Chicago, USA, 
1999).
Results
General characteristics of trial reports
Eighty-four RCTs were chosen from 14 journals (46 in general medicine, 21 in 
cardiology and 17 in oncology journals) 17, 99. They included 44 treatment, 27 
management, 11 prevention, and 2 screening RCTs. One N Engl J Med paper 
reported two trials 97. Reasons for exclusion were: phase II trials (n=5), substud-
ies (n=23), cross-over trials (n=1), equivalence/non-inferiority trials (n=6), small 
trials (n=25) and factorial trials (n=8). The RCTs mainly had 2 arms (n=68). The 
number of patients per RCT ranged from 103  to 266,064 (median 505) 26, 62, and 
76 RCTs were multicentric (range 2 to 519, median 15 centers). The follow-up 
time ranged from 3 days to 11 years (median 1 year). 
Baseline comparability
Fifty-five RCTs (65 percent) presented comparability of 10 or more variables 
(range 0 to 31) (Table 3). Thirty-four tested for baseline differences, and 9 noted 
baseline imbalances. There were 11 significant imbalances at p<0.05, with a total 
of 145 reported tests (7 percent of tests). 
Covariate adjustment
Covariate adjustment was reported in 44 (52 percent) RCTs, using mainly 
logistic or Cox regression analyses. The RCTs included between 1 and 12 base-
line characteristics (Table 4). When both adjusted and unadjusted results were 
given (n=24), covariate adjustment did not alter the conclusions of the unadjusted 
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analyses, and unadjusted analyses received more emphasis (n=14). Twenty RCTs 
only gave adjusted results. Eight RCTs with covariate adjustment did not state 
any reason to choose a covariate. Half of the adjusted analyses (22 out of 44) were 
motivated by prognostic characteristics, which we consider appropriate. 
Subgroup analysis
Forty–seven (55 percent) RCTs reported subgroup analysis, which were fully 
pre-specified in 22 (Table 5). The median number of subgroup factors was three 
(range 1 to 23). Twenty-three RCTs used more than two outcomes. Sixteen and 
six RCTs performed ≥12 and ≥25 subgroup analyses, respectively. Only 20 RCTs 
used the appropriate tests of interaction. Overall, 40 significant subgroups were 
found among 482 tests performed (9 percent), and 16 significant results among 
235 reported interaction tests (7 percent). Twenty-two RCTs overemphasized the 
subgroup findings. 
n=84 %
Number of baseline characteristics 
compared in “table 1” 
0
1 to 4 
5 to 9 
10 to 19 
20 to 29 
30 or more 
  1 
  3 
25
36
15
  4 
  1 
  4 
 30 
 43 
       18 
  5 
Significance tests for baseline 
differences? 
 Number of trials that performed tests 
 Significant imbalance per trial 
 Number of significance tests 
 Significant imbalance per test 
34
  9 
      145
        11 
41
26
  7 
Table 3. Reporting of comparability of baseline chracteristics
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Secondary analyses
The use of baseline characteristics was slightly better in CONSORT-adopting in 
comparison with non-adopting journals: testing for imbalances (13/36 vs. 18/48), 
reporting of covariate adjustment (16/36 vs. 28/48), number of subgroup analyses 
(median 5 vs. 9), and use of interaction tests (11/25 vs. 9/22). Although reporting 
of subgroup analysis was more frequent in CONSORT-adopting journals (25/36 
Table 4. Reporting of covariate adjustment in 44 clinical trials.
n=44 %
Which analysis received more emphasis? 
Unadjusted
Adjusted
Equal emphasis 
14
20
10
32
45
23
Number of covariates 
1
2
3
4
5 to 9 
10 or more 
Unclear
  8 
  4 
  7 
  6 
10
  1 
  8 
18
  9 
     16 
     14 
23
  2 
10
Reasons for choice of covariates*
No reason given 
Covariates were/expected to be prognostic 
    Were prognostic (tested) 
    Were expected to be (pre-specified) 
Imbalances between groups 
Center or country 
Baseline value of quantitative outcome 
Other treatment factor in a factorial trial 
Covariates used in stratified randomization
  8 
22
  6 
16
  5 
12
  8 
NA
  8 
18
50
14
36
11
27
18
18
              * more than one reason in some trials. 
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Table 5. Reporting of subgroup analysis in 47 clinical trials.
n=47       %
Number of baseline characteristics
1 to 3 
4 to 6 
7 or more
29
  9 
  9 
62
19
19
Number of outcomes for subgroups
1 or 2 
3 to 5 
6 or more
24
17
  4 
51
36
13
Total number of subgroup analysis 
1 to 2 
3 to 5 
6 to 8 
9 to 11 
12 to 24 
25 or more
  8 
12
  4 
  7 
10
  6 
17
26
  9 
15
21
13
Statistical method used
Descriptive only 
Subgroup p values 
Interaction test 
  0 
25
20
0
53
43
Subgroups differences claimed?
Yes
No
22
25
47
53
Subgroup findings overemphasized?
Yes
No
20
27
43
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vs. 22/48; p=0.03), it was mainly pre-specified (14/25 vs. 8/22).
RCTs from general medicine and cardiology journals compared more base-
line characteristics than oncology journals (≥ 10 characteristics: 67 percent 
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vs. 90 percent vs. 29 percent; p=0.03). Reporting of other aspects of baseline 
comparability, covariate adjustment, and subgroup analysis was similar among 
specialties. 
Negative and positive trials reported covariate adjustment in similar frequency 
(22/39 vs. 22/45), as well as subgroup analyses (22/39 vs. 25/45). Negative trials 
reported post-hoc subgroups more frequently (15/22 vs. 10/25), but tended to 
use a lower number of subgroups than positive trials (median 7 vs. 9). Subgroup 
differences were claimed in similar frequency in both groups (10/22 vs. 12/25). 
These differences were not significant.
Discussion
Despite the introduction of the revised CONSORT statement and publication of 
a number of methodological papers 4, 9,  the reporting of baseline comparability, 
covariate adjustment and subgroup analysis was not appropriate in RCTs from 
top journals. A third of the 84 RCTs tested for baseline imbalance, which has 
no methodological justification 4, 5. From the 47 RCTs that performed subgroup 
analyses, half were pre-specified, and only 43 percent used the appropriate inter-
action tests. 
The first CONSORT statement suggested that appropriate reporting of de-
sign, conduct, and analysis of parallel RCTs should enable the reader to make 
informed judgements regarding the internal and external validity of the trial 100. 
The revised CONSORT statement sharpened these recommendations further 5, 
6. The adoption of the first CONSORT guidelines led to improvements in quality 
of reporting 10, 11. We provide empirical evidence that, after the introduction of 
the revised CONSORT statement, reporting of baseline comparisons, covariate 
adjustment and subgroup analysis is still a problem. 
Baseline comparisons increased over time. A previous review of 80 RCTs 
published in 1987 in Ann Intern Med, BMJ, Lancet,and N Engl J Med showed 
that 39 percent of the RCTs compared ≥10 baseline characteristics 9. In 1997 
these comparisons were found in 62 percent (31 out of 50) of the RCTs 4, and we 
found 65 percent (55 out of 84) in 2002. A review of 206 RCTs from 10 surgi-
cal journals, published between 1997 and 1999, found that only one-third tested 
baseline differences 101. 
The proportion of significant tests for baseline differences was around the 5 
percent expected by chance. Testing for baseline differences is inappropriate, 
and without practical value, especially if multiple variables are compared 3, 8. 
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Covariate adjustment is especially advantageous when strong predictors are 
used 106, 108, 109. Prognostic covariates were preferentially used in the reviewed 
RCTs.  For example, the SoS investigators properly adjusted for five pre-specified 
prognostic characteristics (age, angina grade, diabetes mellitus, ejection fraction, 
and angiographic severity) 84. However, a fifth of RCTs did not specify the number 
of covariates, or whether adjustment changed the conclusion of the unadjusted 
analysis. Recommendations to perform covariate adjustment include the use of a 
limited number of pre-specified, prognostic covariates, and the avoidance to use 
non-prognostic, imbalanced covariates 4, 6, 106, 109. Pre-specification aims to pre-
clude that investigators perform multiple analyses before arriving at the “final” 
set of adjustment variables that best support their conclusions 110. However, the 
choice of prognostic covariates and the emphasis on adjusted analyses has not 
been fully agreed upon. Reviewers may sometimes have suggested to adjust for 
baseline variables that may be important, but were over-looked by the authors.
Subgroup analysis was overused and overinterpreted. Examples are easy to 
find in cardiology journals, where authors searched subgroups effects in separate 
publications intensively (e.g. pravastatin, metoprolol and estrogen/progestin tri-
als) 111-114. This may be  related to the fact that investigators re-analyze data in 
response to findings from other studies, and suggestions from reviewers to ex-
amine additional subgroups. Likewise, the total number of subgroups evaluated 
was high. For instance, among the reviewed reports, 4 RCTs reported between 28 
and 33 subgroups 44, 47, 71, 82. As expected, some did not succeed 44, 47, and some 
found subgroup effects and claimed differences 71, 82. Subgroups effects were 
usually consistent with the overall trial results 9, 115. Importantly, only 22 out of 
47 reported pre-specified subgroups, and probably the majority were post-hoc 
subgroups 116, 117. 
Interaction testing is the appropriate method to analyze subgroups 7, 118, 119, 
but it was amazingly underutilized in trial reports (only 20 out of 47). However, 
the power of the interaction test is low 118-120. In a trial with 80 percent power for 
the overall effect, the interaction test only has at most 29 percent power to detect 
an interaction effect of the same magnitude of the overall effect 119. For smaller 
interactions effects or unequal distribution of covariates, its power is even more 
limited. In our review, only 7 percent of the interactions tests yielded significant 
results. This finding suggests that substantial true interactions are rare. Moreover, 
RCTs of a size adequate to detect an overall effect cannot be expected to provide 
reliable effect estimates within smaller groups 118. For example, for interactions 
of the same size and the same power of the overall effect, sample sizes should at 
least be inflated fourfold 119.  
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The evaluation of treatment effects in separate groups is misleading since 
false positive subgroup effects can often be found 118-121. Subgroup-specific tests 
are unreliable: A significant effect in one subgroup can be observed in 7 to 64 
percent, depending on trial characteristics 119. This problem worsens when post-
hoc subgroups and multiple comparisons are performed 4, 116, 118. For example, 
one RCT evaluated the effect of antiplatelet therapy following percutaneous 
coronary intervention in the composite end-point of death, myocardial infarction 
or stroke 69. The authors used 3 baseline factors (gender, diabetes, acute coronary 
syndrome) and 10 outcomes, used separate subgroups, and found 5 significant 
subgroups among 60 tests. Likely, some of these subgroup effects are the product 
of chance.
Subgroups therefore should not be overinterpreted, and should be reported 
with caution. A recent RCT and its editorial stressed the finding that vasopressin 
was more effective than epinephrine for cardiopulmonary resuscitation only in 
asystolic patients, and claimed a change in treatment guidelines in these patients 
122, 123. This seems an overinterpretation. Subgroup findings must be replicated 
in other populations before they are accepted, even if an interaction test is sig-
nificant in a limited number of subgroups. For example, the PRAISE II trial 124 
could not replicate the subgroup effect found in the PRAISE trial 125, which 
showed a beneficial treatment effect of amlodipine in a subgroup of patients with 
nonischemic heart failure. Subgroups should also be interpreted in the context 
of known biological mechanisms and patient prognosis 116, 117. Thus, some re-
searchers consider it reasonable to rely only on main effects 119. This reasoning 
is supported by the finding of only 9 percent of significant subgroups among the 
482 assessed, and 7 percent significant results of 235 interaction tests.
A previous paper found that RCTs from CONSORT-adopting journals 
(JAMA, Lancet, BMJ) were reported significantly better than those from a non-
adopting journal (N Engl J Med) 10. Another paper showed that reports from 10 
CONSORT-adopting journals improved the presentation of 11 methodological 
factors (including description of prognostic baseline characteristics) in compari-
son with 16 non-adopting journals 11. However, these two papers evaluated the 
adoption of the first CONSORT guidelines 100. We found no differences accord-
ing to the CONSORT adoption. This finding may be related to the fact that we 
included RCTs from late 2002 only, a year and a half after the publication of the 
revised CONSORT guidelines. Moreover, editors and reviewers of RCTs may 
be aware of the CONSORT guidelines, and may apply them informally in their 
practice. Thus, less differences in reporting can be expected. 
We noted few differences in trial reporting between general medicine and 
specialty journals. A previous paper found subgroup analysis in 58 of 67 (87 
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percent) cardiology RCTs (n>1000) published between 1980 and 1997, addressing 
unstable angina, myocardial infarction, left ventricular dysfunction and conges-
tive heart failure 126. Only 24 RCTs had fully pre-specified subgroups, and 27 
reported interaction tests. These reporting deficiencies have the same direction 
as our findings. 
Our study has some limitations. First, we reviewed a limited number of RCTs 
(n=84), although this number is larger than in two previous studies (38 and 50, 
respectively) 4, 8. This aspect may not affect the general conclusions on reporting, 
but it makes comparisons between CONSORT adoption, among types of journal, 
and between overall results of limited power. Second, the information provided 
in an RCT may not necessarily be the same as what was planned in the study 
protocol 127. Finally, it is possible that the influence of the CONSORT guidelines 
on reporting requires more time to be adopted 10. 
 In conclusion, the reporting of baseline characteristics in RCTs from 
highly influential journals can be improved considerably. Despite the introduction 
of the revised CONSORT recommendations, a number of important problems re-
main, particularly with regard to testing for imbalance, the use of large numbers 
of subgroup analyses, the underuse of interaction tests, and the overinterpretation 
of subgroup effects. The CONSORT guidelines may need to further emphasise 
appropriate reporting recommendations of subgroup analysis, since conclusions 
of RCTs may be misleading otherwise.
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ABSTRACT
Background: Treatment decisions in clinical cardiology are directed by results 
from randomized clinical trials (RCTs). We studied the appropriateness of the 
use and interpretation of subgroup analysis in current therapeutic cardiovascular 
RCTs.
Methods: We reviewed main reports of phase III cardiovascular RCTs, with 
at least 100 patients, published in 2002 and 2004, and from major journals 
(Circulation, JACC, Am Heart J, Am J Cardiol, N Engl J Med, Lancet, JAMA, 
BMJ, Ann Intern Med). Information on subgroups included: pre-specification, 
number, interaction test use, significant subgroups found, and emphasis on 
findings. We examined appropriateness of reporting, and differences according 
to sample size, overall trial result, and CONSORT (Consolidated Standards for 
Reporting of Trials) adoption.
Results: We selected 63 RCTs, with a median of 496 patients (range: 100–15245). 
Thirty-nine RCTs were reported with subgroup analyses, and 26 with >5 sub-
groups. No trial was specifically powered to detect subgroups effects, and only 
14 RCTs were reported with fully pre-specified subgroups. Only 11 RCTs were 
reported with interaction tests. Furthermore, 21 RCTs were reported with claims 
of significant subgroups, and 15 with equal or more emphasis to subgroups than 
to the overall results. Subgroup analyses in large RCTs (>500 patients) were 
reported more often than in small ones (24/30 vs. 15/33; P=0.005). No differ-
ences were found according to overall result (positive/negative) or CONSORT 
adoption.
Conclusions: Subgroup analyses in recent cardiovascular RCTs were reported 
with several shortcomings, including a lack of pre-specification, and testing of a 
large number of subgroups, without the use of the statistically appropriate test for 
interaction. Reporting of subgroup analysis needs to be substantially improved, 
since emphasis on these secondary results may mislead treatment decisions.
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Introduction
Treatment decisions in clinical cardiology are driven by results from randomized 
clinical trials (RCTs). As the number of drugs, devices, and treatment strategies 
has proliferated during the last two decades, so have the trials evaluating them 
1. Indeed, some of these RCTs have provoked major changes in clinical practice 
(e.g. GISSI-1 2, SOLVD 3, 4S 4, NINDS 5, MERIT-HF 6, SIRIUS 7). 
A result of a RCT represents the effect of a particular intervention in an ‘aver-
age’ patient. However, clinicians treat individual patients with complex combina-
tions of characteristics 8. Thus, RCT results may not directly be applicable to one 
patient. Therefore, many investigators are interested to know treatment effects in 
specific subpopulations of patients (‘subgroup analysis’) 9. Subgroups are based 
on patient characteristics measured before randomization 10. Treatment effects in 
subgroups might offer clinicians more insight into treating individual patients. 
Main RCT reports or separate publications have investigated effects of treat-
ments in subgroups. For instance, a substantial number of separate publications 
have given special attention to gender subgroups in acute coronary syndromes 
11-14 or heart failure 15-17. Usually the overall treatment effect was consistent 
with that in subgroups. However, differential subgroup effects may be identified 
by chance, because multiple tests are performed in many subgroups, and by the 
use of inadequate methods 8, 10, 18. 
Even though subgroup analyses are popular and occupy a large number of 
pages in the cardiovascular literature, little attention has been directed to their 
adequate reporting and interpretation. We aimed to review the appropriateness 
of reporting of subgroup analysis in RCTs recently published in major cardiology 
and internal medicine journals. 
Methods
Selection of RCT reports
We handsearched therapeutic cardiovascular RCTs from journals with high 
impact factor in the ISI Journal Citation Report 2002 (categories cardiology 
and general internal medicine). Cardiology journals included Circulation, J Am 
Coll Cardiol, Am Heart J, and Am J Cardiol. General internal medicine journals 
included N Engl J Med, Lancet, JAMA, Br Med J, and Ann Intern Med. Two 
periods of 3 months were arbitrarily chosen: September 1 to November 30 2002, 
and May 1 to July 31 2004. 
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Therapeutic RCTs included interventions such as drugs, devices or therapeutic 
strategies. The diseases included acute coronary syndromes, left ventricular dys-
function, heart failure, arrhythmia, cardiac valve disease, hypertension, stroke, 
atherosclerosis of peripheral arteries (carotid, renal, lower limb), pulmonary 
emolism and venous thromboembolism, venous insufficiency, diabetes mellitus, 
and hypercholesterolemia. We included main reports of phase III parallel RCTs, 
with individual randomization, and we excluded cross-over trials, cluster-ran-
domized trials, equivalence/non-inferiority trials, factorial trials, and trials with 
less than 100 patients. Because it was not the focus of our review, we excluded 
secondary trial reports designed to specifically address post-hoc hypotheses and 
subgroup comparisons. 
Subgroup analysis reporting
Information about subgroup analysis was extracted, which was considered es-
sential to evaluate the appropriateness of the method, and the validity of the 
results 19. This information included: Pre-specification of subgroup analysis (as 
reported in methods), number of subgroup factors (patient baseline characteris-
tics measured before randomization) 10, number of subgroup outcomes (primary 
or secondary endpoints), total number of subgroups (the product of the number 
of subgroup factors and the number of subgroup outcomes), statistical method 
(interaction test or separate analysis), number of significant subgroups found, 
and emphasis in subgroup findings (subgroup results mentioned in abstract 
and/or conclusion).
An interaction test directly assesses differences in treatment effect between 
complementary subgroups, and involves one statistical test irrespective of the 
number of subgroups 9, 19. A significant interaction test means that the treatment 
effect in one subgroup is significantly different from the treatment effect in the 
other subgroup. In contrast, the separate subgroup method assesses treatment 
effects in each group independently, and it involves two or more tests. This is 
inappropriate from a statistical point of view 9.
For consistency in the gathering of information, one of us (A.V.H.) selected 
the RCT reports, checked the inclusion and exclusion criteria, and collected 
the information. Another of us (E.W.S.) independently assessed the same RCT 
reports, and was blinded to the assessments of the first reviewer. There were few 
differences, which were resolved by consensus.
Secondary analyses
We examined differences in reporting between relatively small (<500 patients) 
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and large trials (≥500 patients). We expected that researchers in large trials would 
feel more confident to search for differential treatment effects in subgroups. We 
also examined subgroup reporting between negative (non-significant overall re-
sult) and positive trials. Researchers might try to explore subgroup effects if the 
overall effect was non-significant. Finally, we examined differences according 
to adoption of the CONSORT (Consolidating Standards for Reporting Trials) 
Statement 20, which might improve reporting of subgroup analysis. 
 
Statistical analysis
Descriptive statistics included percentages and medians. Categorical variables 
were tested with Chi-square tests. The software used was EXCEL and SPSS 10.0 
(SPSS Inc., Chicago, USA, 1999).
Results
RCT reports
In total, 63 RCTs 21-83 satisfied the inclusion criteria (Table 1). Fifty-three (84%) 
Table 1. Characteristics of the randomized clinical trials included in this review.
Year 2002 Year 2004 Total
Number of RCTs          33 30 63
Median number of patients (range) 680 (103 – 11484) 477 (100 – 15245) 496 (100-15245) 
RCTs with >500 patients (%) 17 (52) 13 (43) 30 (48) 
Median time of follow up, months 6 6 6
Median number of centers (range) 34 (1 – 432) 4 (1 – 507) 20 (1 – 507) 
RCTs with two arms (%) 27 (82) 26 (87) 53 (84) 
Negative results (%) 13 (39) 20 (67) 33 (54) 
CONSORT adoption (%) 9 (27) 9 (30) 18 (29) 
RCTs denotes randomised clinical trials; CONSORT denotes Consolidated Standards of Reporting 
Trials guidelines. 
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RCTs had two arms. Two thirds (n= 42) of the RCTs evaluated drugs, and one 
third (n=21) devices or strategies. Half of the RCTs had more than 500 patients, 
and the follow-up ranged between 3 days and 4,5 years. Most of the RCTs were 
multicenter. Approximately half of the RCTs yielded negative overall results. 
One third of the RCTs were published in journals which adopted the CONSORT 
statement. 
Subgroup reporting
Two-thirds (39 out of 63) of the RCTs were reported with subgroup analyses 
(Table 2), while 24 RCTs only performed crude analyses. According to what was 
described, full pre-specification of all subgroups was only done in 14 reports, and 
4 others included both pre-specified and non-pre-specified subgroups. Subgroups 
in the other 21 RCTs were reported without a rationale, and these may represent 
after-analysis subgroups.
 The median number of patient baseline characteristics used as sub-
group factors was three. However, some RCTs included higher numbers, with 
a maximum of 23 28. Two thirds (26 out of 39) of the RCTs were reported with 
>5 subgroups. The main factors were: gender (n=20), age (n=16), comorbidi-
ties other than diabetes (n=15), severity of disease (n=13), and diabetes (n=11). 
Likewise, the median number of subgroup outcomes was two, and some reported 
as many as seventeen 48. Therefore, the number of total subgroups (product of 
factors by outcomes) was high, ranging from 7 to 60 55. We found 63 significant 
subgroups among the 508 subgroups assessed (12%): 25 significant subgroups 
were pre-specified, and 38 were post-specified.
 The interaction test was used in 11 out of 39 RCTs, and separate tests in 
28. When interaction tests were used, the authors identified 10 (6%) significant 
subgroup effects among 175 tests performed. With separate subgroups, the au-
thors identified 53 (16%) significant subgroup effects among 333 tests performed. 
Nearly half (21 out of 39) of the RCTs claimed differences between subgroup 
treatment effects and the average treatment effects, and showed them in their 
result sections. Moreover, fifteen reports emphasized their subgroup findings by 
highlighting them either in the main conclusions or in the abstract. Only 6 RCTs 
reports included the appropriate interaction test and did not put emphasis on 
subgroup results.
Secondary analysis
Large trials (n>500) more often reported subgroup analyses than small trials (24/30 
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vs. 15/33, p=0.005). However, we did not observe differences in pre-specification, 
number of subgroups, statistical methods or emphasis in results. Moreover, these 
features of subgroup reporting did not differ between CONSORT-adopting and 
non-adopting trials, and between negative and positive trials.
Discussion
We found several shortcomings in the use and reporting of subgroup analysis in 
recent cardiovascular RCTs from major general medicine and cardiology jour-
Topic n
Reported subgroup analysis  39
Pre-specified subgroup analysis (%) 
       Fully  
       Partially 
14 (36) 
4 (10) 
Median number of subgroup factors (range) 3 (1 – 23) 
Median number of subgroup outcomes (range) 2 (1 – 17) 
Median number of subgroups (range) 7 (1 – 60) 
RCTs claimed subgroup effects (%) 
        using interaction tests 
        using separate subgroups 
21 (54) 
  7/11 
14/28
RCTs emphasized subgroup results in abstract or    
conclusions (%) 
        using interaction tests 
        using separate subgroup tests 
15 (39) 
  5/11 
10/28
RCTs denotes randomized clinical trial. 
Table 2. Description of reporting of subgroup analysis.
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nals. Many subgroups, frequently not pre-specified, were reported. The test of 
interaction was underused, and subgroup findings were commonly emphasized. 
These shortcomings may mislead treatment decisions when particular subgroups 
of patients are being evaluated.
During the last two decades the number of RCTs in cardiology has dramati-
cally increased: from 5,410 in the period 1980-1989 to 14,845 in the period 1990-
2000 1. Simultaneously, the interest to explore treatment effects in subgroups 
of patients has increased 8, 84. In the last two decades, many pages have been 
devoted to look at differential treatment effects in particular subgroups such 
as elderly people, female patients, diabetic patients, and severely-ill patients in 
diseases such as acute coronary syndromes, heart failure, hypertension, stroke, 
and hypercholesterolemia. 
Although subgroups should be clearly defined in the RCT protocol (‘pre-
specified subgroups’) 18, researchers may decide to perform subgroup analysis 
when the RCT is running (‘pre-analysis subgroups’) or when the RCT analysis 
has been completed (‘after-analysis subgroups’). Frequently, the RCT reports do 
not clearly make this differenciation.
One review evaluated 67 large RCTs in unstable angina, myocardial infarc-
tion, left ventricular dysfunction or heart failure 84. Some shortcomings in 
subgroup reporting were noticed: little supporting rationale, lack of pre-speci-
fication, overuse of separate analyses, and underuse of the formal statistical test 
of interaction. However, the authors limited the review to large (>1000 patients) 
drug RCTs, from 1980 to 1997. We included more recent RCTs (2002 and 2004), 
with medium size (two-thirds <1000 patients) and a broader perspective (evalua-
tion of drugs, devices and strategies). Our review may reflect the scope of RCTs 
reviewed by cardiologists nowadays.
Two thirds of the RCTs in our study reported pre-analysis, after-analysis, or 
partially pre-specified subgroups. These findings may be related to the fact that 
investigators re-analyze data in response to preliminary results, results from 
other studies, and suggestions from reviewers. It is possible that investigators 
evaluated an unplanned, large number of subgroups: two thirds of the RCTs 
reported more than 5 subgroups. Remarkably, seven RCTs reported more than 
25 subgroups 29, 30, 37, 39, 55, 61, 79. Three of these RCTs 30, 55, 79 found a high 
number of statistically significant subgroups, ranging from 5 to 18. Moreover, 
the proportion of significant subgroups was higher than the 5% expected (Z 
test= 4.19, p<0.01), especially for separate tests. Most of these subgroups were 
based on non-prognostic baseline characteristics, and may hence be considered 
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with suspicion 85, 86. Pre-specification of a limited number of subgroups based 
on predictive baseline characteristics may decrease the probability of spurious 
subgroup effects (false positives) 19, 20, 84, 86.
Interaction testing is the appropriate method to analyze subgroups 8, 9, 19, 20, 
86. Remarkably, interaction tests were only used in around 30% of cardiovascular 
RCTs which reported subgroups. This method decreases the risk to find false 
positive subgroups, but its power to detect true subgroups is low 20, 86. For in-
stance, in a trial with 80% power for the overall treatment effect, the interaction 
test has at most 29% power to detect an interaction effect of the same magnitude 
of the overall effect 9. The sample size should be increased at least four-fold 
to achieve the same power 10. Likewise, the evaluation of treatment effects in 
separate groups is misleading since false positive subgroup effects can be found: 
A significant effect in one subgroup can be expected in 7%, when the observed 
overall effect was nonsignificant 9. 
The interpretation of subgroups is important for treatment decisions in car-
diology 84, 85. Thus, some treatments may be withhold for some patients who 
require them, and some other patients may be treated with drugs that are not 
needed 84. For instance, aspirin was studied in few women in primary and sec-
ondary prevention RCTs of coronary heart disease, and a non-significant effect 
of aspirin was found in subgroup analysis in women 87. An overinterpretation of 
this subgroup may have led to the undertreatment of women for years, although 
we now know that aspirin is effective in women. Other classic examples include 
the use of thrombolytic therapy and beta blockade only in patients with anterior 
myocardial infarctions 18.
Half of the cardiovascular RCTs claimed significant subgroup effects, and 40% 
gave equal emphasis to subgroup and overall results. This is worrying, because 
subgroup analysis is a secondary, hypothesis-generating exercise to stimulate 
further research 18, 84, 86. Thus, less emphasis should be placed on subgroup 
results. The best estimate of treatment effect to be expected for a patient treated 
outside the trial may be still the overall effect 18. Rather, subgroup analyses should 
measure the consistency of beneficial and harmful treatment effects across dif-
ferent risk and demographic groups. This was shown in recent RCTs on beneficial 
treatment effects for heart failure, coronary intervention, coronary reperfusion 
and secondary prevention with statins, and on harmful effects of inotropic drugs 
for heart failure and oral glycoprotein IIb/IIIa inhibitors for unstable angina 8. 
An example of satisfactory reporting and interpretation of subgroup analysis 
is the MATCH trial 57. This RCT compared the use of aspirin and clopidogrel 
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versus clopidogrel alone after ischemic stroke or transient ischemic attack in 
high–risk patients (n=7599). The overall treatment effect was not significant. The 
authors used 13 pre-specified patient baseline characteristics to define subgroups. 
They used interaction tests to explore differential treatment effects by baseline 
characteristics on one composite outcome, and found that the treatment effect 
differed by patient age (p=0.012). They considered this finding with scepticism, 
and showed the overall effect as the main result.
On the other hand, the ACST trial reported its subgroup analyses less satisfac-
torily 61. The authors evaluated the prevention of disabling and fatal strokes by 
successful carotid endarterectomy in patients without recent neurological symp-
toms (n=3120). They extensively reported 27 partially pre-specified subgroup 
analyses, based on 9 baseline characteristics and 3 outcomes. However, it is not 
clear how many analyses really were performed. Moreover, they analyzed these 
subgroups independently, resulting in 72 p-values. Although the overall effect 
was positive, three subgroup findings were emphasized: effects in women, in 
patients with hypercholesterolemia, and in patients older than 75 years. These 
subgroups were of limited sample size and had few events. In particular, the 
investigators concluded that both men and women had a significant benefit with 
carotid endarterectomy on the risk of stroke, although the effect in women was 
‘not as definite as in men’ 61. 
We summarize some recommendations to appropriately perform and interpret 
subgroup analysis in cardiovascular RCTs, based on current recommendations 
20 and methodologic papers (Table 3) 8-10, 18, 19, 84, 85, 86. Apart from looking at 
subgroup results of prior RCTs and independent subgroup confirmation, meta-
analyses can be used to study subgroups. Meta-analyses have higher power to 
detect significant subgroup effects in comparison to individual RCTs 9, and hence 
give readers more confidence to believe in a potential subgroup. Nice examples 
are readily available from the literature 88-90. For instance, a small meta-analysis 
of the results of the ACST and the ACAS trials has highlighted a significant effect 
of endarterectomy in men and a nonsignificant effect in women on the combined 
risk of any stroke and operative death 90. If a subgroup is still not completely 
reliable and there is a special interest on it, probably the best, but less feasible 
alternative is to design a RCT specifically targeted to study the subgroup. One 
example is to design a confirmatory subgroup analysis within a RCT, which aims 
to find explicit effects of interventions in a prospectively defined subgroup stra-
tum of interest 91. This method usually defines a subgroup sample size between 
40 to 60% of the total sample size 86, 91. 
Our paper has some limitations. We reviewed a limited number of RCTs. 
However, we used a broad sample of major journals, which publish the most 
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influential RCTs in cardiology. Moreover, our main aim was to highlight the 
appropriateness of use and interpretation of subgroup analysis, and this sample 
may well be considered representative of current practice. Finally, we only used 
information that was published in the RCT reports. The information provided in 
the reports may not necessarily be the same as in the RCT protocol, nor comprise 
all analyses that were performed. 
In conclusion, subgroup analyses in recent cardiovascular RCTs were reported 
with several shortcomings, such as a lack of pre-specification, and testing of a 
large number of subgroups, without the use of the statistically appropriate test for 
interaction. Reporting of subgroup analysis needs to be substantially improved 
in cardiovascular RCTs, since emphasis in these secondary results may mislead 
treatment decisions for particular groups of patients.
Table 3. Suggestions to appropriately perform and interpret subgroup analysis.
Specification
      Specify a limited number of subgroups in advance, with a clear rationale. 
Analysis
      Use statistical interaction tests in the full RCT population.
Interpretation 
a. Be sceptical if subgroups were not pre-specified, not biologically plausible or no 
interaction tests were applied. 
b. Interpret in context, e.g. look at prior findings, and independent confirmation. 
c. See subgroup analysis as a hypothesis-generating exercise to stimulate further 
research. 
d. Put emphasis on overall results, which may be considered better estimates of 
treatment effects than the subgroup effects. 
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ABSTRACT
Objective: Few randomized clinical trials (RCTs) in the field of traumat-
ic brain injury (TBI) have shown a significant treatment benefit. We aimed 
to critically review the uses of two types of secondary analyses, covari-
ate adjustment and subgroup analysis, which may be common in TBI trials.
Methods: We performed a systematic review of therapeutic phase III RCTs, 
including acute, adult, moderate-to-severe TBI patients. Glasgow Out-
come Scale (GOS) at ≥3 months as outcome, and ≥50 patients per arm were 
required. We compared the actual reporting of covariate adjustment and 
subgroup analyses with the CONSORT (Consolidated Standards of Re-
porting Trials) recommendations. Likewise, we reviewed six protocols of 
large multicenter RCTs, and compared planned and reported subgroups.
Results: We identified 18 RCTs (n= 6439). Sixteen trials used GOS at 6 months 
as outcome. Five RCTs reported covariate adjustment. The number of covari-
ates was limited (≤5), most frequently including age. Many covariates were 
outcome predictors. Four RCTs reported only adjusted treatment effects as the 
main efficacy parameter. Eleven RCTs reported subgroup analyses. Several 
subgroup factors (≤7, mainly outcome predictors) and outcomes (≤4) were in-
cluded. The highest total number of subgroups was fifteen, and only three RCTs 
completely pre-specified subgroups. Notably, 10 out of 11 RCTs performed in-
appropriate separate subgroup analyses. Five out of 11 RCTs gave subgroups 
the same emphasis as the overall effect. Reported subgroup analyses were in-
sufficiently described, and clearly differed from those planned in the protocol.
Conclusions: The reported covariate adjustment and subgroup analy-
ses from TBI trials had several methodological shortcomings. Ap-
propriate performance and reporting of covariate adjustment and sub-
group analysis should be considerably improved in future TBI trials, 
since interpretation of treatment benefits may be misleading otherwise.
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Introduction
Acute traumatic brain injury (TBI) is a leading cause of premature death and 
disability and remains a major public health problem around the world 30, 35. 
Brain injury management is primarily aimed at measures to prevent and limit 
the development of secondary brain damage 4, 19, 40. Many therapeutic random-
ized clinical trials (RCTs) have failed to demonstrate significant improvement in 
outcomes in patients with moderate and severe TBI 18, 39, 40. These failures have 
been attributed to many causes, including insufficient pre-clinical and initial 
clinical work-up, small sample size, inadequate use of the outcome measure, too 
optimistic expectations, ineffective therapies, inappropriate target mechanism, 
and heterogeneity of patients 7, 11, 17, 18, 32, 39, 47. 
The heterogeneity of the TBI patients remains despite strict inclusion and 
exclusion criteria 28, 32, 33. Patient baseline characteristics, collected at entry to 
a RCT, give information on prognosis and type of injury, and reflect this hetero-
geneity. Proposals for dealing with heterogeneity in the design of RCTs include: 
Stratified randomization 7, 10, 32, block randomization 7, inclusion of patients 
with similar types of injury 7, and targeting patients most likely to benefit from 
the treatment (e.g. exclude patients with very good and very bad prognosis) 32, 33, 
39. Other proposals have focused on the analysis of RCTs: covariate adjustment 9, 
10, 24, 25, 27, 44, and subgroup analysis 6, 10, 13, 39, 50. 
The CONSORT (Consolidated Standards of Reporting Trials) statement 
includes recommendations to improve the analysis and reporting of covariate 
adjustment and subgroup analyses in RCTs 1. Recently, the misuse of baseline 
data, especially the overinterpretation of subgroup analyses, has been noted in 
general medicine RCT reports 2. It is likely that such misuse may have been more 
common in TBI trials because of the significant problems of heterogeneity. No 
formal evaluation of covariate adjustment and subgroup analysis in TBI trials has 
been performed so far. 
 We aimed to describe the appropriateness of reporting covariate adjust-
ment and subgroup analysis in published phase III RCTs including acute, closed, 
and moderate to severe TBI adult patients, with a substantial sample size and with 
clinically relevant outcomes. We further reviewed a sample of the protocols of 
the largest multicenter TBI trials, in order to compare the concordance between 
planned and reported subgroup analyses.
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Methods
RCT report search strategy 
We searched MEDLINE (1966 to 1 April 2004), EMBASE (1974 to 1 April 2004), 
the Cochrane Controlled Trials Register and the Cochrane Database of Systematic 
Reviews (Cochrane Library, Issue 2, 19 April 2004) for RCTs in TBI. All searches 
used the key words traumatic brain injury or traumatic head injury or traumatic 
cranial injury in conjunction with each of the following words: severe, moderate, 
acute, treatment, randomized controlled trials, and randomized clinical trials. 
The searches were limited to RCTs in English, French, German and Spanish. We 
reviewed the bibliographies of relevant studies (RCTs and non-RCTs) to search 
for additional eligible RCTs. Only data accessible in peer-reviewed journals were 
included, and we were not masked with regard to authors or journal. 
Inclusion and exclusion criteria of RCTs
We selected RCTs that met the inclusion and exclusion criteria (Box). One of 
us (A.V.H.) screened the titles and abstracts to exclude non-human studies and 
review articles, retrieved potentially relevant manuscripts for detailed evaluation, 
and selected publications compliant with the inclusion and exclusion criteria. 
Jointly with another of us (A.I.R.M.), both researchers reassessed inclusion and 
exclusion criteria. Reports that did not meet all these criteria were excluded. 
Differences were resolved by discussion until consensus was reached. 
Data extraction
The eighteen eligible trials underwent data extraction from the full-text papers 
by one of us (A.V.H.) using a pre-designed extraction form. This form was previ-
ously used in another related review by two of the authors (A.V.H. and E.W.S.) 
and the information obtained was highly reproducible. Patient attributes mea-
sured before randomization were considered as baseline characteristics 13. The 
information retrieved included general information, such as sample size, number 
of centers, and primary outcome. Information on covariate adjustment included 
number of covariates, pre-specification, selection strategy, statistical method, 
primary use of covariate adjustment, and emphasis with respect to unadjusted 
analysis. Information on subgroup analyses included number of subgroup factors, 
number of subgroup outcomes, number of subgroup analyses (product of factors 
by outcomes), pre-specification, statistical method (interaction test or separate 
subgroup p value), and emphasis given to subgroups. 
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Methodological standards
The CONSORT statement established standards of trial reporting, based on a 
large amount of methodological and applied information regarding appropriate 
design and analysis of trials 1. This document proposed 22 items that should be 
reported in every RCT in order to allow the readers to judge the validity of the 
findings, and to be more confident when applying these findings in their practice. 
The CONSORT items 12, 15, and 18 refer to covariate adjustment and subgroup 
analysis. Covariate adjustment should use a limited number of covariates, and 
should clearly establish the reasons to choose covariates 1, 2, 13, 44. Subgroup 
analysis should use a limited number of pre-specified subgroups, use interaction 
tests, and be considered a secondary analysis 1, 2, 6, 13, 50. 
Definitions
An interaction test directly assesses differences between complimentary sub-
groups by studying treatment*subgroup factors. It involves one statistical test 
irrespective of the number of subgroups 6, 13. In contrast, the separate subgroup 
p value method evaluates treatment effects in each complementary group inde-
pendently 50. This is inappropriate from a methodological point of view 1, 13. 
Box. Inclusion and exclusion criteria for the systematic review.
Inclusion criteria 
a. Prospective, parallel-groups, phase III RCT with random assignment to 
either 
             a new medication/intervention or placebo/best intervention available. 
b. Main RCT report. 
c. Patients with non-missile, closed, clinically diagnosed TBI. 
d. Acute TBI presentation (<24 hours between injury and treatment). 
e. Moderate or severe TBI (i.e. Glasgow Coma Scale [GCS] � 12). 
f. Primary outcome expressed as Glasgow Outcome Score (GOS) at � 3 
months.
g. Patients older than 15 years. 
h. More than 50 patients per treatment arm. 
Exclusion criteria 
a. Phase II RCTs. 
b. Mild TBI (GCS: 13 to 15). 
c. Chronic TBI treatments (e.g. rehabilitation). 
d. Pediatric TBI patients 
e. Primary outcome other than GOS. 
    RCT denotes randomized clinical trial; TBI denotes traumatic brain injury 
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Subgroups were pre-specified if they were clearly established in the methods part 
or if they were clearly labeled as pre-specified. 
Subgroups were post-hoc if they were shown only in results and/or discussion 
or if they were clearly labeled as post-hoc 13. Emphasis on subgroups was clas-
sified as similar to the overall effect if subgroups were reported in the abstract 
or main conclusion of the paper 43. If the subgroups were only presented in the 
results and/or discussion, the overall effect had more emphasis.
RCT Protocols  
We hypothesized that results on subgroup analyses might differ from subgroup 
analyses as specified in the protocol. Six protocols of some of the largest multi-
center TBI trials were reviewed. We focused on the number of subgroup factors 
Potentially relevant
citations with titles 
and abstracts 
identified through 
systematic searches
(N=297)
Potentially relevant
RCT reports and 
abstracts evaluated
with more detail 
(N=214)
Excluded non-human
studies, review articles, 
and non-randomized
studies
(N=83)
Potential RCT reports
for inclusion in
systematic review
(N=30)
RCT reports included 
in systematic review 
(N=18)
RCT reports with <50
patients in each study 
arm
(N=12)
Excluded pilot studies, 
non-parallel, duplicate 
publication, and not 
relevant RCTs [phase II, 
non-GOS outcome,
missile, open skull, 
mild, >24h, pediatric] 
(N=184)
Figure. Flow diagram of literature search and selection of trials. RCT denotes 
randomized controlled trial.
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and outcomes, whether subgroups were pre-specified, and statistical method of 
subgroup analysis. Thus, we compared the planned subgroup analyses with the 
reported subgroup analyses, in order to evaluate their concordance and discrep-
ancies.
Statistical analyses
Descriptive statistics included percentages and medians. The software used was 
EXCEL and SPSS 10.0 (SPSS Inc., Chicago, USA, 1999).
Results
General RCT characteristics 
The systematic review of the literature identified 297 potentially relevant citations 
with titles and abstracts. We finally included 18 RCTs 3, 5, 12, 14, 15, 16, 20, 21, 22, 
31, 34, 36, 41, 42, 45, 48, 49, 51 (Figure). All RCT reports were published in English, 
from 1981 to 2004 (Table 1). The number of patients included ranged between 
100 and 1120 (median: 265), originating from 1 to 95 centers (median: 8) mainly 
from developed countries 34, 36.
 
Eleven trials investigated drugs, and they were published before the year 
2000. The time of follow up ranged between 6 and 14 months (median 6 months). 
The primary end point was mainly GOS at 6 months (16 out of 18 trials), which 
was dichotomized in 9 trials. Notably, from six trials that yielded positive results 
14, 16, 31, 48, 49, 51, five were single center studies, and used a therapy other than a 
drug— i.e. surgery, hypothermia, mannitol and hyperbaric oxygen 15, 31, 41. 
Covariate adjustment
Five trials published before 1997 reported covariate adjustment 20, 22, 45, 48, 49 
(Table 2). The number of covariates included ranged from one to five. Covariates 
from 2 trials were not clearly defined 45, 48. Age was the most commonly chosen 
covariate 22, 45, 48, 49. Most of the covariates were well-known outcome predictors 
(e.g. age, initial Glasgow Coma Scale [GCS], motor score, pupilary reactivity, 
and initial Computed Tomography [CT] abnormalities) but this reason was not 
clearly established in the RCT reports. Center was considered as a covariate in 
two older trials 20, 48, and imbalance in age and GCS was reported as the reason 
for adjustment in one trial 22. Logistic regression was the main method of adjust-
ment in 3 trials 22, 45, 48. Four RCTs gave only adjusted results, and one RCT 22 
reported adjusted and unadjusted results. In this trial, the unadjusted treatment 
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Table 1. General characteristics of trial reports included in the review (n=18).
  Author reference, year   Country* Centers n (arms) Treatment Target
population†
 GOS¶ 
  Positive trials (n=6)
Lu 31, 2003   CHN  1 230 (2)   Craniotomy Severe    6m 
Zhi 50, 2003   CHN  1 396 (2)   Hypothermia Severe    6m 
Cruz 16, 2002   BRA  1 141 (2)   Mannitol Coma, Acute 
IPH
   6m 
Cruz 15, 2001   BRA  1 178 (2)   Mannitol Coma, Acute 
SDH
   6m 
Harders 22, 1996   GER 21   123 (2)   Nimodipine SAH    6m 
Rockswold 40, 1992   USA   1   168 (2)   Hyperbaric O2 Severe    12, 6, 18m 
Negative trials (n=12)  
Cooper 14, 2004 AUS 12   226 (2)   Hypertonic 
     saline 
Severe    6m (usual &
     extended) 
Clifton 12, 2001   USA 11   3
693 (2) 
92 (2)   Hypothermia Severe    6m 
Morris 36, 1999   USA, ISR, 
  EUR, CAN, 
  AUS, ARG. 
95   NMDA
    antagonist 
    (Selfotel) 
Severe    6m 
Marshall 34, 1998   EUR, AUS,
  ISR. 
50 1120 (2)   Tirilazad Severe (85%), 
Moderate (15%)
   6m 
Young 48, 1996   USA 29   463 (3)   Pegorgotein Severe    3m 
Grumme 21, 1995   GER, AUT   9   396 (2)   Triamcinolone Severe    Discharge 
     & 1y 
European Study Group 
Nimodipine 44, 1994 
  EUR 21   852 (2)   Nimodipine Severe,
Not obeying    
  commands 
 6m 
Gaab 20, 1994   GER    10   300 (2)   Dexamethasone Severe
Moderate
   12m    
    (modified)
Wolf 47, 1993   USA  2   149 (2)   Tromethamine Severe    3, 6, 12m 
Bailey 3, 1991   UK, FIN  6   351 (2)   Nimodipine Not obeying 
commands 
   6m 
Braakman 5, 1983   NED  2   161 (2)   Dexamethasone Coma,  
Severe
   6m &    
    Survival 1y
Saul 41, 1981   USA  1   100 (2) Methylpredni- 
   solone 
Severe    6m 
*AUS: Australia; CHN: China; BRA: Brazil; USA: United States of America; ISR: Israel; EUR: Europe; GER; 
Germany; AUT: Austria; UK: United Kingdom; FIN: Finland; NED: Netherlands. 
†Severe TBI: Glasgow Coma Score (GCS) <9; Moderate TBI: GCS 9 to 12; IPH: Intraparenchymal hemorrhage; 
SDH: Subdural hematoma; SAH: Subarachnoid hemorrhage. 
¶GOS: Glasgow Outcome Scale; extended: GOSE, Glasgow Outcome Score Extended; modified: mGOS, Modified 
GOS; m: months; y: year. 
Subgroup analysis and covariate adjustment in traumatic brain injury trials
99
Author reference Covariates included Reason to 
include
Emphasis in 
results
Change in 
conclusion
n Definition*
Method used 
in covariate 
  adjustment 
Young 48, 1996 1 Age (<45; �45) Not given Stratified Mantel 
Haenzel 
Adjusted** NA††
Harders 22, 1996 4 Age (continuous), GCS† at 
entry (�12, >12); amount of 
blood in initial CT (ordinal, 
3); Fisher grade in initial 
CT (ordinal, 4) 
Imbalance 
(age, GCS); 
rest not 
given
Logistic
regression
Unadjusted No
European Study 
Group
Nimodipine 44,
1994
5 Age (ns‡); gender (ns), 
craniotomy (ns); pupilary 
reaction (ns); GCS motor 
responses (ns) 
Not given Logistic
regression
Adjusted** NA
Gaab 20, 1994 1 Center (categorical, 10) Center Stratified Mantel 
Haenzel 
Adjusted** NA
Wolf 47, 1993 5 Age (ns); GCS motor score 
(ns); strata of neurological 
insult (ns); elevated ICP§ 
(ns); center (categorical, 2) 
Center; rest 
not given 
Logistic
regression
Adjusted** NA
* Definition refers to the way they were considered in analyses: continuous, categorical or ordinal. In 
case of categorical or  ordinal covariates, it is written the number of categories considered.  
† GCS: Glasgow Coma Scale. 
‡ ns: Non specified.  
§ ICP: Intracranial pressure. 
** Only adjusted effect given. 
†† Not available. 
Table 2. Covariate adjustment on five trial reports.
TBI trials Internal Medicine trials‡ 
Results of 
trial 
n Covariate
adjustment
Subgroup
analyses
  n Covariate
adjustment
Subgroup
analyses
Negative 12    4 (33%)† 9 (75%) 
39
22 (56%) 22 (56%) 
Positive  6  1 (17%) 2 (33%) 
45
22 (49%) 25 (56%) 
Total 18  5 (28%)  11 (61%) 84 44 (52%) 47 (56%) 
* No significant differences between positive and negative trials, and between TBI and internal    
   medicine trials. 
† Percentages are separated by topic (TBI or Internal Medicine), and correspond to:  number of    
   trials with the analyses /  number of trials (n) in the same row. 
‡ Internal Medicine includes: General Internal Medicine, Cardiology and Oncology (reference            
   26). 
Table 3. Number of reported covariate adjustment and subgroup analyses in 
positive and negative trials: Comparison between traumatic brain injury and 
internal medicine trials*
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Author reference Subgroup
factors
Subgroup
outcomes
Total
¶
Pre-
specified?**
Statistical 
method
Subgroup
found?
(n)†† 
Emphasis
in
results
Cooper 14,
2004
GCS GOSE†6m 1 Yes Separate
test
No Overall
Clifton 12,
2001
Age, GCS, 
compressed cisterns, 
surgical hematoma, 
initial hypothermia 
Poor
outcome‡, 
death,
ICP>30
mmHg
    15 No Separate
test
Yes (2) Overall
Morris 36,
1999
EDH*, SDH, IPH, 
GCS, secondary 
ischemic events 
Favorable
outcome‡, 
death
    10 Yes  Separate 
test
No Overall
Marshall 34,
1998
Gender, SAH, GCS. Favorable
outcome, 
death
6 Partially  Separate 
test
Yes(3) Equal
subgroup & 
overall
Young 48,
1996
GCS. Good
outcome‡, 
favorable
outcome 
(3m & 6m)
4 No  Separate 
test
No Overall
Harders 22,
1996
GCS, amount of 
blood-CT, Fisher 
grade-CT
Favorable
outcome 
3 No Separate
test
No Overall
Grumme 21,
1995
Age, focal lesions, 
GCS, EDH, SDH, 
admission <1h, initial 
steroid treatment  
GOS at 
discharge,
GOS 1y 
    14 Partially Separate
test
Yes(1) Equal
subgroup & 
overall
European
Study Group 
Nimodipine 44,
1994
Brain damage, SAH, 
others (unknown) 
Favorable
outcome 
    >2 Partially  Separate 
test
Yes(1) Equal
subgroup & 
overall
Rockswold 40,
1992
GCS, mass lesion, 
contusion, pupilary 
reactivity 
Favorable
outcome, 
death (1y) 
8 Partially  Separate 
test
Yes(2) Equal
subgroup & 
overall
Bailey 3, 1991 Age, motor GCS, 
intracerebral lesion, 
motor response, 
others (unknown)  
Favorable
outcome, 
death
    >8 Partially Interaction
test
No Overall
Braakman 5,
1983
Probability of 
survival§, center 
Survival
1m & 6m 
4 Yes Separate
test
No Equal
subgroup & 
overall
* EDH: Epidural hemorrhage. 
† GOSE categories (8): dead, vegetative, lower severe disability, upper severe disability, lower moderate disability, 
upper moderate disability, lower good recovery, upper good recovery. 
‡ GOS at 6 months, unless otherwise indicated. Categories (5); Poor outcome=severe disability, vegetative state and 
death; Favorable outcome= good recovery and moderate disability; Good outcome= Good recovery. 
§ Probability of survival was calculated at admission, based on age, pupil reactivity to light and best motor response 
of the arms. 
¶ Total number of subgroup analyses= number of factors * number of outcomes. 
** Yes: Subgroups described in methods; No: Subgroups only described in results/discussion; Partially: some 
subgroups described in methods and some others only in results/discussion.  †† n: number of significant (p<0.05) 
subgroups.   
Table 4. Subgroup analyses in trial reports.
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effect received more emphasis than the adjusted one, but it did not affect the 
overall conclusion. One positive trial reported a covariate adjusted treatment 
effect 22 (Table 3).
Subgroup analysis
Eleven trials reported subgroup analyses 3, 5, 12, 14, 21, 22, 34, 36, 41, 45, 49 (Table 
4). The maximum number of subgroup factors was seven, including mainly GCS 
and mass lesions. The maximum number of subgroup outcomes was four, mainly 
favorable outcome of GOS at 6 months (both good recovery and moderate dis-
ability). Two trials did not report the complete number of subgroup factors 3, 45. 
The highest total number of examined subgroups was fifteen 12. Three trials did 
not report pre-specified subgroups 12, 22, 49. Some of the trials reported partially 
pre-specified subgroups 3, 21, 34, 41, 45. Ten out of 11 trials performed separate 
subgroup analyses, and only one performed the statistically appropriate interac-
tion test 3. Five trials found subgroup effects 12, 21, 34, 41, 45, and five trials gave 
equal emphasis to the subgroup effects and overall effects 5, 21, 34, 41, 45. Two 
positive trials reported subgroup analyses 22, 41 (Table 3).
Subgroup analysis in protocols and reports
The protocols corresponded to six RCT reports 3, 12, 34, 36, 45, 49 (Table 5). All 
six reported on subgroup effects, and the reported analyses clearly differed from 
those specified in the protocols. Two protocols did not define any subgroup fac-
tors, while they were considered in the reports 3, 12. In the three protocols that 
pre-specified outcomes, these were also considered in the subgroup analyses 34, 
36, 45. Subgroup analyses were not pre-specified in three protocols 3, 12, 49. When 
subgroup analyses were pre-specified in the protocols 34, 36, 45, only one trial 
reported them as planned 36. Finally, five trials reported separate subgroup tests, 
but protocols specified an interaction test, a combination of separate and interac-
tion test, or nothing 12, 34, 36, 45, 49. These findings supported our hypothesis that 
trial reports included different subgroups than those planned in the protocols.
Discussion
Many RCTs have been published in acute TBI, but most of these have failed to 
yield convincing treatment benefits 18, 32, 33, 39, 40. Various explanations for these 
failures have been put forward: Most of the TBI trials have insufficient sample 
size, and are poorly designed to detect or refute treatment benefits 17. Others have 
suggested that the hypothesized absolute treatment benefit was too large and too 
optimistic (e.g. 10-15%), that investigating a more modest absolute benefit (e.g. 
5-8%) would be desirable, and that larger trials are necessary 32, 39. The largest 
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phase III trial in our review had 1120 patients (34).  Here, most of the patients 
had severe TBI (85%), and hence more than 20% of baseline risk of unfavorable 
outcome. Even, in this study, the power to find an absolute benefit of less than 
8% was limited 17. 
These disappointing results have led to an increased interest in subgroup 
Subgroup factors‡ Subgroup outcomes Pre-specified? Method
Author reference Protocol Report Protocol Report Protocol Report¶ Protocol Report
Clifton 12, 2001 Not defined Age, GCS, 
cisterns,
surgical
hematoma, 
hypothermia 
Not defined Poor
outcome, 
death,
ICP>30
mmHg
No No Not defined Separate 
test
Morris 36, 1999 Time 
between
injury and 
treatment*
EDH, SDH, 
IPH,
severity, 
secondary 
ischemic 
events
Favorable
outcome, 
death, GOS 
4 categories, 
DRS§(all at 
6m &3m) 
Favorable
outcome, 
death
(both 6m)
Yes Yes Interaction
test
Separate
test
Marshall 34,
1998
GCS, SBP†,
center
Gender,
SAH, GCS. 
Favorable
outcome, 
death.
Favorable
outcome, 
death
Yes Partially Interaction
test/Separate
test
Separate
test
Young 48, 1996 Age GCS Not defined Good + 
favorable
outcome 
(3m &6m)
No No Not defined Separate 
test
European Study
Group
Nimodipine 44,
1994
Age, sex, 
motor 
GCS,
pupilary 
reactivity, 
surgery 
for
occupying 
lesion
Brain
damage, 
SAH,
others
(unknown) 
Favorable
outcome 
Favorable
outcome
Yes Partially Not defined Separate 
test
Bailey 3, 1991 Not defined Age, motor 
GCS, intra- 
cerebral
lesion.
Not defined Favorable
outcome, 
death
No Partially Not defined Interaction
test
* Defined as subgroup factor in protocol, but not considered baseline characteristic in our review (see 
methods). 
† Systolic blood pressure 
‡ Abbreviations as in previous tables. 
§ Disability Rating Scale. 
¶ Yes: Subgroups described in methods; No: subgroups only described in results/discussion;    
           Partially:some subgroups described in methods and some others only in results/discussion. 
Table 5. Subgroup analysis in selected traumatic brain injury trials: protocol vs. 
report
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analyses, trying to identify more homogeneous subgroups who may benefit from 
the intervention. This stems from the realization that heterogeneity of patients 
is a major confounding factor in the design and analysis of TBI trials, and that 
heterogeneity is related to injury patterns and prognostic risk 32, 33. Approaches 
for dealing with heterogeneity relate to both the design and analysis phases. In the 
design phase stratified randomization can be employed. Alternatively, treatment 
can be targeted to patients with a defined type of pathology or to patients with 
an intermediate prognosis, e.g. between 20 and 80% probability of unfavorable 
outcome 27, 32, 33, 39. A reduction of the sample size of 30% may be achievable, 
for the same power as when the whole population is considered 33. In the analysis 
phase, covariate adjustment and subgroup analysis may be employed. 
Covariate adjustment uses covariates in order to provide a more individual-
oriented treatment effect, that is also corrected for imbalance. It increases power, 
and reduces the required sample size 9, 10, 24, 25, 27, 44. Subgroup analysis assesses 
differences in treatment effect across different subpopulations of patients 6, 13, 25, 
50. Covariate adjustment and subgroup analysis are common in RCTs, but their 
reporting has shown many flaws in trials from general medicine journals, espe-
cially for subgroup analysis 2. The revised CONSORT statement recommended 
guidelines to improve the reporting of the RCTs, and facilitates informed judg-
ments regarding the validity of the trials  1. We found that reporting of covariate 
adjustment and subgroup analysis in TBI clinical trials has several shortcomings. 
Further, reported subgroups differed substantially from those planned in the 
protocols.
Covariate adjustment was reported in trials that mainly had negative treat-
ment benefits and were multicenter. Some papers have recommended using 
covariate adjustment in TBI trials, especially for prognostic factors 9, 10, 27, 32, 
44. An appropriate small number of baseline characteristics were used in the 
trials, including age 22, 45, 48, 49, GCS 22, 45, 48, pupilary reactivity 45, elevated 
intracranial pressure 48, CT abnormalities 22, gender 45, and center 20, 48. Most 
of these baseline characteristics are known prognostic factors 30, 35. Although 
covariates were appropriately few, the reasons to select these were not clearly 
stated. We also found that covariate definitions (i.e. dichotomized, ordinal or 
continuous) were insufficiently reported. We consider that covariate adjustment 
using a limited number of pre-specified, clearly defined prognostic factors is a 
valid procedure.
Age is the strongest predictor of unfavorable outcome in TBI, as demonstrated 
in data from epidemiological studies 23, 29, 37 and RCTs 37. Age is continuously 
associated with unfavorable outcome, and should be used as a continuous variable 
in covariate adjustment 29. Motor GCS is another strong predictor, and should be 
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used as covariate 9, 32. Indeed, adjusting for age and motor GCS could reduce the 
sample size by 25 to 30% in TBI trials 9, 10. Other severity characteristics (e.g. 
pupilary reactivity, CT severity, hypoxia, hypotension) may also be included  32. 
Gender has not been suggested as a variable to adjust for 32, and its potential 
predictive value could be related to its association with other strong predictors. 
Center/country also may be considered 10, 44, because differences in patient 
baseline characteristics have been demonstrated across continents and regions 
28. 
A moderate number of subgroup analyses were noted in TBI reports. Limiting 
the number of subgroups is strongly recommended, as this decreases problems 
arising from multiplicity and helps define valid statistical tests 50. The subgroup 
factors were mainly predictors of unfavorable outcome 30, 35, 39. TBI trials might 
focus on appropriate subgroups of patients, defined by predictors: age, gender, 
GCS, pupilary reactivity, hypotension, CT severity and SAH 10, 39. Moreover, 
interaction tests are appropriate to assess differences between complementary 
subgroups. The separate subgroup p value method evaluates treatment effects in 
independent subgroups, which is inappropriate from a methodological point of 
view 1, 13.
Remarkably, the reporting of subgroups in TBI trials had important method-
ological shortcomings 1, 2, 13, 50: most trials reported partially or did not report 
pre-specified subgroups, used separate subgroup testing, and performed post-
hoc subgroup analyses. Moreover, nearly half of the trials overemphasized any 
statistically significant effect found.
For example, the Tirilazad trial 34 and the hyperbaric oxygen trial 41 reported 
partially pre-specified subgroups, used separate analyses, and emphasized their 
subgroup findings. The former found a lower mortality in males, moderately 
head injured and non-SAH patients; the latter found lower mortality in severely 
head injured (GCS 4 to 6) and in patients with surgical mass lesions. However, 
without a good a priori rationale for subgroup differences, the overall treatment 
effect should provide a reasonable estimate for each subgroup of TBI patients, 
unless confirmatory evidence of treatment differences become available. These 
subgroups may be unreliable (i.e. based on small number of patients), should be 
considered exploratory, and should only serve to motivate further trials rather 
than drawing definite conclusions 13, 43.
It can be argued that good or poor subgroup analysis reporting is not completely 
related to a good or poor practice in the analysis of TBI trials. It is clear that most 
physicians have only access to trial reports, and take decisions based on reports. 
Hence, the evaluation of reporting in TBI trials is worthwhile 46. Moreover, the 
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CONSORT guidelines based their recommendations on papers dealing with 
design, conduct, analysis, and reporting of trials. These reporting guidelines 
may therefore include a part of good practice on trial analysis. However, it is 
also possible that an analysis plan may differ from a reported analysis. Results 
from Table 5 show that the most plausible explanation for poor subgroup analysis 
reporting is a poor analysis plan, especially for pre-specification of subgroups 
and statistical methods.
Differences in subgroup definitions between the TBI protocols and trial 
reports were substantial. We observed differences regarding subgroup factors, 
pre-specification, and method of analysis. This seems an indication of post-hoc 
analyses. Thus, the protocol stated a particular definition of subgroups, but the 
results only became statistically significant when an alternative definition of 
the subgroups was used 50. Further, post-hoc subgroups should be treated with 
skepticism, as they test data-derived hypotheses rather than hypotheses stated 
a priori 50, 13. A recent paper found that trial reporting of outcomes was not 
only frequently incomplete, but also biased and inconsistent with protocols 8. 
Our results confirm the inconsistency and incompleteness of subgroup analyses 
between trials and protocols.
We have recently studied the reporting of covariate adjustment and subgroup 
analyses in high impact internal medicine (IM) journals (general medicine, 
cardiology and oncology) 26. As shown in Table 3, TBI trials reported less co-
variate adjustment than IM trials, independently of their final result (positive or 
negative). Moreover, TBI trials adjusted for fewer covariates (≤5) than IM trials 
(mainly between 5 and 9). However, reasons to include covariates were poorly 
reported in TBI trials in comparison to IM trials (36 out of 44 reports). TBI and 
IM trials reported subgroup analyses in a similar frequency. However, negative 
TBI trials reported more subgroup than negative IM trials, and positive TBI trials 
reported fewer subgroups than IM trials. Moreover, TBI reports fully pre-speci-
fied subgroup analyses less commonly (3/11 vs. 22/47), and used interaction test-
ing less frequently (1/11 vs. 20/47) than IM trials. This is an additional indication 
that TBI trials inappropriately reported subgroup analyses.
Future design of TBI trials should incorporate covariate adjustment for im-
portant predictors. Such an adjustment should be pre-specified in the trial proto-
col, including the coding of predictors. Alternatively, inclusion can be restricted 
to certain prognostic groups, defined by predictors. For example, patients with 
intermediate prognosis (20%-80% of favorable outcome) or patients with focal 
injury may be hypothesized to benefit from treatment. Such a targeting approach 
may decrease the sample size requirements by 30% 33. If subgroup effects are 
studied, the number of subgroups should be pre-specified with a clear rationale, 
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and should be analyzed with the appropriate test of interaction. Treatment effects 
can also be tested in a pre-specified subgroup within a TBI trial, such as the focal 
injury subgroup (‘confirmatory subgroup analysis’) 38.
Our paper has some limitations.  We did not include phase II TBI trials. 
However, we observed that most of them were small (n<100) and did not report 
relevant clinical outcomes (data not shown). We evaluated only reported results, 
and it is possible that there may be differences between the planned and the 
reported analysis. For subgroup analysis, we found clear discrepancies between 
protocols and reports. No evaluation was possible for covariate adjustment. It is 
also possible that investigators explored, for instance, more subgroups than those 
planned and reported. We could not evaluate this possibility. Finally, we used 
only a limited number of protocols.
In conclusion, reporting of covariate analyses and subgroup analyses in TBI 
clinical trials had several shortcomings, particularly for subgroup analyses. 
Likewise, reported subgroup analyses clearly differed from those planned in 
the protocols. The appropriate reporting of these secondary analyses should be 
considered in future TBI trials, since interpretation of treatment benefits may be 
misleading otherwise.
References
1. Altman DG, Schultz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche 
PC, Lang T; CONSORT GROUP (Consolidated Standards of Reporting Trials): The 
revised CONSORT statement for reporting randomized trials: explanation and elabora-
tion. Ann Intern Med 134:663-694, 2001.
2. Assmann SF, Pocock SJ, Enos LE, Kasten LE: Subgroup analysis and other 
(mis)uses of baseline data in clinical trials. Lancet 355:1064-1069, 2000.
3. Bailey I, Bell A, Gray R, Gullan R, Heiskanan O, Marks PV, Marsh H, Mendelow 
DA, Murray G, Ohman J, Quaghebeur G, Sinar J, Skene A, Teasdale G, Waters A: A 
trial of the effect of nimodipine on outcome after head injury. Acta Neurochir (Wien) 
110:97-105, 1991.
4. Bayir H, Clark RSB, Kochanek PM: Promising strategies to minimize second-
ary brain injury after head trauma. Crit Care Med 31[Suppl.]:S112-S117, 2003.
5. Braakman R, Schouten HJA, Blaauw-van Dishoeck M, Minderhoud JM: 
Megadose steroids in severe head injury. Results of a prospective double blind clinical 
trial. J Neurosurg 58:326-330, 1983.
6. Brookes ST, Whitley E, Egger M, Davey Smith G, Mulheran PA, Peters TJ: 
Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and 
sample size for the interaction test. J Clin Epidemiol 57:229-236, 2004.
Subgroup analysis and covariate adjustment in traumatic brain injury trials
107
7. Bullock MR, Merchant RE, Choi SC, Gilman CB, Kreutzer JS, Marmarou A, 
Teasdale GM: Outcome measures for clinical trials in neurotrauma. Neurosurg Focus 
13, 2002; Accessible at http://www.aans.org/education/journal/neurosurgical/july02/13-
1-nsf-toc.asp
8. Chan A, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG: Empirical evi-
dence for selective reporting of outcomes in randomized trials. Comparison of protocols 
to published results. JAMA 291:2457-2465, 2004.
9. Choi SC: Sample size in clinical trials with dichotomous endpoints: use of 
covariables. J Biopharm Stat 8:367-375, 1998.
10. Choi SC, Bullock R: Design and statistical issues in multicenter trials of severe 
head injury. Neurol Res 23:190-192, 2001.
11. Choi SC, Clifton GL, Marmarou A, Miller ER: Misclassification and treat-
ment effect on primary outcome measures in clinical trials of severe neurotrauma. J 
Neurotrauma 19:17-22, 2002.
12. Clifton GL, Miller ER, Choi SC, Levin HS, McCauley S, Smith KR, Muizelaar 
JP, Wagner FC, Marion DW, Luerssen TG, Chesnut RM, Schwartz M: Lack of effect of 
induction of hypothermia after acute brain injury. N Engl J Med 344:556-563, 2001.
13. Cook DI, Gebski VJ, Keech AC: Subgroup analysis in clinical trials. Med J 
Aust 180:289-291, 2004.
14. Cooper DJ, Myles PS, McDermott FT, Murray LJ, Laidlaw J, Cooper G, 
Tremayne AB, Bernard SS, Ponsford J, for the HTS Study Investigators: Prehospital 
hypertonic saline resuscitation of patients with hypotension and severe traumatic brain 
injury. A randomized controlled trial. JAMA 291:1350-1357, 2004.
15. Cruz J, Minoja G, Okuchi K: Improving clinical outcomes from acute subdural 
hematomas with the emergency preoperative administration of high doses of mannitol: 
a randomized trial. Neurosurgery 49:864-871, 2001.
16. Cruz J, Minoja G, Okuchi K: Major clinical and physiological benefits of early 
high doses of mannitol for intraparenchymal temporal lobe hemorrhages with abnormal 
pupilary widening: a randomized trial. Neurosurgery 51:628-638, 2002.
17. Dickinson K, Bunn F, Wentz R, Edwards P, Roberts I: Size and quality of 
randomised controlled trials in head injury: review of published studies. BMJ 320:1308-
1311, 2000.
18. Doppenberg EMR, Choi SC, Bullock R: Clinical trials in traumatic brain injury: 
lessons for the future. J Neurosurg Anesthesiol 16:87-94, 2004.
19. Dutton RP, MacCunn M: Traumatic brain injury. Curr Opin Crit Care 9:503-
509, 2003.
20. Gaab MR, Trost HA, Alcantara A, Karimi-Nejad A, Moskopp D, Schultheiss R, 
Bock WJ, Piek J, Klinge H, Scheil F, Osterwald P, Samii M, Brawanski A, Meixensberger 
J, Schurmann K, Schubert R, Arnold H, Kehler U, Deisenroth K, Benker G, Vester JC, 
Dietz H: “Ultrahigh” dexamethasone in acute brain injury. Results from a prospective 
randomized double-blind multicenter trial (GUDHIS). Zentralbl Neurochir 55:135-143, 
1994.
Chapter 3.3
108
21. Grumme T, Baethmann A, Kolodziejczyk D, Krimmer J, Fischer M, Eisenhart 
Rothe B, Pelka R, Bennefeld H, Pollauer E, Kostron H, Leheta F, Necek S, Neeser G, 
Sachsenheimer W, Sommerauer J, Verhoeven F: Treatment of patients with severe head 
injury by triamcinolone: a prospective, controlled multicenter clinical trial of 396 cases. 
Res Exp Med (Berl) 195:217-229, 1995.
22. Harders A, Kakarieka A, Braakman R, and the German tSAH Study Group: 
Traumatic subarachnoid hemorrhage and its treatment with nimodipine. J Neurosurg 
85:82-89, 1996.
23. Harris C, DiRusso S, Sullivan T, Benzil DL: Mortality risk after head injury 
increases at 30 years. J Am Coll Surg 197:711-716, 2003.
24. Hauck WW, Anderson S, Marcus SM: Should we adjust for covariates in non-
linear regression analyses of randomized trials?. Control Clin Trials 19:248-256, 1998.
25. Hernández AV, Steyerberg EW, Habbema JDF: Clinical trials with dichotomous 
end-points: covariate adjustment increased power and potentially reduces sample size. J 
Clin Epidemiol 57:454-460, 2004.
26. Hernández AV, Steyerberg EW, Habbema JDF: Inappropriate use of baseline 
characteristics in clinical trials: Assessment of high impact factor medical journals. Med 
Decis Making 2004; 24: 426.
27. Hukkelhoven CWPM, Steyerberg EW, Maas AIR: Quality of randomised 
controlled trials in head injury. BMJ 321:704, 2000.
28. Hukkelhoven CWPM, Steyerberg EW, Farace E, Habbema JDF, Marshall 
LF, Maas AIR: Regional differences in patient characteristics, case management, and 
outcomes in traumatic brain injury: experience from tirilazad trials. J Neurosurg 97:549-
557, 2002.
29. Hukkelhoven CWPM, Steyerberg EW, Rampen AJJ, Farace E, Habbema JDF, 
Marshall LF, Murray GD, Maas AIR: Patient age and outcome following severe trau-
matic brain injury: an analysis of 5600 patients. J Neurosurg  99:666-673, 2003.
30. Jennett B: Epidemiology of head injury. J Neurol Neurosurg Psychiatry 60:362-
369, 1996.
31. Lu LQ, Jiang JY, Yu MK, Hou LJ, Chen ZG, Zhang GJ, Zu C: Standard large 
trauma craniotomy for severe traumatic brain injury. Chin J Traumatol 6:302-304, 
2003.
32. Maas AIR, Steyerberg EW, Murray GD, Bullock R, Baethmann A, Marshall 
LF, Teasdale GM:Why have recent trials of neuroprotective agents in head injury failed 
to show convincing efficacy? A pragmatic analysis and theoretical considerations. 
Neurosurgery 44:1286-1298, 1999.
33. Machado SG, Murray GD, Teasdale GM: Evaluation of designs for clinical tri-
als of neuroprotective agents in head injury. J Neurotrauma 16:1131-1138, 1999.
34. Marshall LF, Maas AIR, Marshall SB, Bricolo A, Fearnside M, Iannotti F, 
Klauber MR, Lagarrigue J, Lobato R, Persson L, Pickard JD, Piek J, Servadei F, Wellis 
GN, Morris GF, Means ED, Musch B: A multicenter trial on the efficacy of using tirilazad 
mesylate in cases of head injury. J Neurosurg 89:519-525, 1998.
Subgroup analysis and covariate adjustment in traumatic brain injury trials
109
35. Masson F: Epidemiology of severe cranial injuries [in French]. Ann Fr Anesth 
Reanim 19:261-269, 2000. 
36. Morris GF, Bullock R, Marshall SB, Marmarou A, Maas A, the Selfotel 
Investigators, Marshall LF: Failure of the competitive N-methyl-D-aspartate antagonist 
Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III 
clinical trials. J Neurosurg 91:737-743, 1999.
37. Mosenthal AC, Lavery RF, Addis M, Kaul S, Ross S, Marburger R, Deitch 
EA, Livingston DH: Isolated traumatic brain injury: Age is an independent predictor of 
mortality and early outcome. J Trauma 52:907-911, 2002.
38. Moyé LA, Deswal A. Trials within trials: confirmatory subgroup analyses in 
controlled clinical experiments. Control Clin Trials 22:605-619, 2001
39. Narayan RK, Michel ME, and the Clinical Trials in Head Injury Study Group: 
Clinical trials in head injury. J Neurotrauma 19:503-557, 2002.
40. Reinert MM, Bullock R: Clinical trials in head injury. Neurol Res 21:330-338, 
1999.
41. Rockswold GL, Ford SE, Anderson DC, Bergman TA, Sherman RE: Results 
of a prospective randomized trial for treatment of severely brain-injured patients with 
hyperbaric oxygen. J Neurosurg 76:929-934, 1992.
42. Saul TG, Ducker TB, Salcman M, Carro E: Steroids in severe head injury. A 
prospective randomized clinical trial. J Neurosurg 54:596-600, 1981.
43. Simes RJ, Gebski VJ, Keech AC: Subgroup analysis: application to individual 
patient decisions. Med J Aust  180:467-469, 2004.
44. The European Agency for the Evaluation of Medicinal Products. Committee for 
Proprietary Medicinal Products (CPMP): Points to consider on adjustment for baseline 
characteristics. Document CPMP/EWP/2863/99, EMEA, London, UK, 22 May 2003. 
45. The European Study Group on Nimodipine in Severe Head Injury: A multicenter 
trial of the efficacy of nimodipine on outcome after severe head injury. J Neurosurg 
80:797-804, 1994.
46. Vranos G, Tatsioni A, Polyzoidis K, Ioannidis JPA: Randomized trials of neu-
rosurgical interventions: a systematic appraisal. Neurosurgery 55:18-26, 2004.
47. Wilson JTL: Assessing outcome in head injury trials. Curr Pharm Des 7:1537-
1552, 2001.
48. Wolf AL, Levi L, Marmarou A, Ward JD, Muizelaar PJ, Choi S, Young H, 
Rigamonti D, Robinson WL: Effect of THAM upon outcome in severe head injury: a 
randomized prospective clinical trial. J Neurosurg 78:54-59, 1993.
49. Young B, Runge JW, Waxman KS, Harrington T, Wilberger J, Muizelaar JP, 
Boddy A, Kupiec JW: Effects of pegorgotein on neurologic outcome of patients with 
severe head injury. A multicenter, randomized controlled trial. JAMA 276:538-543, 
1996.
50. Yusuf S, Wittes J, Probstfield J, Tyroler HA: Analysis and interpretation of 
treatment effects in subgroups of patients in randomized clinical trials. JAMA 266:93-
98, 1991.

Clinical applications 
4

Adjustment for strong 
predictors of outcome 
reduces sample size 
requirements by 25% in 
traumatic brain injury 
trials
4.1
Chapter 4.1
114
ABSTRACT
Purpose: To quantify the potential reduction in sample size that can be achieved 
by adjustment for predictors of outcome in traumatic brain injury (TBI) trials.
Methods: We used individual patient data from eight therapeutic phase III 
randomized clinical trials (RCTs, n=6292) in moderate or severe TBI, and three 
TBI surveys (n=2238). The primary outcome was the dichotomized Glasgow 
Outcome Scale at six months (favorable/unfavorable). Baseline predictors of 
outcome considered were age, motor score, pupillary reactivity, CT classifica-
tion, traumatic subarachnoid hemorrhage, hypoxia, hypotension, glycemia, 
and hemoglobin. We calculated the potential sample size reduction obtained by 
adjustment of a hypothetical treatment effect for one to seven predictors with 
logistic regression models. 
Results: The distribution of predictors was more heterogeneous in surveys than 
in trials. Adjustment of the treatment effect for the strongest predictors (age, 
motor score and pupillary reactivity) yielded a reduction in sample size between 
16% and 23% in RCTs, and between 28% and 35% in surveys. Adjustment for 
seven predictors yielded a reduction of about 25% in most studies: between 
20% and 28% in RCTs, and between 32% and 39% in surveys. 
Conclusions: A major reduction in sample size can be obtained with covariate 
adjustment in TBI trials. The design and analysis of future clinical trials should 
adjust for important predictors of outcome.
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Introduction
Traumatic Brain Injury (TBI) is an important public health problem worldwide 
(Jennett, 1996; Masson 2000). Unfortunately the search for effective treatments 
has not been very successful to date because of limitations in clinical develop-
ment programs and methodological weaknesses in phase III trials. Problems have 
included limited pre-clinical evaluation, inadequate sample sizes, insensitive 
outcome measures, over-optimistic expectations, ineffective therapies, inappro-
priate selection of patients, and heterogeneity of the patient population (Narayan 
et al., 2002; Doppenberg et al., 2004; Maas et al., 1999; Dickinson et al., 2000; 
Choi et al., 2002; Wilson, 2001).  
Adjustment of the treatment effect for important predictors of outcome (‘cov-
ariates’) can increase the statistical power to identify an efficacious treatment or 
intervention in a randomized clinical trial (RCT) (Gail et al., 1984; Hauck et al., 
1998; Steyerberg et al., 2000; Hernández et al., 2004; Hernández et al., in press 
a). Covariate adjustment also provides a more subject-specific treatment effect 
and corrects for any imbalance in measured patient characteristics. Many predic-
tors of outcome are known, including age, Glasgow Coma Scale (GCS) motor 
score, pupillary reactivity, and computed tomography (CT) abnormalities (Maas 
et al., 1999). In spite of this, covariate adjustment is not a standard procedure in 
TBI trials (Hernández et al., in press b).
 An adjusted analysis needs fewer patients than an unadjusted analysis 
for the same statistical power. Therefore, one way to quantify the increase in 
power with covariate adjustment is by calculation of the reduction in sample size 
(RSS) (Hernández et al., 2004; Hernández et al., in press a; Choi, 1998). A previ-
ous investigation to quantify the RSS was performed with data from a Medical 
College of Virginia TBI survey (Choi, 1998). Adjustment of the treatment effect 
for age and GCS motor score yielded a reduction in sample size of 30%. However, 
a survey population would be expected to be more heterogeneous than a typical 
RCT population, where strict inclusion and exclusion criteria are applied. Thus 
this previous study may have over-estimated the potential reduction achievable 
in the context of a RCT.
 No further evaluation of covariate adjustment has been reported in TBI. 
As part of the work of the IMPACT (International Mission for Prognosis of Head 
Injury and Analysis of Clinical Trials) Group we aimed to quantify the RSS 
achievable by adjustment for predictors of outcome for TBI patients included in 
RCTs and in surveys. 
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Methods
RCTs and Surveys
IMPACT links researchers based in the Netherlands, the UK, and the USA in 
a project addressing methodological problems in the design and the analysis of 
TBI trials. We have access to individual data from eight large phase III RCTs 
(Tirilazad International [TINT], Tirilazad USA [TIUS], Selfotel, SAPHIR, 
PEGSOD, HIT-I, HIT-II, SKB) and three TBI surveys (TCDB, EBIC, UK4).
Outcome and predictors
The primary outcome was the Glasgow Outcome Scale (GOS) at 6 months, 
dichotomized as unfavorable (death, vegetative state, and severe disability) or 
favorable (moderate disability, and good recovery). Age is a strong predictor of 
outcome in moderate to severe TBI patients (Hukkelhoven et al., 2003), as are 
GCS motor score and pupillary reactivity (Choi, 1998; Mushkudiani et al., 2004). 
Most of these prognostic studies were performed before the general availability 
of CT scans. Hukkelhoven et al. (in press) recently developed a model including 
seven early accessible clinical features and CT abnormalities: age, GCS motor 
score, pupillary reactivity, Marshall CT classification, traumatic subarachnoid 
hemorrhage (tSAH), hypoxia, and hypotension. Other novel potential predictors 
that we secondarily considered in our analyses were biochemical values: hyperg-
lycemia (Jeremitsky et al., 2005) and anemia (Ariza et al., 2004). 
Imputation of missing data
We selected patients with complete data on outcome, age and motor score (in-
cluding a ‘not testable’ category for the motor score). Further, only patients aged 
14 years and above were included in this analysis. Some of the other potential 
predictors were incomplete (Table 1). The SAPHIR and SKB trials did not record 
pupillary reactivity. The Tirilazad trials had few missing values (<14% over 9 
predictors). The PEGSOD trial did not record CT classification, hypoxia, and 
hypothension. Glycemia and hemoglobin were not available for the Selfotel and 
HIT-II trials, and the three surveys. We performed a two-stage single imputation 
technique where we estimated the expected values for the patients with missing 
covariate values based on correlations with other variables (Little, 1992). Values 
were randomly imputed to reflect the variability around the expected values us-
ing the aregImpute function in the Hmisc library of S-plus (Little, 2004). 
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Prognostic Models
A reference model including only the treatment variable was used as the com-
parator for other models. Five increasingly complex logistic regression models 
were then used to quantify the RSS, with a treatment indicator being included 
in every model. The first regression model included age. Then GCS motor score 
was added, followed by pupillary reactivity to give the ‘Core model’. CT classifi-
cation, tSAH, hypoxia, and hypotension were then added to give the ‘7-predictor 
model’, followed by glucose and hemoglobin to give the ‘Full model’. Each model 
was fitted for each of the studies. 
 Age, glucose and hemoglobin were treated as continuous variables, and 
the remainder as categorical variables: GCS motor score (5 categories – see Table 
2), pupillary reactivity (3 categories – see Table 2); Marshall CT classification 
(Marshall et al., 1991) (3 categories: normal CT [I] /cisterns present –shift<5mm 
[II]; cisterns compressed or absent-shift<5mm [III] /shift>5mm [IV]; evacu-
ated mass lesion [V] /non-evacuated mass lesion [VI]); tSAH (yes/no); hypoxia 
(yes/no); and hypotension (yes/no). The independent prognostic effects of the 
covariates were examined on the log-likelihood scale, providing chi-square (χ2) 
statistics.
Model performance was evaluated using the c-statistic and Nagelkerke’s R2. 
The c-statistic quantifies the discrimination of the model, i.e. the ability to dis-
tinguish unfavorable from favorable outcome. For binary outcomes the c-statistic 
is identical to the area under the receiver operating characteristic (ROC) curve. 
The c-statistic lies between 0.5 and 1 and indicates better model discrimination 
if closer to 1 (Steyerberg et al., 2001). Nagelkerke’s R2 measures the variability of 
the outcome explained by the model (i.e. the strength of association between the 
covariates and outcome). Nagelkerke’s R2 ranges from 0 to 1, with larger values 
indicating a better fit (Nagelkerke, 1991). The full models included glucose and 
hemoglobin, which were totally missing in the Selfotel and HIT-II trials and in 
the three surveys (Table 1). Therefore, we showed performance measures up to 
the 7-predictor models across all trials and surveys. 
Simulations
None of the RCTs included had demonstrated a significant treatment effect. We 
simulated a positive treatment effect that gave an unadjusted odds ratio (OR) of 
0.57 (coefficient: -0.557, corresponding to an average absolute risk reduction of 
10% in unfavorable outcome) (Machado et al., 1999). Fifty percent of the patients 
were randomly allocated to the hypothesized treatment. A new outcome variable 
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was generated per study and per simulation, based on the comparison of a ran-
dom uniform distribution (from 0 to 1) and the probability of poor outcome. This 
probability was based on the combination of the predictors of the full model and 
the treatment effect. Each regression model was applied in turn for this outcome 
to compare estimates of treatment effect. One thousand simulations were run 
using the original sample size for each study.  
  
Reduction in sample size
We calculated the RSS to express the gain in power for each of the adjusted mod-
els. The formula used was: 100 - 100*[(mean of Z score for reference model) / 
(mean of Z score for adjusted model)]2 (Hernández et al., 2004), where Z score is 
equal to the Wald statistic of the treatment effect coefficient. We only calculated 
RSS when data were available on the predictors included in the adjusted models 
(Table 1). Data on pupillary reactivity was not available in the SAPHIR and SKB 
trials, and the RSS was not calculated for their core models. Likewise, RSS was 
not calculated for the full models on trials or surveys with 100% of missings on 
biochemical values. We used S-plus 6 software (Insightful Inc, Seattle, WA). 
Results
Predictors of outcome
Age, GCS motor score and pupillary reactivity were the strongest predictors of 
outcome and had a χ2 of around 400. Other important predictors were tSAH 
(χ2=175), CT classification (χ2=102), hypotension (χ2=82), and hypoxia (χ2=30). 
Glucose and hemoglobin were weaker predictors.
The three strongest predictors were distributed differently across the datasets 
(Table 2). Patients enrolled in TBI trials (median age [25th-75th percentile]: 30 
[21-43]) were younger than patients enrolled in surveys (32 [22-53]). The UK4 
and EBIC surveys had the oldest patients, and the TCDB survey the youngest. 
A substantial proportion of patients from surveys had untestable GCS motor 
scores (n=375, 17%). However, a higher proportion of patients with GCS motor 
score ≥4 was seen in trials (56%) in comparison with surveys (46%). A lower 
proportion of patients from trials had bilateral non-reactive pupils (21%) than 
patients from surveys (32%). Thus, patients from trials had lower risks of unfa-
vorable outcome than patients from surveys (Table 2).
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Performance of the prognostic models
The performance of most models derived from surveys was better than for models 
derived from trials (Table 3). The c-statistics for the core model ranged between 
0.69 and 0.82, and increased substantially in the 7-predictor model, ranging be-
tween 0.74 and 0.87. Likewise, Nagelkerke’s R2 of the core model ranged between 
16% and 39%, and between 24% and 51% for the 7-predictor model. 
Reduction in sample size
The RSS for each model and across all studies is illustrated in Figure 1. We 
showed the RSS where data were available for the predictors included in the 
adjusted models. Adjustment of the treatment effect for age, motor score and 
pupillary reactivity yielded a RSS between 16% and 23% in trials, and between 
28% and 35% in surveys (Table 3). Adjustment for seven predictors yielded even 
larger reductions: between 20% and 28% in trials, and between 32% and 39% in 
surveys. Further adjustment for 9 predictors (full model) increased the reductions 
in sample size limitedly (not shown). The positive relationship between both the 
c-statistic and Nagelkerke’s R2 with the RSS is shown in Figures 2a and 2b for 
the core and 7-predictor models.
Discussion
A substantial reduction in the sample size requirements for TBI trials can be 
obtained with adjustment for important predictors. Adjustment of treatment ef-
fect for seven predictors (clinical, radiological and hypoxia) gave a reduction 
in sample size requirements between 20% and 28%. Adjustment for just three 
core clinical predictors showed a reduction between 16% and 23%. As expected, 
adjustment for predictors in population-based TBI surveys usually gave larger 
reductions in sample size requirements than trials. 
The first formal attempt to explore the potential reduction in sample size with 
covariate adjustment in the context of clinical trials with dichotomous outcomes 
was made by Choi (1998). He simulated a trial from data of a registry of 555 
patients of the Medical College of Virginia. The registry was divided into 2 in-
dependent treatment groups (A and B): group A retained its observed probability 
of favorable outcome, and group B was reconstructed by changing a proportion 
of patients (10%) from unfavorable to favorable outcome. A 30% reduction in 
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Figure 1. Reduction in sample size across studies for different logistic regression 
models. For each trial/survey: the first column to the left represents the model 
with age adjustment, the column in the middle the core model, and the last column 
the full model. Larger reductions in sample size are achieved in surveys (UK4, 
TCDB and EBIC) than in trials. Motor denotes GCS motor score; Pupils: pupillary 
reactivity; CT: Marshall CT classification; tSAH: traumatic subarachnoid 
hemorrhage; Hypox: hypoxia; Hypot: hypotension; Hb: hemoglobin.
sample size was found with adjustment for two strong predictors (age and GCS 
motor score). 
The main concern with Choi’s procedure is that the change to outcomes of 
group B patients was rather artificial. In clinical practice, a patient in a vegetative 
state is less likely to move to a good recovery state than a patient with severe 
disability with a given treatment. An alternative approach was described by 
Machado et al. (1999). They incorporated a positive treatment effect (OR= 0.57) 
into a logistic model with 3 predictors (age, GCS motor score, and Marshall CT 
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Figure 2. Relation between the reduction in the sample size, the c-statistic (Figure 
2a), and Nagelkerke’s R2 (Figure 2b). Empty and solid symbols represent values 
for the core model and 7-predictor model, respectively. A positive relationship 
between the RSS and both the c-statistic and Nagelkerke’s R2 is observed.
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classification) to create a new outcome. Thus, this outcome incorporated infor-
mation from predictors, and patients with better prognosis had a greater chance 
of moving from an unfavorable to a favorable outcome in comparison to patients 
with a worse prognosis. We followed the latter approach, but found that Choi’s 
approach gave very similar results (data not shown).  
In our simulations the core model (age, GCS motor score, pupillary reactivity) 
achieved good discrimination, which improved with the inclusion of more covari-
ates. This is consistent with findings that it is possible to make better predictions 
of GOS outcome with more predictors (Maas et al., 1999; Machado et al., 1999). 
Using the same seven predictors as in Hukkelhoven et al. (in press), improved 
the predictive ability of the core model substantially, but a further extension with 
glucose and hemoglobin yielded only minor added value. 
A similar pattern was observed in the RSS calculations. A larger RSS was 
observed when the 7-predictor model was used in comparison to the 3-predictor 
model. Reductions in sample size of approximately 20% with the core model and 
around 24% with the full model in TBI trials are greater than those obtained in 
trials of other fields in medicine. For instance, adjustment for 17 predictors of 
30-day mortality in patients with acute myocardial infarction included in the 
GUSTO-I trial reduced the sample size requirements by only 15% (Steyerberg et 
al., 2000). 
 
Other approaches to achieve a RSS have been suggested. Machado et al. 
(1999) used data from the EBIC survey, and defined models on different TBI 
prognostic groups, based on three predictors. They quantified the power that 
could be achieved when the analysis was targeted to some prognostic groups (e.g. 
defined by clinical or radiological characteristics), and when different treatment 
effects were defined for different prognostic groups (e.g. treatment benefit only 
in patients with intermediate prognosis). For instance, for a moderate/severe TBI 
population and with a uniform treatment effect, a trial with 344 patients with 
intermediate prognosis per arm had the same 90% power as a trial with 500 
unselected patients per arm –that is, the sample size could be reduced by 31% 
with no decrease in the power. 
More recently, Murray et al. (2005) proposed another approach to analyze TBI 
trials with ordered outcomes (such as GOS), called the ‘sliding dichotomy’. Using 
data from the Tirilazad International and Tirilazad USA trials, this approach 
increased the treatment OR from 1.38 to 1.71, and increased the statistical power 
to detect a significant treatment effect. These increases in power are equivalent 
to halving the trial sample size in a conventional analysis. Another approach is 
to use a proportional odds model. A formal comparison of these approaches to 
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quantify their benefits is required. 
Our work has several limitations. First, information was incomplete for seven 
of the nine predictors, particularly glucose and hemoglobin. However, it was 
possible to replace missing values using a well-accepted imputation technique 
based on correlations with other variables (Little, 1992). Second, the RSS may 
vary in other trials according to their inclusion criteria. More or less restrictive 
criteria will produce less or more heterogeneous trial populations, respectively. 
Trials with more homogeneous patients may have a more limited benefit from 
covariate adjustment. Mega-trials, such as CRASH (n=10008), have considerable 
heterogeneity (CRASH trial collaborators, 2004, 2005). It is expected that cov-
ariate adjustment might yield a substantial RSS, although completeness of data 
for predictors may be of concern. Third, we used trials conducted between 1984 
and 1997, and more recent trials may contain more or less heterogeneous popula-
tions. Finally, further work should indicate the incremental benefit to the RSS for 
the combination of the covariate adjustment with newer analysis approaches that 
exploit the ordinal nature of the outcome, such as the sliding dichotomy (Murray 
et al., 2005).  
 In conclusion, adjustment of the treatment effect for seven strong predictors 
yielded a reduction in sample size requirements by 25% in TBI trials, whilst 
adjustment for the three strongest predictors achieved a reduction of sample size 
of about 20%. Covariate adjustment for strong predictors should be incorporated 
in the design and analysis of future TBI trials. 
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ABSTRACT
Purpose
To investigate whether the effects of platelet glycoprotein (GP) IIb/IIIa receptor 
blockers in patients with non-ST-elevation acute coronary syndromes (NSTE-
ACS) depend on patient age.
Methods
An individual data meta-analysis of 6 trials (PRISM, PRISM-PLUS, PARAGON-
A, PURSUIT, PARAGON-B, GUSTO4-ACS; n=31,402) was performed. Patients 
were randomized to a GP IIb/IIIa receptor blocker or placebo/control. We applied 
multivariable logistic regression analyses to evaluate the drug effects on death 
or non-fatal MI at 30 days, as well as on major bleeding, by age subgroups (<60, 
60-69, 70-79, ≥80 years). We quantified the reduction of death or MI as number 
needed to treat (NNT), and the increase of major bleeding as number needed to 
harm (NNH) across age subgroups.
Results
Overall, 11,155 (35%) patients were <60, 9,727 (31%) were 60-69, 8,468 (27%) 
were 70-79, and 2,049 (7%) were ≥80 years-old. The relative benefit of GP IIb/
IIIa receptor blockers did not differ significantly (p=0.5) across age subgroups 
(odds ratio [95% CI] for death or MI: 0.86 [0.74-0.99], 0.90 [0.80-1.02], 0.97 
[0.86-1.10], 0.90 [0.73-1.16]; overall 0.91 [0.86-0.99]). Odds ratios (95% CIs) for 
major bleeding were 1.9 (1.3-2.8), 1.9 (1.4-2.7), 1.6 (1.2-2.1), and 2.5 (1.5-4.1), 
respectively. The overall NNT was 105, and the overall NNH was 90. The oldest 
patients had larger absolute increases in major bleeding, but also had the largest 
absolute reductions of death or MI. Patients ≥80 years had a half of the NNT and 
a third of the NNH in comparison with patients <60 years.
Conclusions
In patients with NSTE-ACS, the relative reduction of death or non-fatal MI with 
GP IIb/IIIa receptor blockers was independent of patient age. Larger absolute 
outcome reductions were seen in the elderly, but with a higher risk of major 
bleeding. Thus, a close monitoring of these patients is warranted.
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Introduction
Platelet glycoprotein (GP) IIb/IIIa receptor blockers decrease the risk of death or 
non-fatal myocardial infarction (MI) at 30 days in patients with non-ST elevation 
acute coronary syndromes (NSTE-ACS) who are not routinely scheduled for 
early revascularization 1-4. Age is an important risk factor for these patients, and 
if the relative benefits of effective interventions are the same across age groups, 
physicians should treat the elderly even more aggressively than the younger, since 
the absolute benefit may be larger 5. However, in clinical practice, the utilization 
of GP IIb/IIIa receptor blockers is lower among elderly patients 6.
Elderly patients may be undertreated because of several reasons: they were 
underrepresented or excluded from randomized clinical trials (RCTs), clinicians 
may believe that benefits in younger may not generalize to the elderly, or they 
may be worried about harmful effects in elderly patients 5. Researchers have 
argued that the benefit of GP IIb/IIIa receptor blockers is greater in younger 
patients 7, similar in old and younger patients 8, or greater in older patients given 
their higher baseline risk 5, 9. 
Yet, it is difficult to determine how the efficacy of GP IIb/IIIa receptor blockers 
varies among age subgroups because most trials are not large enough to provide a 
reliable answer. Individual ACS trials have been inconclusive or even conflicting 
regarding the presence or absence of relative differences in drug effects across 
ages 10-15. Usually, the patient population was only split in two age groups (e.g. 
<65 years, ≥65 years) 11, 13-15, and different primary endpoints were considered. 
An evaluation of the drug effects across age groups in a meta-analysis using 
individual data can better define its relative and absolute efficacies in older vs. 
younger patients.
One more issue is relevant in the interpretation of the effects of GP IIb/IIIa 
receptor blockers by age groups. The incorporation of harmful major bleeding 
rates in the evaluation of effects should be considered to further understand the 
net drug effectiveness across age strata 5, 9, 16.
We investigated whether the relative effects of GP IIb/IIIa receptor blockers 
were consistent across age subgroups in non-ST-segment elevation ACS patients. 
Further, we evaluated whether the absolute benefits and harms differed across 
age subgroups.
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Methods
Trial selection
A meta-analysis of individual patient data was performed, including trials re-
ported since 1990 with the following characteristics: randomization of patients 
with NSTE-ACS, comparison of a GP IIb/IIIa receptor blocker with placebo or 
control therapy, no-recommendation for early (<48h) coronary revascularization 
during study-drug infusion, and enrolment of at least 1000 patients. Six trials 
met the inclusion criteria -PRISM, PRISM-PLUS, PARAGON-A, PURSUIT, 
PARAGON-B, and GUSTO IV-ACS- 10-15 with a total of 31,402 patients. Details 
of the trial designs are available elsewhere 3.
Patient baseline characteristics
An electronic database consisting of data from individual patients in all eligible 
trials was available 3. These data were checked for completeness, for internal 
consistency of patients’ records, and for consistency with the published reports. 
For this analysis, baseline characteristics regarded as important predictors of the 
outcome for which information was almost complete (i.e. less than 1% miss-
ing) were age, gender, diabetes, smoking, previous myocardial infarction [MI], 
previous heart failure [HF], previous coronary artery bypass surgery (CABG), 
previous percutaneous coronary intervention (PCI), and ST-segment depression. 
Other important predictors had more than 20% of missing data: blood pressure 
and heart rate were not recorded in the GUSTO IV-ACS trial (n=7800, 25%); and 
baseline creatine kinase MB (CK-MB) was missing in 7469 patients (24%) across 
different trials. Blood pressure, heart rate and CK-MB were used in addition to 
the other predictors in secondary analyses that yielded largely similar results.
Endpoints
For this analysis, the primary efficacy endpoint was defined a priori as the 
composite of death of any cause or non-fatal MI at 30 days. MI was part of the 
composite outcome of all trials. The MI definitions had subtle differences across 
trials regarding the CK-MB threshold 3. However, all trials had pre-specified 
definitions of MI 17, 18. Secondary endpoints were: death; non-fatal MI; coronary 
artery bypass graft (CABG); percutaneous coronary intervention (PCI); and 
CABG or PCI. The primary harm endpoint was major bleeding within 30 days. 
Individual trial definitions of major bleeding had also at most subtle differences, 
and trial-specific definitions were retained 3.
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Efficacy analysis by age
We divided the patient data into four subgroups according to age: <60, 60-69, 
70-79, and ≥80 years old. The decision to group patients in these intervals was 
made a priori, and was based on decade intervals of common clinical use. The 
choice of other cut-off points (e.g. quartiles) yielded similar results (not shown). 
Relative differences between GP IIb/IIIa receptor blockers and placebo/control 
on the primary endpoint by age subgroups were assessed, within each trial and 
across all trials. Logistic regression models were used, and odds ratios (OR) and 
corresponding 95% confidence intervals (95% CI) were calculated. To evalu-
ate GP IIb/IIIa receptor blocker effect modification by age in each individual 
trial and in all trials, interaction tests were used 19. These tests also evaluated 
heterogeneity of effects across trials. The effects of GP IIb/IIIa receptor blockers 
and the interactions were adjusted for the previously described predictors, for 
trial, and for potential differences in age-related trends between trials. These 
effects were combined using random effects calculations 20. Heterogeneity of 
interactions across trials was evaluated with the random effects inverse variance 
model (with trial being the random effect) 21. 
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We performed analyses that incorporated the relation among the baseline risk 
(eBR, proportion of patients in the placebo/control group with the primary effi-
cacy endpoint), the efficacy Odds Ratio (eOR), and the respective number needed 
to treat [NNT]. The calculation of NNT was done using eBR and eOR, with the 
formula: [1-eBR(1-eOR)]/ [eBR(1-eBR)(1-eOR)] 22. The NNT is the number of 
patients who need to be treated in order to prevent one additional death or non-
fatal MI. It is the inverse of the absolute risk reduction (ARR). Further, we looked 
at the relation among the baseline proportion of the primary harm endpoint in 
the placebo/control group (hBR), the harm Odds Ratio (hOR), and the respective 
number needed to harm [NNH]. The NNH was calculated using hBR and hOR, 
with the formula: [hBR(hOR-1)+1]/[hBR(1-hBR)(hOR-1)] 22. The NNH is the 
number of patients who need to be treated in order to cause one major bleeding. 
It is the inverse of the absolute risk increase (ARI). The NNT and NNH calcula-
tions were done overall and by age subgroups. 
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Role of the funding source
The trials included in this analysis were sponsored by several pharmaceutical 
companies, which are mentioned in the main trial reports 10-15, and in the acknowl-
edgements. This study was designed, conducted, and interpreted independently 
of the sponsors. These had the right to review the manuscript, but not censor the 
findings. No separate industrial grant was obtained for this investigation.
 
Results
Age subgroups and predictors
Overall, 11,155 (35%) patients were < 60, 9,727 (31%) were 60-69, 8,468 (27%) 
were 70-79, and 2,049 (7%) were ≥ 80 years-old. Baseline characteristics across 
age subgroups are shown in Table 1. The proportion of women and of patients 
with a history of diabetes, MI or HF, and ST depression increased with age. 
Further, patients ≥80 years had lower proportions of previous revascularization 
procedures than younger patients. The proportion of patients older than 70 years 
ranged between 30% in the PURSUIT and PRISM trials and 40% in the GUSTO 
IV-ACS trial.
Endpoints at 30 days by age subgroups
The overall adjusted relative reduction in the odds of death or MI at 30 days was 
9% (OR 0.91; 95% CI [0.85-0.99]). There was no difference in the relative benefit 
of GP IIb/IIIa receptor blockers across age subgroups (p for interaction = 0.5) 
and this was true also for secondary efficacy endpoints (Table 2). Interestingly, 
the ratio of non-fatal MI over death decreased with increasing age. The overall 
adjusted relative increase in the odds of major bleeding was 83% (OR 1.83 [1.5-
2.2]). This was especially high for patients ≥80 years (OR 2.5 [1.5-4.1]), but there 
were no significant differences across ages (p for interaction=0.3) (Table 2). 
Benefit of GP IIb/IIIa receptor blockers per trial by age subgroups
With regard to the incidence of death or non-fatal MI, two trials showed signifi-
cantly different relative effects across age subgroups, but in opposite directions 
(Table 3). The PRISM trial patients had a clear gradient of GP IIb/IIIa receptor 
blocker effect across ages: older patients had larger odds reductions than younger 
ones (p for interaction=0.01). Conversely, younger PURSUIT patients had larger 
Benefit and harm of GP IIb/IIIa receptor blockers in NSTEMI across age subgroups
137
<60 years
(n=11,155)
  60-69 years 
(n=9,727)
70-79 years 
(n=8,468)
�80 years
(n=2,049)
N % N % N % N %
Gender
Male   8275  74    6274 65   4841 57     997 49
Diabetes
   Yes   1771  16    2360 24   2269 27     461   23 
Smoking
Never
   Former 
Current
  3931 
  3144 
  4036 
 35 
 28 
 36 
   3439 
   3537 
   2709 
36
37
28
  3269 
  3133 
  2015 
39
37
24
    861 
    621 
    552 
  42 
  31 
  27 
Previous MI
   Yes   3164  28    3445 36   3162 37     877   43 
Previous HF
   Yes     578    5      962 10   1191 14     437   21 
Previous CABG
   Yes   1088  10    1305 13   1194 14     185     9 
Previous PCI 
   Yes   1454  13    1251 13     956 11     162     8 
ST depression 
   Yes   5096  46    5475 57   5441 65   1403   69 
Trial
PRISM
   PRISMPLUS 
   PARAGON-A 
   PURSUIT 
   PARAGON-B 
   GUSTO4-ACS
  1274
    693 
    737 
  4082 
  1976 
  2393 
 11 
   6 
   7 
 37 
 18 
 21 
   1005 
     603 
     728 
   3553 
   1513 
   2325 
10
  6 
  8 
37
16
24
    781 
    495 
    631 
  2763 
  1374 
  2424 
  9 
  6 
  8 
33
16
29
    172 
    124 
    183 
    550 
    362 
    658 
    8 
    6 
    9 
  27 
  18 
  32 
MI denotes myocardial infarction, HF: heart failure, CABG: coronary artery bypass graft, PCI: percutaneous 
coronary intervention, y: years. Differences among age subgroups were highly significant (p<0.001). 
Table 1. Patient characteristics by age subgroups.
odds reductions than the older ones (p for interaction=0.03). The interactions 
between GP IIb/IIIa receptor blockers and age subgroup were heterogeneous 
across trials (p=0.002).
Benefit and harm of GP IIb/IIIa receptor blocker across age subgroups
The absolute risk of death or MI at 30 days correlated with age, varying from 
8% in the youngest (<60 years) to 21% in the oldest group (≥80 years). Major 
bleeding at 30 days also correlated with age, from 0.8% in the youngest to 2.3% 
in the oldest. For the overall relative reduction in the odds of death or MI of 9%, 
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the NNT was 105. For the overall relative increase in the odds of major bleeding 
of 83%, the NNH was 90. 
The oldest patients had the largest absolute reductions of death or MI, but also 
had larger absolute increases in major bleeding. Patients younger than 70 years 
had higher NNTs and NNHs (149 and 163 for those younger than 60 years, and 
105 and 110 for those between 60 and 69 years) than those older than 70 years (87 
and 55 for those between 70 and 79 years, and 67 and 56 for those older than 80 
years). The Figure shows the absolute event rate difference between GP IIb/IIIa 
receptor blocker and placebo/control arms across age subgroups. We noted a 
rather larger harm in patients ≥70 years and a somewhat variable benefit across 
all age subgroups.
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Figure. Absolute event rate differences between treatment arms (GP IIb/IIIa vs. 
placebo/control) by age subgroups in beneficial (death or myocardial infarction) 
and harmful (major bleeding) endpoints. GP IIb/IIIa denotes platelet glycoprotein 
IIb/IIIa receptor blockers.
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Discussion
In patients with ACS without ST elevation, the relative reduction in the odds of 
death or MI at 30 days with GP IIb/IIIa receptor blockers was largely independent 
of age. The oldest patients had about 3-fold the baseline risk of the youngest ones, 
not only for death or MI, but also for major bleeding. In the oldest patients, the use 
of GP IIb/IIIa receptor blockers yielded larger absolute reductions of death/MI, 
but also larger absolute increases in major bleeding rates in comparison with the 
youngest patients. 
This meta-analysis had more statistical power than individual trials to explore 
how the GP IIb/IIIa receptor blocker effects vary by age 7-9, 23. Individual trials 
did not report these effects in detail across similar age subgroups 10, 11, 13-15, and 
they analyzed different endpoints. Previous analyses of the age effects in single 
trials have yielded inconclusive results 24. Only the PURSUIT and GUSTO IV-
ACS reported the same primary endpoint as we used in this paper. Also, these 
analyses did not adjust for important predictors of the primary endpoint. We found 
that the PRISM and the PURSUIT trials showed significant differential relative 
effects of GP IIb/IIIa receptor blockers across ages, but differences were in the 
opposite direction. We do not fully understand this phenomenon. We speculate 
that it could be related to the doses used as well as the duration of the study drug 
infusion. This might have resulted in different levels of platelet inhibition in the 
PRISM trial (where the dose was later shown to produce suboptimal platelet 
inhibition in young patients) as compared to the PURSUIT trial (where the dose 
was not adjusted for older age or modest renal impairment), which might have 
had different consequences in younger and older patients.
 
The effects of other antithrombotics have been evaluated in elderly patients 
with unstable angina or NSTE-ACS 9. The low molecular weight heparin enoxa-
parin, compared with unfractionated heparin, appeared to have greater relative 
and absolute benefit in patients aged 65 years and older, as compared with younger 
patients. When comparing clopidogrel plus aspirin to aspirin alone, there was a 
consistent 20% relative reduction in cardiovascular death, myocardial infarction, 
or stroke in both elderly and younger patients. For GP IIb/IIIa receptor blockers, 
we found an equivalent relative benefit across age subgroups, which translated 
into a greater absolute benefit in older in comparison with younger patients.
Most trials, meta-analyses, and systematic reviews have neglected the contri-
bution of major bleeding rates in the evaluation of the net GP IIb/IIIa receptor 
blocker effectiveness across age subgroups in NSTE-ACS patients 1-4, 10-15, 25-30. 
Elderly patients have higher absolute risks of major bleeding 6, 31. Therefore, 
the interpretation of the overall GP IIb/IIIa receptor blocker efficacy needs to 
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incorporate this harm. We should acknowledge that death or non-fatal MI and 
major bleeding do not have the same utility, and therefore are not comparable 
events. Determining the relative weights of these events is largely subjective. 
A recent review identified that the weight of a major bleeding related to a drug 
in the context of an acute coronary syndrome was 0.87, in comparison with the 
weight of death, which was equal to zero 32. In order to describe the relative gain 
in primary efficacy end points by age subgroups, we defined a ratio of reduction 
of non-fatal MIs to reduction of deaths. For instance, a ratio higher than 1 shows a 
larger benefit in reduction of non-fatal MIs in comparison to reduction of deaths. 
Given that the ratio of non-fatal MI to death decreased with increased age, the 
use of GP IIb/IIIa receptor blockers in the oldest likely aborted more deaths than 
non-fatal MIs. 
 An appropriate dosing of GP IIb/IIIa receptor blockers is a requisite to 
obtain a higher benefit and a lower harm in elderly NSTE-ACS patients. The 
CRUSADE registry demonstrated that GP IIb/IIIa receptor blockers were un-
derutilized and mis-dosed in elderly patients, who are at higher risk for adverse 
cardiac events 33. An essential factor that increases the risk of major bleeding in 
elderly patients is low renal function, which is associated with higher serum levels 
of GP IIb/IIIa receptor blockers. Doses used in early trials were more aggressive 
than currently recommended doses, which are adjusted for renal dysfunction. 
Thus, elderly NSTE-ACS patients should receive adequate doses of GP IIb/IIIa 
receptor blockers to obtain the expected clinical benefit, and these doses should 
be adjusted for their level of renal function to avoid major bleeding events. 
A recent decision analysis evaluated the efficacy of an unspecified potential 
drug on survival in patients with MI and unstable angina 5, and included serious 
adverse events (fatal complications) as an element of the evaluation of benefit-
risk balance by age-related baseline risks. The authors used a registry database, 
and a hard primary endpoint (mortality at 1 year). The estimate of effectiveness 
was larger than in our randomized data (relative risk reduction 25%, absolute 
risk reduction 2%), and the registry population was more heterogeneous in risk 
(baseline risk of 2.3% in the youngest vs.27% in the oldest). They defined a 
threshold beyond which the treatment benefit would be outclassed by the treat-
ment harm, and found that the fatal complication rate would have to be sevenfold 
greater in the oldest compared with the youngest age group to outweigh the 
survival benefits associated with treatment. These results need to be interpreted 
cautiously given that most major events in these patients do not lead to death. 
Moreover, retrospective observational data may sometimes inflate estimates of 
treatment efficacy 34. 
Some limitations should be acknowledged. First, even with over 30,000 ran-
Benefit and harm of GP IIb/IIIa receptor blockers in NSTEMI across age subgroups
143
domized patients, subtle age interactions could have been missed, especially for 
rare events such as death. We did not see any age interactions for death based on 
the available data (not reported) and the clinical significance of subtle interactions 
is debatable. Second, a substantial amount of missing values for a few important 
predictors (blood pressure, heart rate, CK-MB) limited some possibilities of 
adjusted analysis. However, the results with imputed data yielded similar conclu-
sions (not shown). Third, additional research into the appropriate weighting of 
events is needed, that can allow a more direct comparison between benefits and 
harms. 
A series of nuances should be considered in interpreting these results. The 
trials included broad populations of patients with ACS. Through analysis of 
subgroups, it seems evident that higher risk patients, such as those with positive 
troponins, diabetes, and perhaps ST segment depression, achieve the greatest 
benefit. Further, it is likely that patients treated with the aggressive revascular-
ization strategy achieve more benefit than those treated with the conservative 
strategy. The trials themselves were heterogeneous, as GUSTO IV-ACS showed 
no benefit and perhaps a detriment of abciximab, and PURSUIT used a very lib-
eral definition of myocardial infarction that minimized the differences between 
eptifibatide and placebo. Finally, the category of major bleeding overestimates 
risk relative to the risk of blood transfusion, which is a more direct measure of 
risk and occurs less frequently (Mahaffey KW et al., Circulation, in press). The 
EARLY ACS trial is enrolling patients without age limits, it is testing whether 
the benefit of antithrombotic drugs is similar between elderly and young patients, 
and it is also addressing each of the above issues 35. Allowing for these caveats, 
our analysis provides estimates for NNTs and NNHs by age subgroups that may 
be used in clinical decision making for the use of GP IIb/IIIa receptor blockers 
in NSTE-ACS patients.
 In conclusion, the relative risk reduction of death or MI with GP IIb/IIIa 
receptor blocker is independent of age in patients with non-ST-elevation acute 
coronary syndromes. Larger absolute reductions of death or MI were observed 
in the oldest in comparison with the youngest patients, as well as larger absolute 
increases in major bleeding rates. Attention should be given to optimizing the 
benefit to elderly patients without increasing bleeding, by ensuring that doses 
adjusted for renal function are given. Moreover, elderly patients should be moni-
tored more intensively.
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ABSTRACT
Purpose
Stroke is an uncommon but serious complication in patients with non-ST-segment 
elevation acute coronary syndromes (NSTE-ACS). We studied baseline patient 
characteristics that predict the development of stroke at 30 days.
Methods
We pooled data from 6 trials (n=31402) that randomized NSTE-ACS patients 
either to platelet glycoprotein (GP) IIb/IIIa receptor blockers or placebo/control. 
Potential predictors of stroke included treatment, and demographic and clinical 
characteristics. We quantified predictors using univariable and multivariable 
logistic regression models, and their performance was evaluated with calibration 
(Hosmer-Lemeshow test) and discrimination (c-statistic).
Results
We found 228 (0.7%) all-cause strokes: 155 (0.5%) non-hemorrhagic, 20 (0.06%) 
hemorrhagic, and 53 without CT confirmation. Patients with any type of stroke had 
a 30-day mortality of 25%. Randomization to GP IIb/IIIa receptor blockers was 
not significantly associated with all-cause stroke (OR [95% CI] 1.08 [0.83 – 1.41]. 
Older age (OR per increase of 10 years 1.5 [1.3-1.7]), prior stroke (2.1 [1.4-3.1]) 
and elevated heart rate (per increase of 10 beats 1.1 [1.0-1.2]) were the strongest 
predictors of 30-day all-cause stroke. Similar predictors were found for non-
hemorrhagic and hemorrhagic strokes. Secondary predictors of all-cause stroke 
included smoking, previous myocardial infarction, diabetes and hypertension. 
The multivariable model to predict all-cause stroke was well calibrated, but the 
discriminative power was only moderate (c-statistic 0.69 [0.65 – 0.72]).
Conclusions
Stroke is a rare complication occurring early after NSTE-ACS, but is associated 
with high mortality. We found no evidence that GP IIb/IIIa receptor blockers 
increase stroke risks. There were few clinical characteristics that predicted a 
higher stroke risk. Thus, incident strokes in NSTE-ACS patients remain largely 
unexplained.
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Introduction
The non-ST-segment elevation acute coronary syndrome (NSTE-ACS) is a 
heterogeneous disease. Risk stratification is essential for predicting prognosis, 
planning treatment strategy, and providing information to patients and relatives 
1, 2. Previous papers in patients with NSTE-ACS have evaluated the predictors 
associated with a range of clinical outcomes at 30 days or 6 months, such as 
death, cardiovascular death, and cardiovascular death or myocardial infarction 
(MI) 2-5.
Stroke is an uncommon but severe event in patients presenting with NSTE-
ACS. Analyses with a few events in the PURSUIT trial found several clinical 
predictors of non-hemorrhagic stroke at 30 days 6. These patients are also at 
increased risk for hemorrhagic strokes from polypharmacy anticoagulation. 
However, the confirmation of the importance of these predictors of stroke with a 
larger number of patients and events is desirable.
We aimed to identify baseline clinical and demographic patient characteristics 
that predict the development of all-cause, non-hemorrhagic and hemorrhagic 
strokes within 30 days. We analyzed 31,387 patients with NSTE-ACS from 6 
large international trials. Moreover, we evaluated whether the use of GP IIb/IIIa 
receptor blockers was associated with an increased risk of stroke.
 
Methods
Clinical trials
We used individual patient data from 6 trials (PRISM, PRISM-PLUS, PARAGON-
A, PURSUIT, PARAGON-B, and GUSTO IV-ACS) 7-12. These trials were 
reported since 1990 with the following characteristics: randomization of patients 
with NSTE-ACS, comparison of platelet glycoprotein (GP) IIb/IIIa receptor 
blockers with placebo or control therapy, no-recommendation for early (<48h) 
coronary revascularization during study-drug infusion, and enrolment of at least 
1000 patients. A total of 31,402 patients participated in these trials. Details of the 
trial designs are available elsewhere 13.
Potential predictors
An electronic database consisting of data from individual patients in all eligible 
trials was available 13. These data were checked for completeness, for internal 
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consistency of patients’ records, and for consistency with the published reports. For 
this analysis, we used available baseline demographic and clinical characteristics 
regarded as potential predictors of stroke 6. Those with almost complete 
information (<1% of missing values) included age, gender, smoking, weight, and 
prior history all the following: hypertension, diabetes, stroke, MI, heart failure, 
angina pectoris, coronary artery bypass surgery (CABG), percutaneous coronary 
intervention (PCI), and use of aspirin. Two variables had 2% of missing values: 
history of hypercholesterolemia, and ST-depression at baseline.
Other variables had more than 20% of missing data: race, heart rate, blood 
pressure (systolic and diastolic), and prior use of beta blockers, ACE inhibitors, 
nitrates and calcium antagonists. Blood pressure and heart rate were not recorded 
in the GUSTO IV-ACS trial (n=7800); baseline creatine kinase MB (CK-MB) 
was missing in 7469 patients across different trials. Predictors with more than 
20% of missing were imputed using the EM (estimated mean) procedure in SPSS 
(SPSS Inc., Chicago IL, USA, 1999). Atrial fibrillation and creatinine clearance 
were not available. The body mass index could not be calculated (i.e. no height 
was available) and it was not included in the analysis. The use of GP IIb/IIIa 
receptor blockers was also included as a potential predictor of stroke.
Outcomes
For this analysis, the primary outcomes defined a priori were all-cause stroke, 
non-hemorrhagic stroke, and hemorrhagic stroke within 30 days of the index 
ACS. Non-hemorrhagic and hemorrhagic strokes needed CT confirmation. All-
cause stroke was missing for 12 patients. Non-hemorrhagic stroke was missing 
in 7434 patients, and hemorrhagic stroke was missing in 7474 patients. No formal 
attempt to impute these outcomes was done.
Statistical analysis
Univariable logistic regression models were used to evaluate the association 
between each potential predictor and the outcome. The predictive weight of 
each variable was expressed as a χ2 statistic, which was calculated on the –2 log 
likelihood scale. The higher the number, the more important the predictor; a χ2 
exceeding 3.84 corresponds to p<0.05 for a predictor with 1 degree of freedom. 
All predictors were entered in a multivariable logistic regression model without 
further selection to properly evaluate their predictive effects while adjusting for 
the effects of each other predictor 14.
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The performance of the multivariable models was studied with respect to 
discrimination and calibration. Discrimination refers to the ability to distinguish 
a stroke from no stroke. It was quantified by a measure of concordance, the c-
statistic. For binary outcomes the c-statistic is identical to the area under the 
receiver operating characteristic (ROC) curve. The c-statistic lies between 0.5 
and 1, and is better if closer to one 15. Since the apparent c-statistic is optimistic 
with low numbers of events, we used a standard bootstrapping procedure to 
correct the estimates 14, 15. Calibration refers to whether the predicted risks agree 
with the observed risk frequencies. Calibration was measured with the Hosmer-
Lemeshow goodness-of-fit test 16. Analyses were performed in SPSS 10.0 and 
S-PLUS 2000 (Insightful Inc, Seattle WA, USA).
 
Results
Patient characteristics
We found 228 (0.7%) all-cause strokes in the study population: 155 (0.5%) 
were non-hemorrhagic, 20 (0.06%) hemorrhagic, and 53 (0.2%) without CT 
confirmation. Older patients, those with a prior stroke, prior MI, diabetes, 
hypertension, and patients with elevated heart rate had higher risks of all-cause 
and non-hemorrhagic strokes (Table 1). Smoking was not clearly related with the 
stroke incidence. Patients with previous PTCA were at lower risk to develop any 
stroke. Less clear associations were seen in hemorrhagic strokes, probably due 
to small numbers.
A high proportion of patients who suffered a stroke died: 56 (25%) of those 
with all-cause stroke, 27 (17%) of those with non-hemorrhagic stroke and 13 
(65%) of those with hemorrhagic stroke. The difference in mortality between 
non-hemorraghic and hemorrhagic strokes was highly statistically different 
(p<0.001). No clear relation was observed between predictors and death in 
patients who suffered any type of stroke (Table 1).
 
Predictors of stroke
The use of GP IIb/IIIa receptor blockers was not associated with a higher 
incidence of all-cause (OR [95% CI] 1.08 [0.83-1.41]), non-hemorrhagic (1.06 
[0.77-1.47]), and hemorrhagic (1.70 [0.65-4.45]) strokes.
The strongest univariable predictors of all-cause stroke were older age 
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(χ2=69), prior stroke (χ2=19), prior MI (χ2=12), hypertension (χ2=10), elevated 
heart rate (χ2=9), lighter weight (χ2=9), diabetes (χ2=8), and smoking (χ2=6). 
The associations are shown in Table 2. No interactions between predictors were 
statistically significant. The three most important predictors were older age (OR 
[95% CI] per 10 years: 1.5 [1.3-1.7]), prior stroke (2.1 [1.4-3.1]), and elevated heart 
rate (per 10 beats: 1.1 [1.0-1.2]). Multivariable predictors with relatively minor 
effects included smoking, prior MI, diabetes mellitus and hypertension.
The strongest univariable predictors of non-hemorrhagic stroke were older 
age (χ2=38), prior stroke (χ2=18), elevated heart rate (χ2=9), prior MI (χ2=7), 
and diabetes (χ2=7). Lighter weight (χ2=4), and hypertension (χ2=3) had minor 
importance. The three most important predictors of non-hemorrhagic stroke had 
All-cause strokes 
n=228
Non-hemorrhagic strokes 
n=155
Hemorrhagic strokes 
n=20
Predictor N n (%) deaths (%)†    N n (%) deaths (%)† N n (%) deaths (%)
Age*
<70 y 
�70y
20874
10513
   98 (0.5) 
 130 (1.2) 
20 (20) 
36 (28) 
15836
 8132 
   69 (0.4) 
   86 (1.1) 
  10 (15) 
  17 (20) 
15822
  8108 
   6 (0.03) 
 14 (0.17) 
   4 (67) 
   9 (64) 
Prior stroke* 
    No 
    Yes 
29890
  1446 
 201 (0.7) 
   27 (1.9) 
   50 (25) 
     6 (22) 
22777
  1141 
 134 (0.6) 
   21 (1.8) 
    24 (18) 
      3 (14) 
23744
  1134 
 16 (0.07) 
   4 (0.35) 
 10 (63) 
   3 (75) 
Heart rate 
   <75 
�75
16807
14580
 104 (0.6) 
 124 (0.9) 
   18 (17) 
   23 (19) 
12577
11391
   70 (0.6) 
   85 (0.7) 
    11 (16) 
    10 (12) 
12564
11364
 10 (0.08) 
 10 (0.09) 
   5 (50) 
   8 (80) 
Smoking
   Never 
   Former 
   Current 
11499
10429
  9307 
 68 (0.6) 
 91 (0.9) 
 68 (0.7) 
   15 (22) 
   21 (23) 
   20 (29) 
 9516 
 7577 
 6768 
 55 (0.6) 
 55 (0.7) 
 44 (0.7) 
      8 (15) 
    10 (18) 
      9 (20) 
  9511 
  7557 
  6753 
   7 (0.07) 
   6 (0.08) 
   7 (0.10) 
   4 (57) 
   4 (67) 
   5 (71) 
Prior MI 
   No 
   Yes 
20648
10646
 125 (0.6) 
 103 (1.0) 
   31 (25) 
   25 (24) 
 16345 
 7531 
 90 (0.6) 
 65 (0.9) 
    14 (16) 
    13 (20) 
16317
  7519 
 14 (0.09) 
   6 (0.08) 
   9 (64) 
   4 (67) 
Diabetes mellitus 
No
   Yes
24488
  6860 
 159 (0.6) 
   68 (1.0) 
   43 (27) 
   12 (18) 
 18612 
 5317 
 106 (0.6) 
   49 (0.9) 
    18 (17) 
      9 (18) 
18590
  5299 
 16 (0.08) 
   4 (0.08) 
  11 (69) 
    2 (50) 
Hypertension 
No
   Yes 
14417
16935
   81 (0.6) 
 147 (0.9) 
   21 (26) 
   35 (24) 
10908
13025
 60 (0.6) 
 95 (0.7) 
    11 (18) 
    16 (17) 
10891
13002
  7 (0.06)
13 (0.09)
   5 (71) 
   8 (62) 
GP IIb/IIIa RB ‡ 
   No 
Yes
13097
18290
   91 (0.7) 
 137 (0.8) 
   21 (23) 
   35 (26) 
  
  9928 
14040
 62 (0.6) 
 93 (0.7) 
    9 (15) 
  18 (19) 
  9908 
14020
    6 (0.06)
  14 (0.09)
   2 (33) 
 11 (79) 
* P<0.001 for the comparison between categories 
   † Deaths within 30 days. The percentage refers to the number of deaths in patients who   
      suffered a stroke 
‡ Denotes platelet glycoprotein IIb/IIIa receptor blocker 
Table 1:  Distribution of patient baseline characteristics across stroke types 
(all-cause, non-hemorrhagic, and hemorrhagic).
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comparable associations as those described for all-cause stroke. For hemorrhagic 
strokes, the strongest univariable predictors were older age (χ2=12), prior stroke 
(χ2=8), and lighter weight (χ2=5). Similarly, the three most important predictors 
were those of the non-hemorrhagic strokes (Table 2).
Performance of predictive models
The calibration of the predictive model of all-cause stroke was good (Hosmer-
Lemeshow test 10.4, p=0.24), but the discriminative power of this model was 
moderate (c-statistic [95% CI]: 0.69 [0.65-0.72]). Although the calibration of the 
predictive models of non-hemorrhagic and hemorrhagic strokes was good, the 
discriminative power was either moderate (c-statistic 0.67 [0.63-0.71]) or poor 
(c-statistic 0.58 [0.54-0.63]), respectively.
 
Discussion
Stroke occurred in 0.7% of patients within 30 days of presenting with NSTE-
ACS. Two thirds of the strokes were non-hemorrhagic. Older age, prior stroke and 
elevated heart rate were the strongest predictors of all-cause, non-hemorrhagic, 
and hemorrhagic strokes. However, the discriminative power of these predictors 
was moderate, and especially poor for hemorrhagic strokes. Thus, it is difficult to 
accurately predict the incidence of stroke in this population.
 
The incidence of 30-day all-cause stroke in our patients is comparable to the 
incidence in similar populations: 0.8% in the GUSTO-IIb trial 17, and 0.5% in 
the OPUS-TIMI 16 trial 18. However, in clinical practice the incidence of 30-day 
all-cause stroke may be larger, because the in-hospital incidence already reaches 
0.7% 19. In a Spanish nationwide registry (DESCARTES) the incidence of 30-day 
all-cause stroke was 0.9% (95% CI 0.4-1.3%) 20. For comparison, the incidence of 
30-day all-cause stroke in patients with ST-segment elevation-ACS (STE-ACS) 
treated with thrombolytics was 1.4% (between 1.2% and 1.6%) in the GUSTO-I 
trial 21, and 0.8% in nine trials from a meta-analysis 22. The VALIANT registry, 
including both NSTE- and STE-ACS patients, had 1.5% in-hospital strokes 23. 
The proportion of hemorrhagic strokes was around 50% of the total number of 
strokes in the GUSTO-I trial 21, and 13% in the meta-analysis 22. Strokes in 
NSTE-ACS patients were associated with a high mortality rate (25%), which is 
lower than that observed in STE-ACS patients (41%) 21.
Importantly, the use of GP IIb/IIIa receptor blockers was not clearly associated 
with an increased incidence of all-cause stroke, non-hemorrhagic stroke or 
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hemorrhagic stroke. However, it should be recognized that the conclusion about 
the effect of GP IIb/IIIa receptor blockers on hemorrhagic strokes has substantial 
uncertainty, given the low numbers of events available and, hence, the limited 
power of the statistical analysis. The low frequency of hemorrhagic stroke in 
the overall population, coupled with lack of clear evidence of increased risk, 
provides reassurance that fear of intracranial hemorrhage should not be a reason 
to avoid these drugs. However, when patients receive these drugs on top of 
more aggressive antithrombotic therapy, the incidence of hemorrhagic strokes 
increases, as in patients with STE-ACS who received thrombolytics 24. In our 
NSTE-ACS patients, predictors associated with the incidence of hemorrhagic 
stroke were similar to those associated with non-hemorrhagic stroke. In contrast, 
STE-ACS patients who take oral anticoagulation before admission, with less than 
70 kg, and older than 65 years were at increased risk of hemorrhagic stroke. 
Stroke has only been studied as an outcome in a secondary analysis of the 
PURSUIT trial 6. Sixty-six non-hemorrhagic strokes in 9461 NSTE-ACS patients 
were studied. Hemorrhagic strokes were not studied. The strongest predictors 
were higher heart rate, older age, prior anterior MI, prior stroke or transient 
ischemic attack, and diabetes mellitus. Our analysis of 6 trials with a sample size 
of 31,387 patients increased the number of events and the power to find predictors 
of any type and all-cause stroke. However, the number of hemorrhagic strokes 
was still limited.
Age was an important predictor of non-hemorrhagic stroke in the PURSUIT 
trial 6, and the GUSTO-I trial 25. In our analysis, age was the strongest predictor of 
all-cause, non-hemorrhagic, and hemorrhagic strokes, and its relative importance 
was slightly higher than the results of the PURSUIT trial. Elderly patients 
probably have a higher risk of stroke due to multiple co-morbidities associated 
with older age, such as atrial fibrillation, hypertension, physical inactivity, and 
asymptomatic carotid stenosis 26.
Prior stroke has been described as a predictor of stroke in the OPUS-TIMI 
16 trial 27. In this trial, the proportion of 10-month all-cause stroke was 2.9% 
in 1,173 patients with prior extra-cardiac vascular disease (peripheral + stroke 
+ transient ischemic attack [TIA]) in comparison with 1.1% in 9108 patients 
without prior extra-cardiac vascular disease. In the PURSUIT trial and in the 
GUSTO-I trial 25 prior stroke was analyzed in conjunction of prior TIA, and this 
combined predictor was important. Prior stroke may be a marker of underlying 
cardiac, carotid or cerebral vascular disease in ACS patients.
Elevated heart rate was very important in the PURSUIT trial 6, and in the 
GUSTO-I trial 25. An explanation for the association between elevated heart rate 
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and stroke is not clear 6. The heart rate may correlate with larger infarctions that 
predispose patients to a higher likelihood of atrial arrhythmia and left ventricular 
thrombi. Heart rate is strongly associated with the presentation of atrial fibrillation 
in patients with NSTE-ACS 28. Atrial fibrillation is a common complication of 
these patients, occurring in 6.4% of patients enrolled 29. Moreover, an elevated 
baseline heart rate may simply be an expression of a prior atrial fibrillation. 
Unfortunately, our dataset did not provide information over prior or incident atrial 
fibrillation. Finally, a high heart rate may be an expression of a decompensated 
heart failure, related to the extent of the MI. Heart failure on admission has 
been described as an independent predictor of in-hospital all-cause stroke in the 
VALIANT registry 23.
Diabetes and prior MI were important predictors of stroke in the PURSUIT 
trial 6, but not in our analysis. Diabetes has a known association with a widespread 
atherosclerosis, and prior MI is associated with the formation of mural thrombus 
and emboli. Finally, lighter weight was weakly associated with hemorrhagic 
stroke. This was probably related to doses of GP IIb/IIIa receptor blockers and 
anticoagulants that were not reduced in lighter patients, and especially for the 
elderly. 
Our study has some limitations. We had about 7500 patients with missing 
values for the non-hemorrhagic and hemorrhagic stroke outcomes. The number 
of non-hemorrhagic strokes was still larger (n=155) than the largest previously 
published (n=66) 6. However, the number of hemorrhagic strokes was small 
(n=20), and this limited the conclusions about the predictors of hemorrhagic 
stroke. We imputed several patient characteristics. Of them, only heart rate 
remained as strong predictor, as was demonstrated previously 6.
In conclusion, stroke is an infrequent but serious early complication of patients 
with NSTE-ACS. Mortality is high, especially for hemorrhagic strokes. Platelet 
GP IIb/IIIa receptor blockers were not significantly associated with any type of 
stroke. Three main predictors of stroke were older age, prior stroke and elevated 
heart rate. Since the discriminative ability of these patient characteristics was at 
best moderate, it is difficult to predict which ACS patients will suffer a stroke.
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This thesis describes theoretical and practical aspects of covariate adjustment 
and subgroup analysis in randomized clinical trials (RCTs) with heterogeneous 
populations, with special interest in traumatic brain injury and acute coronary 
syndrome trials. In this chapter, we mention some theoretical aspects of covariate 
adjustment and subgroup analysis. Subsequently, use, reporting, and interpreta-
tion of covariate adjustment and subgroup analysis in recently published RCTs, 
and the practical application of these aspects in traumatic brain injury and acute 
coronary syndrome trials are discussed in the light of the theory. Finally, some 
general recommendations are formulated.
Summary answers to the research questions
Question 1: Which are the pros and the cons of adjustment of the treatment 
effect in RCTs for baseline covariates?.
Answer: Covariate adjustment increases the power to detect a significant 
treatment effect, and reduces the sample size requirements. This reduction in 
sample size is directly related to the strength of the adjusted predictors, and it is 
independent of the treatment effect and sample size of the trial. When time-to-
event outcomes are considered, this reduction in sample size is independent of 
the censoring level. Adjustment for imbalance yields a very limited gain in the 
reduction of sample size.
Question 2: How well are covariate adjustment and subgroup analysis used, 
reported and interpreted in current internal medicine, oncology, cardiology, 
and neurosurgery trials?
Answer: Covariate adjustment was used as primary analysis in about 50% of 
trials, and few predictive covariates were utilized. Subgroup analysis was used 
in over 50% of trials, but the appropriate interactions tests were underutilized. 
Moreover, a minority of subgroup analyses were pre-specified, and an overem-
phasis on results of subgroups was common.
Question 3: How much can the adjustment for important predictors of unfa-
vorable outcome decrease the requirements in sample size in TBI trials?
Answer: Adjustment for seven strong predictors of 6-month unfavourable 
Glasgow Outcome Scale reduced the sample size requirements by 25% in TBI 
trials. Adjustment for the three strongest predictors reduced the sample size 
requirements by 20%.
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Question 4: Are the effects of GP IIb/IIIa receptor blockers similar in the 
young and the elderly in a meta-analysis of non-ST-segment elevation acute 
coronary syndrome trials?.
Answer: In an individual data subgroup meta-analysis of 6 large trials, GP 
IIb/IIIa receptor blockers had similar relative beneficial effects in old and young 
patients with NSTE-ACS. Absolute beneficial effects in old patients were larger 
than in young patients, given a higher baseline risk. However, these beneficial 
effects in the elderly were outweighed by a higher risk of major bleeding.
Question 5: Which subgroups of patients are at higher risk to develop a stroke 
after a non-ST-segment elevation acute coronary syndrome? 
Answer: Patients who are old, with a prior stroke and with a high heart rate are at 
higher risk of stroke after sustaining a NSTE-ACS. GP IIb/IIIa receptor blockers 
did not increase the risk of any type of stroke.
Research Question 1: Simulations using covariate adjustment
Covariate adjustment provides a more individual-oriented treatment effect esti-
mates, corrects for chance imbalance in baseline characteristics, and increases 
the power to detect an important treatment benefit 1, 2. We performed simulation 
studies with dichotomous outcomes. In chapter 2.1, we showed that adjustment 
for a strong covariate (either pre-specified or tested) in logistic regression models 
led to a more beneficial treatment effect, with larger variability (i.e. broader 
confidence intervals) in direct relation to the strength of the covariate. However, 
the overall result was a gain in power. When we only adjusted when covariates 
were imbalanced, the gain in power was very limited. Moreover, we obtained 
a conservative type I error when the adjustment was performed due to imbal-
ance, which is explained by the fact that adjusting for imbalances constrains the 
outcome variability between treatment groups 3. 
In practical situations (Odds Ratio [OR] of the covariate between 2 and 5), 
a reduction in sample size between 3% and 14% was obtained with an outcome 
incidence of 50% and a covariate prevalence of 50%. The reduction was indepen-
dent of the treatment effect and sample size, and makes it an attractive summary 
measure to express the benefit of covariate adjustment. We did not present calcu-
lations for covariate adjusted sample sizes in the RCT design phase. To quantify 
any anticipated sample gains, we would need to specify covariate effects and 
covariate distributions 4. We would have to meet these assumptions to achieve 
Chapter 5.1
168
the calculated power. We advised to perform unadjusted sample calculations, 
which need fewer assumptions. However, reductions of sample size of about 10% 
can be expected when adjusting for one known strong covariate.
In chapter 2.2, we applied the same methodology in simulated RCTs with 
time-to-event outcomes, analyzed with the Cox proportional hazards model. The 
power to detect the treatment effect was higher when covariates were pre-speci-
fied and/or predictive of the outcome. The type I error was usually at the nominal 
level. The reduction in sample size for a covariate Hazard Ratio (HR) between 2 
and 5 ranged between 15% and 44% (covariate prevalence of 50%) and between 
4% and 12% (covariate prevalence 10%). The reduction was independent of the 
treatment effect and sample size. Importantly, this measure was also independent 
of the censoring level. We should notice that the RSS were not directly compa-
rable between a RCT with dichotomous outcomes and a RCT with time-to-event 
outcomes. When a covariate prevalence of 50% and no censoring were settled, a 
given value of HR corresponded to a higher OR (OR=HR*p2/p1, where p2 was the 
survival in the covariate group with the best prognosis, and p1 the survival with 
the covariate with the worst prognosis). Thus, a reduction of 16% was achieved 
with adjustment for a moderately predictive covariate (HR=2), and a reduction of 
14% was obtained with adjustment for a highly predictive covariate (OR=5). 
Research Question 2: Current reporting of covariate adjustment and sub-
group analysis
When adequately reported, RCTs provide clinicians with valuable informa-
tion that helps them to accept or reject treatments or interventions, and hence 
to improve their practice 5. The revised recommendations of the Consolidated 
Standards of Reporting Trials (CONSORT) statement highlighted the appropri-
ate use and interpretation of covariate adjustment and subgroup analysis 6, 7. 
Covariate adjustment should be performed for a limited number of covariates, 
and the reasons for their choice should be clearly stated 1. Likewise, only a limited 
number of pre-specified subgroup analyses should be performed, the appropriate 
interaction tests should be used, and subgroup analysis is to be considered as 
secondary analysis. Evaluation showed that the reporting of covariate adjustment 
and subgroup analysis in RCTs from the 80’s and 90’s often was inappropriate, 
such as inconsistencies in the use of covariate adjustment, underuse of tests of 
interactions, and overinterpretation of subgroup analyses 3, 8, 9.
We evaluated the reporting of covariate adjustment and subgroup analysis 
in RCTs from high impact factor medical journals, in general internal medicine 
(n=46), cardiology (n=21) and oncology (n=17) journals, published in an arbitrary 
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3-month period at the end of 2002. In chapter 3.1, it is described that covariate 
adjustment was used as primary analysis by only 50% of the RCTs, and predic-
tive covariates were mainly used. Over 50% of RCTs used subgroup analysis, 
and about 20% used the appropriate interaction tests 8. Remarkably, 25% of the 
RCTs overemphasized the subgroup results. The reporting of covariate adjust-
ment has improved in comparison to previous reports in the last two decades 
8, 9. However, the reporting of subgroup analysis has not improved. Therefore, 
subgroup analysis had major shortcomings that may have resulted in incorrect 
medical decisions.
Then, we focused on the reporting of subgroup analysis in 63 therapeutic car-
diovascular RCTs published in 2002 and 2004, in the same cardiology journals 
chosen for the previous evaluation, with a median of 500 patients (Chapter 3.2). 
The number of trials in this clinical area has increased dramatically in the last 
20 years: from 5410 in the period 1980-1989 to 14845 in the period 1990-2000 
10. The interest to explore treatment effects in subgroups has also increased, due 
to the heterogeneity of these patients respect to their clinical outcome 11. Thus, 
many analyses have been done to look at differential treatment effects in groups 
such as elderly patients, female patients, diabetic patients, severe patients with 
acute coronary syndromes, heart failure, hypertension, hypercholesterolemia 
and stroke. 
All 39 RCTs that reported subgroup analysis were not powered to detect 
subgroup effects, and 26 RCTs reported more than 5 subgroups. Fourteen trials 
reported fully pre-specified subgroups, only 11 RCTs used the appropriate tests 
of interaction, and 15 overemphasized the subgroup results. These results were 
worse than those from the assessment of RCTs as detailed in Chapter 3.1. A 
prior assessment of reporting of subgroup analysis was published 12. Here, large 
cardiovascular trials (n>1000 patients) published between 1980 and 1997 had 
similar shortcomings as we found in smaller and more recent trials. However, 
subgroup analysis in larger trials have more power to detect true subgroups than 
the smaller trials. Many physicians and cardiologists may misinterpret the re-
sults, and can use a harmful treatment in a “wrong” subgroup of patients, or even 
worse, can withhold a beneficial treatment in the “right” subgroup of patients. 
Finally, we studied the reporting of covariate adjustment and subgroup analy-
sis in 18 traumatic brain injury trials (Chapter 3.3). This is another clinical area 
with substantial interest in these methods due to the heterogeneity of patients, 
and negative results of the therapeutic trials. Five of the RCTs reported covariate 
adjustment, and 4 of them used the adjusted effect as main efficacy parameter. 
They correctly used few covariates, which mainly were predictors. Eleven RCTs 
reported subgroup analyses, but only 3 were completely pre-specified, 1 used the 
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appropriate interaction testing, and 5 gave the subgroup results a similar emphasis 
as the overall results. These mistakes in the reporting of subgroup analysis may 
have been planned, or may have been driven by the results (post-hoc analyses) 
13. We had the opportunity to evaluate the correspondence between subgroup 
analysis planning and reporting for 6 protocols-trials combinations. The cor-
respondence was poor, and this seems an indication of post-hoc analyses. The 
results of post-hoc subgroup analyses should be treated with skepticism, as they 
are data driven rather than stated a priori 14. A better translation of the CONSORT 
recommendations on appropriate reporting of covariate adjustment and subgroup 
analysis can improve the understanding of clinicians about the findings in trials 
with heterogeneous populations. 
Research Questions 3, 4, and 5: Clinical applications
We focused in two clinical areas: traumatic brain injury 15, and non-ST-segment 
elevation acute coronary syndromes 16. 
Reduction in sample size with covariate adjustment for strong predictors in TBI 
trials
Most of the trials of patients with moderate or severe traumatic brain injury have 
not demonstrated the efficacy of treatments or interventions 17. One of the expla-
nations to this failure has been the reduced sample sizes of previously reported 
trials 18. It seems unrealistic to increase the sample size of explanatory TBI trials 
due to financial and administrative constraints. One way to achieve a smaller 
sample size is to adjust for important predictors of the clinical outcome. RSSs 
were calculated in 8 trials of moderate to severe TBI, with sample sizes ranging 
from 126 to 1118 (Chapter 4.1). We sequentially adjusted for 1 to 9 strong pre-
dictors (clinical, radiological, biochemical) of a 6-month dichotomous Glasgow 
Outcome Scale. 
We found that the adjustment for the 3 strongest predictors (age, motor score 
and pupils) yielded RSS between 16% and 23%, and adjustment for 9 strong pre-
dictors yielded RSS between 23% and 30%. Adjustment for 7 strong predictors 
gave similar results to adjustment for 9 predictors. These RSS were smaller than 
the ones in the context of TBI registries, which have less restrictive inclusion 
criteria and hence is expected to have more heterogeneous populations. These 
results highlighted the importance of the adjustment for strong predictors, and 
it is valuable tool in the analysis phase of new TBI trials. However, other more 
sophisticated methods (e.g. sliding dichotomy or proportional odds models) 19 
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may reduce the sample size requirements even more. A reduction in sample size 
of 25% can be expected when adjusting for a group of known strong predictors. 
Platelet glycoprotein IIb/IIIa receptor blocker effects in elderly patients with 
non-ST-segment elevation acute coronary syndromes
We performed a individual data subgroup meta-analysis of 6 large international 
trials, with a total of 31402 patients, to try to overcome the underrepresentation 
of the elderly in previous trials, and increase the power to find more reliable 
subgroup effects 20 (see Chapter 4.2). The appropriate interactions tests were 
used, and age subgroup effects were combined using random effects models 21. 
The relative GP IIb/IIIa effects were similar across age subgroups, and, conse-
quently, the absolute drug effects were larger in the elderly. This is related to the 
fact that elderly patients have a larger baseline risk than younger patients, and 
therefore receive a larger benefit from this drug 22. However, elderly patients had 
larger major bleeding rates than younger patients. These results are more reliable 
than subgroup effects in each individual trial, and we studied a large number of 
elderly patients (n=2049). Likewise, harmful major bleeding complications have 
to be remembered when the decision to use these drugs is taken, and a close 
monitoring of these patients is warranted.  
Subgroups of patients at higher risk of stroke after a non-ST-segment elevation 
acute coronary syndrome
We used the large meta-analysis database, with 155 non-hemorrhagic stroke 
and 228 all-cause strokes (Chapter 4.3). Elderly patients, with a prior stroke and 
elevated heart rate were at the highest risk to develop any type of stroke. The 
other previously reported predictors were not found in our analysis, and this is 
probably an indication of the selection of non-predictors when few events were 
available. Use of GP IIb/IIIa receptor blockers was not related to the presentation 
of any type of stroke. Although the model was well calibrated, the discriminative 
power of these 3 predictors was moderate (c-statistic 0.70). Thus, the prediction 
of stroke is difficult. We did not study long-term outcomes, and this can change 
the chosen predictors, and the performance of the models.
Recommendations for appropriate analysis of RCTs
Information about the appropriate analysis of RCTs with covariate adjustment 
and subgroup analysis in patients with heterogeneous populations is limited. 
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We summarize our recommendations, based on the literature and the papers 
presented in this thesis (Tables 1 and 2). 
Subgroup analyses should be pre-specified 7. Limitation to a small number 
of subgroups is desirable. This minimizes multiple testing and false-positive 
Table 1: Recommendations for Covariate Adjustment 
a.  Specify the adjustment for few strong predictors in advance.
b.  If no predictors are known, specify that you will test a limited number of them, and 
adjust if one or more are predictive 23.
c.  Adjust for imbalances in covariates only when these covariates are predictors of the 
outcome.
d.  Define in advance the type of model to be used. 
e.  Define the importance of the adjusted treatment effect in relation to the unadjusted
effect (primary or secondary). 
f.  Perform usual unadjusted sample size calculations in the design phase. A 10% of
     reduction in sample size can be expected when adjusting for one strong covariate,
     and a 25% when adjusting for a group of strong covariates.
Table 2: Recommendations for Subgroup Analysis 
Specification
a. Specify a limited number of subgroups in advance 
    b.     Detail the rationale of the chosen subgroups.
Analysis
a. Use statistical interaction tests 
b. Avoid performing analysis of the treatment effect within small subgroups of patients 
(‘separate subgroup analysis’). 
Interpretation
a. Be sceptical if subgroups were not pre-specified, not biologically plausible, or no
        interaction tests were applied. 
b. Evaluate previous reports for similar findings, and work on independent confirmation
such as subgroup meta-analysis.
c. Subgroup analyses are mostly hypotheses-generating exercises to stimulate further 
research.
d. Keep emphasis on the overall results.
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subgroup effects 8. Subgroups should have a clear biological or pathophysiologi-
cal rationale, and the appropriate interaction tests should be used. Subgroups 
must be confirmed independently to be more reliable. When possible, a subgroup 
meta-analysis increases the power to detect subgroup effects 17. Finally, subgroup 
analysis only generates new hypotheses to be tested. Thus, the overall trial result 
is the best estimate of the treatment effect.
Conclusions
1. Covariate analysis is a valuable method to obtain more individual-
oriented treatment effects. Covariate analysis allows a substantial gain in the 
power to demonstrate a significant treatment effect, and reduces the sample size 
requirements. 
2. Covariate analysis is recommended in the analysis of RCTs when predic-
tors are scientifically established. If predictors are not known, testing for them 
and adjustment for significant predictors are recommended. 
3. A reduction of sample size of 10% can be expected when adjusting for 
one strong predictor, and a reduction of 25% can be expected when adjusting for 
a group of strong predictors. Adjustment for moderate predictors yields reduc-
tions in sample size about 5%.
4. Subgroup analysis generates hypotheses to test in further trials, and 
rarely provides definitive answers about subgroup effects. Its reporting is poor in 
current clinical trials, in different clinical and surgical medical fields. 
5. A full pre-specification of subgroups, the use of interactions tests, and 
the consideration as secondary analysis may improve the sceptical vision of 
subgroup analysis. 
6. Subgroup meta-analysis of trials improves the power to detect differen-
tial subgroup effects, and should be recommended when individual patient data 
of trials are available.
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Summary
Randomized clinical trials (RCTs) are essential to evaluate the usefulness of 
treatments and interventions, and clearly influence clinical practice. Trials are 
often performed in heterogeneous populations, such as patients with traumatic 
brain injury (TBI), acute coronary syndromes (ACS), stroke and cancer. Patients 
are heterogeneous regarding to their characteristics, such as age, gender, or dis-
ease severity. Heterogeneity may produce imbalance in randomized groups with 
respect to prognosis, and may dilute the beneficial effect of treatments in some 
subgroups of patients. 
However, heterogeneity of patients offers some solutions to deal with these 
problems. Covariate adjustment and subgroup analysis are two methods used in 
the analysis phase of the trials. Covariate adjustment leads to adjusted estimates 
of treatment effects that relate to the “average” patient with a certain risk profile. 
It corrects for imbalance, and increases the statistical power to detect significant 
treatment effects. Subgroup analysis assesses differences in treatment effect 
across different subpopulations of patients. 
We aimed to know which are the pros and cons of adjustment of the treat-
ment effect for baseline characteristics in trials with dichotomous outcomes, to 
know how well are used, reported and interpreted both covariate adjustment and 
subgroup analysis in current clinical trials, and to apply these methods in trials 
performed in heterogeneous patient populations. We wanted to know how much 
can adjustment for important predictors decrease the sample size in TBI trials, 
whether the effects of glycoprotein IIb/IIIa receptor blockers were similar in the 
young and elderly patients with ACS, and which subgroups of patients were at 
higher risk to develop a stroke after an ACS.
Part 2 focuses on simulations studies to quantify the gain in power and the 
reduction in sample size requirements with the use of covariate adjustment in 
trials with dichotomous outcomes. In Chapter 2.1 we showed that adjustment 
for a strong covariate (pre-specified or tested) in logistic regression models led 
to a more extreme estimate of the treatment effect, and a gain in power. With a 
strong covariate (OR between 2 and 5), adjustment yielded a reduction in sample 
size between 3% and 14%. This reduction was independent of the treatment 
effect and sample size, and it was an attractive summary measure to express 
the benefit of covariate adjustment. When we adjusted for covariates that were 
imbalanced, the gain in power and the reduction in sample size was very limited. 
In Chapter 2.2 we applied the same methodology in simulation that considered 
time-to-event outcomes, analyzed with the Cox proportional hazards model. The 
statistical power to detect a significant treatment effect was higher than without 
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adjustment. Reductions in sample size were between 15% and 44% when adjust-
ment was made for strong covariates (HR between 2 and 5), and lower when 
lower covariate prevalences were considered. The reduction in sample size was 
independent of treatment effect, sample size and censoring level.
Part 3 focuses on use, reporting and interpretation of covariate adjustment and 
subgroup analysis in internal medicine, oncology, cardiology and neurosurgery 
trials. In Chapter 3.1 we evaluated internal medicine, cardiology and oncology 
trials published in 2002. Covariate adjustment was used in 50% of trials, and pre-
dictive covariates were used. Subgroup analysis was also used in 50% of trials. 
However, only 20% used the appropriate interaction tests, and 25% overempha-
sized the subgroup results. Subgroup analysis hence had major shortcomings that 
may be translated onto incorrect medical decisions. Chapter 3.2 describes the 
situation of subgroup analysis in cardiovascular trials from 2002 and 2004. The 
interest in subgroup analysis in this field has increased dramatically in the last 20 
years. Thirty-nine out of 63 trials reported subgroup analysis. Only 14 reported 
fully pre-specified subgroups, 11 used interaction tests, and 15 overemphasized 
the subgroup findings.  The results were worse than those reported in chapter 
3.1. Thus, many cardiologists may misinterpret the results of these subgroups, 
and can use a harmful treatment in “wrong” patients, and withhold a beneficial 
treatment in “right” patients. In Chapter 3.3 we evaluated covariate adjustment 
and subgroup analysis in 18 TBI trials. Five trials used covariate adjustment, and 
correctly used few predictors. Eleven trials reported subgroup analysis, but only 
3 fully pre-specified the subgroups, one used interactions testing, and 5 empha-
sized the results. We also evaluated whether these shortcomings in subgroup 
analysis were planned or were data-driven, by analyzing 6 available protocols 
of 6 trials. The correspondence was poor, and seems an indication of post-hoc 
analyses. Overall, the use, reporting and interpretation of covariate adjustment 
seems appropriate, but subgroup analysis have evident shortcomings.
Part 4 focuses on clinical applications of covariate adjustment and subgroup 
analysis in trials performed in two heterogeneous patient populations, such as 
TBI and ACS. In Chapter 4.1 we evaluated the reduction in sample size that 
could be obtained when adjusting for strong predictors of unfavorable outcome 
in 8 TBI trials. We found that adjustment for the three strongest predictors 
yielded a reduction in sample size of 20%, and adjustment for the seven strong-
est predictors a reduction of 25%. For comparison, adjustment in TBI surveys, 
with more heterogeneous populations, yielded a larger reduction in sample size 
(reaching 40%). Adjustment for predictors is a valuable tool in the analysis phase 
of TBI trials. Chapter 4.1 describes a subgroup meta-analysis of 6 large trials, 
which evaluated whether the effect of glycoprotein IIb/IIIa receptor blockers 
were similar between young and elderly patients with non-ST-segment-elevation 
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(NSTE) ACS. The relative beneficial effects of the drug were similar across age 
subgroups, and the absolute beneficial effects were larger in the elderly. This 
was due to a higher baseline risk of elderly patients. However, elderly patients 
had a higher absolute risk of major bleedings. Thus, these drugs are useful in the 
elderly as well as in the young, and the higher risk of bleeding warrants a careful 
close monitoring in the elderly. Finally, in Chapter 4.3 we analyzed which sub-
groups of patients were at higher risk to develop a stroke after a NSTE-ACS. We 
found that patients with older age, with a prior stroke and with high heart rates 
were at increased risk of any type of stroke. Other previously described high-risk 
subgroups of patients (e.g. diabetics, hypertensive) were not at higher risk in 
our analysis. However, the model built with those 3 predictors had a moderate 
discrimination, making the prediction of stroke difficult.
Finally, in Part 5 we put the main findings on perspective, and general recom-
mendations for an appropriate use, reporting and interpretation of covariate ad-
justment and subgroup analysis are given. We conclude that covariate adjutment 
is a valuable method to obtain more individual-oriented treatment effects in tri-
als, and substantial reductions in sample size requirements can be obtained when 
adjusting for predictors. Covariate adjustment should be recommended for future 
trials in heterogeneous populations. Subgroup analysis is commonly performed 
in current trials, but important shortcomings were found. Full pre-specification, 
use of interaction tests, and recognition of its secondary importance are essential 
to improve the sceptical vision on subgroup analysis. Subgroup meta-analysis 
substantially improves the power to detect subgroup effects across trials, and 
should be recommended as a standard procedure when individual data are avail-
able.
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Samenvatting
Gerandomiseerde, klinische trials (RCT’s) zijn zeer belangrijk voor onderzoek 
naar het nut van behandelingen en interventies en hebben veel invloed op de 
klinische praktijk. Trials worden vaak gedaan in heterogene populaties, zoals bi-
jvoorbeeld patiënten met traumatisch hersenletsel (traumatic brain injury, TBI), 
acuut coronair syndroom (ACS), beroerte of kanker. De kenmerken van deze 
patiënten, zoals leeftijd, geslacht en ernst van de aandoening, zijn heterogeen. 
Deze heterogeniteit kan in gerandomiseerde groepen prognostische onbalans met 
zich meebrengen, waardoor het gunstige effect van een behandeling in sommige 
subgroepen van patiënten verwatert.
Er zijn verschillende oplossingen voor het probleem van de heterogeniteit 
van patiënten. De volgende twee methoden worden toegepast in de analysefase 
van trials: correctie voor covariabelen en subgroepanalyse. Correctie voor co-
variabelen leidt tot een aangepaste schatting van het behandeleffect voor een 
“gemiddelde” patiënt met een bepaald risicoprofiel. De onbalans wordt gecorri-
geerd en het statistisch onderscheidingsvermogen (de power) voor het vaststellen 
van een significant behandeleffect wordt groter. Bij subgroepanalyse worden de 
verschillen in behandeleffect tussen verschillende subpopulaties van patiënten 
onderzocht.
We wilden onderzoeken welke voor- en nadelen correctie voor baseline ken-
merken heeft op het behandeleffect in trials met dichotome uitkomstmaten, en in 
hoeverre correctie voor covariabelen en subgroepanalyse in de huidige klinische 
trials juist worden toegepast, beschreven en geïnterpreteerd. Tenslotte wilden we 
beide methoden toepassen in trials in heterogene patiëntenpopulaties: we wilden 
met name weten welke invloed correctie voor belangrijke voorspellers heeft op de 
steekproefomvang in trials naar TBI; of glycoproteïne-IIb/IIIa-receptorblockers 
in jonge en oudere patiënten met ACS een vergelijkbaar effect hebben; en welke 
subgroepen van patiënten na een ACS een hoger risico op een beroerte hebben.
In deel 2 worden enkele simulatiestudies beschreven waarin voor trials met 
een dichotome uitkomstmaat de verandering in de power en de vereiste steek-
proefomvang door correctie voor covariabelen gemeten werd. In hoofdstuk 2.1 
laten we met behulp van logistische regressiemodellen zien dat correctie voor 
een sterke covariabele (vooraf bepaald of na toetsing) een extremere schatting 
van het behandeleffect en een grotere power met zich meebrengt. Correctie voor 
een sterke covariabele (OR tussen 2 en 5) resulteerde in een 3-14% kleinere 
steekproef. Deze reductie was onafhankelijk van het behandeleffect en de steek-
proefomvang, en bleek een geschikte samenvattende maat om de voordelen van 
correctie voor covariabelen in uit te drukken. Correctie voor ongebalanceerde 
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covariabelen had slechts een beperkte invloed op de power en de steekproefom-
vang. In hoofdstuk 2.2 pasten we met behulp van Cox-regressieanalyse dezelfde 
methode toe in een simulatie met time-to-event uitkomstmaten. De statistische 
power om een significant behandeleffect aan te tonen was groter met correctie 
dan zonder correctie. Wanneer voor sterke covariabelen (HR tussen 2 en 5) 
werd gecorrigeerd, nam de steekproefomvang met 15-44% af; deze reductie was 
minder wanneer voor laagprevalente covariabelen werd gecorrigeerd. De mate 
van reductie van de steekproefomvang was onafhankelijk van het behandeleffect, 
de steekproefomvang en het niveau van censurering.
Deel 3 gaat in op de toepassing, de beschrijving en de interpretatie van cor-
rectie voor covariabelen en subgroepanalyse in interne, oncologische, cardiolo-
gische en neurochirurgische trials. In hoofdstuk 3.1 evalueerden we de in 2002 
gepubliceerde interne, oncologische en cardiologische trials. In 50% van de trials 
werd correctie voor covariabelen toegepast en gebruik gemaakt van voorspellende 
variabelen. In de andere helft van de trials werd subgroepanalyse toegepast. In 
slechts 20% echter werd een geschikte toets voor interactie gebruikt en in 25% 
werden de resultaten voor de subgroepen teveel benadrukt. Subgroepanalyse 
heeft dus belangrijke tekortkomingen die tot verkeerde medische beslissingen 
kunnen leiden. Hoofdstuk 3.2 beschrijft de toepassing van subgroepanalyse in 
cardiovasculaire trials in de periode van 2002 tot 2004. In de laatste twintig jaar 
is de belangstelling voor subgroepanalyse in dit veld drastisch toegenomen. In 
39 van de 63 trials bleek subgroepanalyse te zijn gebruikt. In slechts 14 trials 
was sprake van vooraf bepaalde subgroepen en in 11 trials vond toetsing voor 
interactie plaats; in 15 trials werden de resultaten voor de subgroepen teveel 
benadrukt. Deze bevindingen waren slechter dan die in hoofstuk 3.1. Cardiologen 
kunnen op deze manier de resultaten voor de subgroepen fout interpreteren en 
de “verkeerde” patiënten een schadelijke behandeling geven, terwijl de “goede” 
patiënten een gunstige behandeling onthouden wordt. In hoofdstuk 3.3 onderzo-
chten we correctie voor covariabelen en subgroepanalyse in 18 trials naar TBI. 
Vijf trials pasten correctie voor covariabelen toe en gebruikten - terecht - weinig 
voorspellers. Elf trials pasten subgroepanalyse toe, maar in slechts 3 trials waren 
de subgroepen vooraf bepaald en in 1 trial vond toetsing voor interactie plaats. In 
5 trials kregen de resultaten voor de subgroepen teveel nadruk. We bekeken ook 
de onderzoeksprotocollen die voor 6 trials beschikbaar waren om na te gaan of 
de tekortkomingen in de subgroepanalyse gepland waren of door de data waren 
ingegeven. De inhoud was mager en kan een reden zijn geweest voor post hoc 
analysen. Correctie voor covariabelen wordt in het algemeen correct toegepast, 
beschreven en geïnterpreteerd, maar subgroepanalysen hebben duidelijke 
beperkingen.
Deel 4 gaat in op de klinische toepassing van correctie voor covariabelen 
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en subgroepanalyse in trials in twee heterogene patiëntenpopulaties met TBI en 
ACS. In hoofdstuk 4.1 onderzochten we de reductie van de steekproefomvang in 
8 trials naar TBI door te corrigeren voor sterke voorspellers van een ongunstige 
uitkomst. We vonden dat correctie voor de 3 sterkste voorspellers tot een 20% 
kleinere steekproef leidde; bij correctie voor de 7 sterkste voorspellers was deze 
reductie 25%. Ter vergelijking: correctie in onderzoeken naar TBI, in hetero-
genere populaties, leidde tot een grotere reductie van de steekproefomvang (tot 
40%). Correctie voor voorspellers is een bruikbare methode in de analysefase van 
trials naar TBI. Hoofdstuk 4.2 beschrijft een meta-analyse op subgroepniveau 
van 6 grote trials waarin het effect van glycoproteïne-IIb/IIIa-receptorblockers 
vergeleken werd bij jonge en bij oudere patiënten met ACS zonder elevatie van 
het ST-segment (NSTE-ACS). Relatief gezien waren de gunstige effecten van 
het geneesmiddel hetzelfde in de twee leeftijdsgroepen. Absoluut gezien waren 
de gunstige effecten het grootst bij oudere patiënten; dit had te maken met een 
hoger absoluut basisrisico. Oudere patiënten hadden echter ook een hoger ab-
soluut risico op ernstige bloedingen. Dit houdt in dat dit middel bij zowel oudere 
als jongere patiënten nuttig is, maar dat oudere patiënten zorgvuldig in de gaten 
moeten worden gehouden vanwege het hogere risico op bloedingen. In hoofdstuk 
4.3 onderzochten we tenslotte subgroepen van patiënten met een hoger risico op 
een beroerte na NSTE-ACS. We vonden dat oudere patiënten, patiënten met een 
eerdere beroerte en patiënten met een snellere hartslag een verhoogd risico op 
een beroerte hadden. Andere eerder beschreven subgroepen van patiënten met 
een verhoogd risico (bijvoorbeeld patiënten met diabetes of hypertensie) hadden 
in onze analyse géén verhoogd risico. Het model met 3 voorspellers had echter 
een matig onderscheidend vermogen, waardoor het moeilijk was om een beroerte 
te voorspellen.
In deel 5 plaatsen we de belangrijkste bevindingen in een breder perspectief 
en doen we algemene aanbevelingen voor een juiste toepassing, beschrijving en 
interpretatie van correctie voor covariabelen en subgroepanalyse. Wij conclu-
deren dat correctie voor covariabelen in trials een bruikbare methode is voor 
het vaststellen van een meer op het individu gericht behandeleffect, en dat de 
steekproefomvang substantieel gereduceerd kan worden door te corrigeren voor 
voorspellers. Voor toekomstige trials in heterogene populaties is correctie voor 
covariabelen aan te bevelen. In huidige trials wordt vaak subgroepanalyse toege-
past, maar deze schiet vaak tekort. Uitsluitend bepaling vooraf, toetsing voor 
interactie en onderkenning van het ondergeschikte belang zijn essentieel om de 
sceptische kijk op subgroepanalysen te verbeteren. Meta-analyse op subgroep-
niveau van verschillende trials vergroot de power om het effect in subgroepen te 
meten en is aan te bevelen als standaard procedure wanneer individuele gegevens 
beschikbaar zijn.
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Resumen
Los estudios clínicos randomizados (RCTs) son esenciales para evaluar la 
utilidad de tratamientos e intervenciones, y claramente influencian la practica 
clínica. Estos estudios son frecuentemente hechos en poblaciones heterogéneas, 
tales como pacientes con daño cerebral traumático (TBI), sindromes coronarios 
agudos (ACS), enfermedad cerebrovascular, y cáncer. Estos pacientes son het-
erogeneos respecto a algunas de sus características, tales como edad, género o 
severidad de enfermedad. La hetorogeneidad puede producir imbalance en los 
grupos randomizados con respecto a pronóstico, y puede diluir el efecto benefi-
cioso de los tratamientos en algunos subgrupos de pacientes.  
Sin embargo, la heterogeneidad de pacientes ofrece algunas soluciones para 
lidiar con estos problemas. El ajuste de covariables y el análisis de subgrupos 
son dos métodos usados en la fase de análisis de los estudios clínicos. El ajuste 
de covariables produce estimaciones ajustadas de los efectos de tratamiento que 
se relacionan al “paciente promedio” con un cierto perfil de riesgo. Además cor-
rige para imbalance e incrementa el poder estadístico para detectar efectos de 
tratamiento significativos. El análisis de subgrupos evalúa las diferencias en los 
efectos de tratamiento a través de diferentes subpoblaciones de pacientes.  
Nos propusimos conocer cuáles son los pros y los contras del ajuste del efecto 
del tratamiento para características basales de los pacientes en estudios clínicos 
con resultados dicotómicos; conocer cuán bien son usados, reportados e inter-
pretados el ajuste de covariables y el análisis de subgrupos en estudios clínicos 
actuales; y, aplicar estos métodos en estudios clínicos con poblaciones heter-
ogéneas. Quisimos conocer cuánto puede el ajuste para predictors importantes 
disminuir el tamaño de muestra en estudios clínicos en TBI, si los efectos de 
los bloqueadores del receptor de glicoproteina IIb/IIIa son similares en jóvenes 
y ancianos con ACS, y cuáles subgrupos de pacientes están en mayor riesgo de 
desarrollar enfermedad cerebrovascular luego de un ACS.
En la Parte 2 presentamos estudios de simulación para cuantificar el incre-
mento del poder estadístico y la reducción del tamaño de muestra que se obtienen 
con el uso del ajuste de covariables en estudios clínicos con resultados dicótomos. 
En el Capítulo 2.1 mostramos que el ajuste para una covariable fuerte (pre-es-
pecificada o probada) en modelos de regresión logística produjo un estimado del 
efecto del tratamiento más extremo, y un incremento en el poder estadístico. Con 
una covariable fuerte (OR entre 2 y 5) el ajuste produjo una reducción del tamaño 
de muestra entre 3% y 14%. Esta reducción fue independiente del la fuerza del 
efecto del tratamiento y del tamaño de muestra, y fue una medida resumen at-
ractiva para expresar el beneficio obtenido con el adjuste de covariables. Cuando 
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ajustamos para covariables que tuvieron imbalance, el incremento del poder 
estadístico y la reducción del tamaño de muestra fue limitado. En el Capítulo 
2.2 aplicamos la misma metodología en un estudio de simulación que consideró 
resultados tiempo-a-evento, analizado con el modelo de hazards proporcionales 
de Cox. El poder estadístico para detectar un efecto de tratamiento significativo 
fue mayor que sin ajuste. Las reducciones en el tamaño de muestra fueron entre 
15% y 44% cuando el ajuste fue hecho para covariables fuertes (HR entre 2 y 
5), y menores cuando las prevalencias de las variables fueron mas pequeñas. La 
reducción del tamaño de muestra fue independiente del efecto del tratamiento, 
del tamaño de muestra y el nivel de censura. 
La Parte 3 se enfoca en el uso, reporte e interpretación del ajuste de cov-
ariables y del análisis de subgrupos en estudios clínicos de medicina interna, 
oncología, cardiología y neurocirugía. En el Capítulo 3.1 evaluamos estudios 
clínicos de medicina interna, cardiología y oncología publicados en el 2002. El 
ajuste de covariables fue usado en el 50% de los estudios clínicos, y las covaria-
bles predictivas fueron usadas. El análisis de subgrupos fue usado en el 50% de 
los estudios. Sin embargo, solo 20% usó las apropiadas pruebas de interacción, 
y 25% sobreenfatizó los resultados obtenidos en los subgrupos. Por lo tanto, el 
análisis de subgrupos pudo importantes deficiencias que pueden ser traducidas en 
decisiones médicas incorrectas. El Capítulo 3.2 describe la situación del análisis 
de subgrupos en estudios clínicos cardiovasculares publicados en 2002 y 2004. 
El interés en el análisis de subgrupos en este campo medico se ha incrementado 
dramáticamente en los últimos 20 años. Treinta y nueve de los 63 estudios re-
portaron análisis de subgrupos. Sólo 14 reportaron subgrupos completamente 
pre-especificados, 11 usaron las pruebas de interacción, y 15 sobreenfatizaron 
los hallazgos de los subgrupos. Estos resultados fueron peores que los reportados 
en el Capítulo 3.1. Así, muchos cardiólogos pueden malinterpretar los resultados 
de estos subgrupos, y pueden usar un tretamiento dañino en pacientes “equivo-
cados”, y pueden restringir su uso en pacientes “correctos”. En el Capítulo 3.3 
evaluamos el ajuste de covariables y el análisis de subgrupos en 18 estudios 
clínicos en TBI. Cinco estudios usaron esl ajuste de covariables, y usaron cor-
rectamente pocos predictores. Once estudios reportaron análisis de subgrupos, 
pero solamente tres los pre-especificaron completamente, uno usó pruebas de 
interacción  y cinco enfatizaron los resultados. También evaluamos si estas de-
ficiencies en el análisis de subgrupos fueron planeadas or fueron basadas en los 
datos, al analizar 6 protocolos y 6 estudios disponibles. La correspondencia entre 
éstos fue pobre, y parece indicar la presencia de análisis post-hoc. En conjunto, 
el uso, reporte e interpretación del ajuste de covariables parece adecuado, pero el 
análisis de subgrupos tiene deficiencias evidentes.
La Parte 4 se centra en las aplicaciones clínicas del ajuste de covariables y del 
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análisis de subgrupos en estudios clínicos realizados en poblaciones con pacientes 
heterogéneos, tales como TBI y ACS. En el Capítulo 4.1 evaluamos la reducción 
del tamaño de muestra que podría ser obtenida cuando se ajusta para predictores 
importantes de resultado desfavorable en 8 estudios de TBI. Encontramos que el 
ajuste para los 3 predictores más fuertes produjo una reducción del tamaño de 
muestra del 20%, y que el ajuste para los 7 predictores más fuertes una reducción 
del 25%. En comparación, el ajuste de covariables en registros de TBI, con más 
poblaciones heterogeneas, proporcionaron una reducción mayor del tamaño de 
muestra (alrededor del 40%). El ajuste para predictores es una herramienta útil 
en la fase de análisis de estudios clínicos en TBI. El Capítulo 4.2 describe un 
meta-análisis de subgrupos de 6 grandes estudios clínicos, los cuales evaluaron 
si los efectos de los bloqueadores del receptor de glicoproteina IIb/IIIa fueron 
similares entre pacientes jóvenes y ancianos con ACS sin elevación del segmento 
ST (NSTE-ACS). Los efectos benéficos relativos de estos fármacos fueron simi-
lares a través de los subgrupos de edad, y los efectos benéficos absolutos fueron 
mayores en los ancianos. Esto se debió a que los ancianos tuvieron un riesgo 
basal más alto que el de los jóvenes. Sin embargo, los pacientes ancianos tuvieron 
un riesgo absoluto mayor de sangrados significativos. Así, estos fármacos son 
útiles en los ancianos y en los jóvenes, y el mayor riesgo de sangrado significativo 
garantiza un monitoreo cuidadoso en los ancianos. Finalmente, en el Capítulo 
4.3 analizamos cuáles subgrupos de pacientes tuvieron un mayor riesgo de 
desarrollar enfermedad cerebrovascular luego de un NSTE-ACS. Encontramos 
que los pacientes ancianos, con una enfermedad cerebrovascular previa y con 
frecuencias cardiacas altas tuvieron mayor riesgo para desarrollar cualquier tipo 
de enfermedad cerebrovascular. Otros grupos de alto riesgo previamente descri-
tos (por ejemplo, diabéticos, hipertensos) no estuvieron en alto riesgo en nuestro 
análisis. Sin embargo, el modelo construido con aquellos 3 predictores tuvo 
una moderada discriminación, haciendo difícil la predicción de la enfermedad 
cerebrovascular en estos pacientes.
Por ultimo, en la Parte 5 pusimos los principales resultados en perspectiva, 
y presentamos recomendaciones generales para un uso, reporte e interpretación 
apropiadas del ajuste de covariables y del análisis de subgrupos. Concluimos que 
el ajuste de covariables es un método valioso para obtener efectos de tratamiento 
más individualizados en los estudios clínicos, y que reducciones substanciales en 
los requerimientos de tamaños de muestra pueden ser obtenidos cuando se ajusta 
para predictores. El ajuste de covariables debería ser recomendado para estudios 
clínicos futuros que incluyan poblaciones heterogéneas. El análisis de subgrupos 
es frecuentemente realizado en estudios clínicos actuales, pero con deficiencias 
importantes. La pre-especificación de los subgrupos, el uso de las pruebas de 
interacción, y el reconocimiento de su papel secundario son esenciales para me-
joras la vision escéptica que se tiene de este tipo de análisis. El meta-análisis de 
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subgrupos mejora substancialmente el poder estadístico para detectar efectos en 
subgrupos a través de estudios clínicos, y debería ser recomendada como un pro-
cedimiento estándar cuando están disponibles datos individuales de pacientes. 
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